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The increasing use of aggressive immunosuppressive regimes over the last half-century has 
been accompanied by an increased incidence of opportunistic invasive fungal infections, with 
Aspergillus fumigatus emerging as one of the main etiologic agents. A. fumigatus is now the 
major airborne fungal pathogen and is a pathogen to be feared; it is difficult to diagnose early 
and accurately, a detailed understanding of the factors regulating its growth and pathogenesis 
is lacking, and invasive infections are associated with high mortality rates, longer hospital 
stays and high treatment costs. In addition, the number of antifungals effective against it is 
limited and resistance is increasing, highlighting the need for the characterisation of novel 
targets for new antifungals. A detailed knowledge of the structure of a protein is essential for 
understanding its underlying molecular mechanism and enabling structure-based drug design. 
This dissertation reports the application a structural genomics-style approach to a pilot set of 
proteins that are involved in a range of processes essential for the growth, cellular homeostasis 
and survival of A. fumigatus in the human host. Following on from preliminary experiments 
to identify proteins amenable to study by X-ray crystallography, three A. fumigatus proteins 
were selected for comprehensive structural and biochemical characterisation:  
(1) Crystal structures of cytosolic thiolase (afCT), which catalyses the first step in isoprenoid 
synthesis, were solved to resolutions between 1.7 and 2.25 Å. One of these crystals trapped 
two previously unobserved tetrahedral reaction intermediates, providing the first direct 
structural observation of the full thiolase reaction cycle. Unexpectedly, afCT is more similar 
structurally and biochemically to human mitochondrial thiolase II (hT2) than it is to human 
cytosolic thiolase (hCT). Here it is shown that, like hT2, afCT is strongly activated by 
monovalent cations, with a preference for K+ ions. Additionally, structural comparisons and 
in silico docking experiments suggest that afCT has a substrate specificity more similar to hT2 
than hCT. 
(2) The structure of proliferating cell nuclear antigen (AfumPCNA), which is essential for 
DNA replication and repair, was solved to 2.6 Å. Strong structural similarities between 
AfumPCNA and human PCNA at their main protein-protein interaction site suggest that the 
structural basis by which PCNA functions is conserved. Consistent with this, it is shown herein 
that the PCNA-interacting peptide of the human tumour-suppressor protein p21 binds 
AfumPCNA with only ten-fold lower affinity than for hPCNA, presenting AfumPCNA as a 
target for potential peptide-based antifungals. 
(3) Thioredoxin reductase (AfTrxR) catalyses the transfer of reducing equivalents from 
NADPH to a number of important biosynthetic and redox-active enzymes. The structure of 
AfTrxR was solved to 3.2 Å, and shows high structural similarity to bacterial, plant and yeast 
TrxRs. It is also shown herein that ebselen (EbSe), a small drug-like molecule, is a nanomolar 
inhibitor of AfTrxR in vitro and a potent inhibitor of A. fumigatus growth. Further investigation 
by mass spectrometry revealed that EbSe interacts covalently with a redox-active cysteine at 
the AfTrxR catalytic site. In silico docking experiments were used to define key enzyme-
inhibitor interactions that will be important to consider when designing potent and specific 
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1.1. Aspergillus fumigatus Infections 
The filamentous fungus Aspergillus fumigatus (Figure 1) is found worldwide. It is a 
saprophyte, usually feeding on decaying organic matter, and disseminates via the production 
of microscopic spores, called conidia (McCormick et al., 2010). Spores are ubiquitous and 
constantly inhaled by humans. Aspergillus infections are therefore most commonly respiratory 
(Figure 2). Infections that involve mycelial growth in the body are classified as allergic 
bronchopulmonary aspergillosis (ABPA), aspergilloma, or invasive aspergillosis (IA) (Latge, 
1999). ABPA is most common in patients with asthma or cystic fibrosis and causes death by 
respiratory failure if left untreated. Aspergilloma, or “fungus ball”, is characterised by a mass 
of spherical mycelial growth in the airways. Although usually asymptomatic, it can cause 
internal bleeding, haemoptysis, and death (Latge, 1999). IA is common in 
immunocompromised hosts such as hematopoietic stem cell (HSC) and solid-organ transplant 
recipients, or patients with haematological malignancy, acute leukaemia or AIDS (Gallien et 
al., 2008; Latge, 1999). Cases of severe IA caused by A. fumigatus are reported in 
immunocompetent patients, albeit rarely (Chen et al., 2011). General symptoms are variable 
and include fever, chest pain, cough, malaise, weight loss, dyspnoea, haemoptysis, 
neurological deficit, and meningitis (Gallien et al., 2008; Latge, 1999). Although most often 
pulmonary, infections of the bronchi, sinuses, and dissemination to the brain and other organs 
are also common (Gallien et al., 2008; Latge, 1999). Early diagnosis of A. fumigatus infections 
is difficult and there is a need for more accurate and sensitive diagnostic methods (Steinbach, 
2013).  
Alveolar macrophages are the major host immune cells involved in the initial response to 
Aspergillus infection, clearing fungal conidia from the lungs via phagocytosis and production 
of reactive oxygen species (ROS). Neutrophils recruited during inflammation play a major 
role in phagocytosis of hyphae and can also ingest conidia missed by macrophages (Latge, 
1999; McCormick et al., 2010). They respond to infection by production of ROS, antimicrobial 
proteases and neutrophil extracellular traps (NETs) (Espinosa and Rivera, 2016). 
Administration of corticosteroids – which inhibit killing of conidia by macrophages, 
inflammation, and recruitment of neutrophils – has been identified as a risk factor for the 
development of IA (Upton et al., 2007). Neutropenia has also been correlated with an increased 
Figure 1: (a) A. fumigatus after 4 days growth on malt extract agar. (b) An A. fumigatus conidial head 
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risk of developing IA and failure of treatment (Gallien et al., 2008; Latge, 1999). Another 
factor that complicates treatment is angioinvasion and occlusion of blood vessels by A. 
fumigatus, often making delivery of anti-fungal drugs to the site of infection difficult 
(Steinbach, 2013). 
 
1.2. Incidence of Invasive Aspergillosis and Associated Mortality Rates 
The incidence of IA is difficult to estimate due to a historical lack of consistency in 
surveillance and case definition (Warnock, 2007). A 2005 review reported that the mean 
incidence of IA in transplant recipients varied from 0.7 to 11% depending on the type of 
transplant, with mortality rates of 63 to 100% (Singh and Paterson, 2005). It is generally 
recognised, however, that Aspergillus infections have become increasingly common in the last 
few decades. This can be attributed to considerable progress in the areas of cancer treatment 
and transplantation, with a concomitant rise in the number of immunocompromised patients. 
Aside from cancer remission or transplant failure, the leading cause of death for these patients 
is infection, in which A. fumigatus is a major player (Latge, 2001; Steinbach, 2013). Indeed, 
IA is one of the most hazardous and common mould infections in immunocompromised 
patients (Gallien et al., 2008) and the most common cause of death due to lung infection in 
HSC transplant patients (Walsh et al., 2008). 
The mortality rate associated with IA is variable, and depends on the patient’s underlying 
medical conditions, the site of infection, and antifungal therapy. All the same, it remains 
unacceptably high. A systematic review of literature from 1995 to 2000 revealed an overall 
IA case-fatality rate of 58%, with rates for HSC transplant patients and those with central 
nervous system (CNS) or disseminated aspergillosis of 86.7% and 88.1%, respectively (Lin et 
Figure 2: Aspergillosis. (a) A case of chronic 
pulmonary aspergillosis. Chest radiographs show the 
progression of the disease over a five-year period (1992 
– 1997) (Denning, Riniotis et al. 2003). (b) Fungal 
hyphae invading lung tissue at the edge of an 
aspergilloma “fungus ball”. Image reproduced from The 
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al., 2001). CNS aspergillosis is associated with particularly high mortality rates (Gallien et al., 
2008; Schwartz et al., 2005). A large study at a single US centre demonstrated that, of over 
400 HSC transplant patients with IA from 1990 to 2004, 90.9% died after being diagnosed 
with IA, with approximately one third of deaths considered to be attributable to IA (Upton et 
al., 2007). 
 
1.3. Limitations of Current Treatment Options 
There are four classes of antifungal agents that have in vitro antifungal activity against 
Aspergillus species: polyenes, echinocandins, allylamines and triazoles (Hadrich et al., 2012; 
Qiao et al., 2008). These all target components of the fungal cell wall or cell membrane, 
directly or indirectly (Figure 3). 
Amphotericin B is a broad-spectrum polyene antifungal that interacts with ergosterol, the main 
fungal cell membrane sterol, and was the standard treatment for Aspergillus infections for 
decades. It binds to ergosterol directly to form transmembrane channels, thereby increasing 
the permeability of the membrane to monovalent cations (Bolard, 1986; Latge, 1999). It also 
results in depletion of cellular energy reserves by inhibiting proton ATPase pumps and 
decreases the integrity of the cell membrane by causing oxidative damage to lipids (Latge, 
1999; Qiao et al., 2008). However, more recent research has suggested that amphotericin B 
primarily kills fungal cells via ergosterol binding per se, and that channel formation is a 















Figure 3: Cartoon representation of the putative organisation of the cell wall of a fungal conidium (adapted from 
Latge, 2010). On the right are representatives of current anti-Aspergillus drug classes and their targets. 
Echinocandins (caspofungin) inhibit β-(1,3)-glucan synthesis, azoles (voriconazole) and allylamines (terbinafine) 
inhibit ergosterol synthesis, and polyenes (amphotericin B) bind ergosterol directly in the membrane. All 
chemical structures were reproduced from Sigma-Aldrich® (http://www.sigmaaldrich.com). 
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means that it must be mixed with detergent to be bioavailable. High patient toxicity commonly 
results in severe side effects; the most notable is acute renal failure, which is associated with 
a high mortality rate in itself (Bates et al., 2001; Gallien et al., 2008; Herbrecht et al., 2002). 
Lipid formulations are less toxic, but more expensive (Chowdhry and Marshall, 2008; Latge, 
1999). It is only available as an intravenous formulation, often resulting in infusion reactions 
(Chowdhry and Marshall, 2008; Herbrecht et al., 2002). 
Echinocandins ‒ including caspofungin and micafungin ‒ target the major subunit of glucan 
synthase, encoded by the FKS1 gene (Arendrup et al., 2009). They inhibit synthesis of the 
essential fungal cell wall component, β-(1,3)-glucan, and are fungistatic against Aspergillus 
spp. Adverse side-effects include rash and hepatotoxicity (Chowdhry and Marshall, 2008; 
Rocha et al., 2007). 
Terbinafine, the main allylamine antifungal, inhibits squalene epoxidase, which is encoded 
by the ergA gene in A. fumigatus and is involved early in the ergosterol biosynthesis pathway. 
Its inhibition results in depletion of ergosterol and accumulation of squalene, resulting in 
fungal cell death (Alcazar-Fuoli and Mellado, 2012; Rocha et al., 2006; Ryder, 1992). 
Triazole antifungals target lanosterol 14-α-demethylase, a cytochrome P450 enzyme and the 
product of the cyp51A gene (also known as erg11). Triazole drugs act by competing with 
oxygen for binding to the iron atom occupying the haem group at the cyp51A active site 
(Hadrich et al., 2012). This prevents the synthesis of ergosterol resulting in the accumulation 
of intermediate sterols, altered membrane fluidity, accumulation of intracellular unsaturated 
fatty acids and phospholipids, and inhibition of fungal growth (Latge, 1999; Lelièvre et al., 
2013). Triazoles are selective for fungal over human cytochrome P450, thereby reducing 
toxicity to the patient. Despite this, effective treatment options may be restricted due to 
interactions with other common drugs that modulate P450 metabolism. Triazoles effective 
against A. fumigatus include voriconazole, itraconazole and posaconazole; however, the latter 
two are only available in oral formulations, limiting their use in ICU (Chowdhry and Marshall, 
2008; Latge, 1999). Common adverse side-effects associated with azole therapy are 
hepatotoxicity, psychosis and temporary visual disturbances including altered colour 
perception, hallucinations, and episodes of confusion (Chowdhry and Marshall, 2008; 
Herbrecht et al., 2002). 
Triazoles are the main class of antifungal for the treatment of IA. Voriconazole is the preferred 
agent for first-line IA therapy, as it has been shown to be more effective and have less severe 
side-effects than amphotericin B (Herbrecht et al., 2002). Current guidelines for the treatment 
of IA from the Infectious Diseases Society of America recommend voriconazole and 
posaconazole for primary treatment and prophylaxis, respectively, in most cases. Liposomal 
amphotericin B, posaconazole, itraconazole, caspofungin or micafungin are recommended for 
salvage therapy in cases where infection is refractory to voriconazole (Patterson et al., 2016; 
Walsh et al., 2008). No allylamines have been approved for clinical use in the treatment of IA 
(Alcazar-Fuoli and Mellado, 2012; Hadrich et al., 2012). The benefit of using combinations 
of currently available drugs has been shown to be limited, highlighting the need for the 
development of new therapies with novel targets (Steinbach, 2013; Upton et al., 2007).  
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1.4. The Rise in Antifungal Resistance 
The rise in A. fumigatus infections has been accompanied by a rise in cases of resistance to 
current antifungal medications (Hadrich et al., 2012; Qiao et al., 2008). It is well recognised 
that A. fumigatus can acquire resistance to triazoles ‒ the main class of antifungal used against 
it. Resistance was first identified in the clinic in 1997 (Chryssanthou, 1997; Denning et al., 
1997b), and although cases were rare for the following decade, its incidence has increased 
dramatically in recent years (Lelièvre et al., 2013; Vermeulen et al., 2013). Azole resistance 
has now been reported in Australia, Canada, China, Columbia, India, Tanzania, USA and 
across Europe (Hadrich et al., 2012; Verweij et al., 2016). Current evidence suggests that 
resistance may be acquired in the clinic due to the selective pressure associated with long-term 
antifungal therapy, or in the environment due to widespread use of azole fungicides in 
agriculture (Lelièvre et al., 2013; Vermeulen et al., 2013). A UK study (Figure 4a) showed 
that, of 519 clinical A. fumigatus isolates from 1992 to 2007, 7% were resistant to itraconazole, 
and of these, 65% and 74% were cross-resistant to voriconazole and posaconazole, 
respectively. The earliest example of azole-resistance was seen in 1999, with a significant 
increase in frequency after 2004; the incidence of azole-resistant isolates in 2007 was 17% 
(Howard et al., 2009). Similar results have been reported in the Netherlands: the overall 
frequency of patients from 1994 to 2007 harbouring an itraconazole resistant A. fumigatus 
isolate was 2.6%, increasing steadily after 1999. In most cases, itraconazole resistant isolates 
showed cross-resistance to other azole antifungals (Snelders et al., 2009). A more recent 
follow up study by the same group showed that this trend has persisted, with the prevalence 
of azole-resistant A. fumigatus increasing from 4.3% in 2008 to 10.1% in 2010 (D. Versteeg 
et al., 2012) (Figure 4b). Results of a study at an institution in the USA showed that triazole 
resistance increased after institutional use of itraconazole began, and that some itraconazole 
resistant isolates also showed decreased susceptibilities to voriconazole, caspofungin or 
amphotericin B (Balajee et al., 2004). Resistance is most often mediated by mutations in the 
Figure 4: Resistance of A. fumigatus to azole antifungals is increasing. (a) Data from a UK study showing 
the incidence of azole resistant A. fumigatus isolates (total percentage indicated above each column) in 
patients from 1997 to 2007. Resistance was probably acquired during or after azole therapy. Figure 
reproduced from Howard et al. (2009). (b) A Dutch study showing the number of patients with a confirmed 
A. fumigatus infection (grey bars; left axis) and the percentage from which an itraconazole resistant A. 
fumigatus strain was isolated (black line; right axis) from 1994 to 2011. Resistance probably originated in the 
environment due to selective pressure from triazole fungicides used in agriculture (Snelders et al., 2009). 
Figure reproduced from Versteeg et al. (2012). 
b a 
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cyp51A gene or its regulatory elements, resulting in structural modifications that preclude 
azole binding or increase gene expression (Hadrich et al., 2012; Lelièvre et al., 2013). Cross-
resistance to azoles is common and depends on the specific amino acid substitution conferred 
by mutations in cyp51A (Arendrup et al., 2008). Other non-cyp51A-related resistance 
mechanisms have also been observed (Vermeulen et al., 2013). For example, drug resistance 
has also been associated with an overexpression of efflux pumps, of which A. fumigatus has 
many (Lelièvre et al., 2013). Multiazole-resistant A. fumigatus has been associated with high 
mortality in patients with IA (van der Linden et al., 2011). Unsurprisingly, a correlation 
between azole resistance and treatment failure in a murine model of IA has also been 
demonstrated (Denning et al., 1997a). Drugs that are effective against filamentous fungi are 
limited, and those of the azole class are the only ones that can be administered orally (Lelièvre 
et al., 2013), therefore the recent increase in resistance to these drugs is of great concern. 
Regarding the other available antifungal drug classes, resistance of A. fumigatus to polyenes 
or echinocandins is rare. However, it has been suggested that reduction in plasma membrane 
ergosterol content or overproduction of enzymes that neutralise oxidative stress could possibly 
confer resistance to amphotericin B (Qiao et al., 2008). In addition, rare cases of resistance to 
echinocandins, which have only more recently become available for clinical use, have been 
reported (Arendrup et al., 2008; Balajee et al., 2004; Madureira et al., 2007). Although the 
exact mechanism has not yet been determined, increased FKS1 expression and growth rate 
have been associated with a caspofungin resistant clinical A. fumigatus isolate (Arendrup et 
al., 2008).  
Although the main cause of IA is A. fumigatus, other Aspergillus species are also commonly 
implicated in the disease (Walsh et al., 2008). Many species show intrinsic resistance or 
variable susceptibility to currently available antifungal drugs. For example, A. terreus shows 
intrinsic resistance to amphotericin B (Hadrich et al., 2012). This further highlights the need 
for a broader range of antifungal treatment options. 
 
1.5. Potential Targets for New Antifungals  
Despite the increasing incidence of IA, limited treatment options, and rise in antifungal 
resistance, the characterisation of novel targets for antifungals effective against A. fumigatus 
has been lacking in recent years. Being a saprophyte, A. fumigatus does not require a human 
host to complete its life cycle. Therefore, there is an absence of selective pressure to facilitate 
development in the human body. This is consistent with the lack of true virulence factors 
identified by single-gene deletion strategies, and indicates that A. fumigatus virulence involves 
numerous factors that make this fungus particularly hazardous to the immunocompromised 
host. The virulence of A. fumigatus has been suggested to be multifactorial, attributed to the 
ability of conidia to penetrate deep into the lower alveolar airways, effectively evade or resist 
host defence mechanisms, readily adapt to the host environment, and invade host tissue (Abad 
et al., 2010; Latge, 1999; Steinbach, 2013). The functions of various proteins key to several 
different pathways, for example: calcineurin, a protein phosphatase involved in stress 
response; IreA, an endoplasmic reticulum stress sensor; LaeA, a master regulator of secondary 
metabolite production and development; and srbA, a putative transcription factor essential for 
hypoxic adaptation, have all been shown to be significantly correlated with virulence 
8 | C h a p t e r  1  
 
(McCormick et al., 2010; Steinbach, 2013). Thermotolerance is a factor that has also been 
shown to contribute to virulence (Abad et al., 2010; McCormick et al., 2010). These findings 
suggest that a more promising approach to antifungal development may be to target key 
components of important regulatory pathways rather than specific putative virulence factors. 
Uncovering proteins that are essential for the growth and virulence of A. fumigatus is only the 
first step in identifying new antifungal targets. Indeed, it must be shown that the protein in 
question is also ‘druggable’, such that bioavailable molecules can bind to and modulate the 
function of the protein to give the desired therapeutic outcome (Steinbach, 2013). To this end, 
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Drug Discovery 
  
10 | C h a p t e r  2  
 
2.1. Structural Genomics 
Detailed macromolecular structural information is invaluable for understanding the 
fundamental mechanisms that underlie biological processes. This information is important not 
only for gaining a detailed understanding of the basic biology of an organism, but also in 
facilitating the rational design of therapeutics targeted to specific components of a process ‒ 
two outcomes that are often intrinsically linked (Ennifar, 2013; Zheng et al., 2015). In the past, 
the selection of a particular protein for structural characterisation has typically followed from 
the prior study and characterisation of its function by traditional biochemical and molecular 
biology methods. The advent of technologies for efficient large scale heterologous protein 
production, purification and structure determination, in addition to large scale sequencing 
projects making available whole-genome sequence data, has made a less biased approach 
possible ‒ where structural characterisation of proteins often occurs prior to elucidation of 
their function (Anderson, 2009; Weigelt, 2010). 
The field of Structural Genomics (SG) has thus emerged in the last fifteen years or so as an 
approach to address two broad goals: (1) To expand our knowledge of protein fold space by 
determining structures for proteins with novel sequences, therefore providing structural 
templates for all proteins; and (2) To systematically determine the structures of all proteins 
from a particular organism in order to understand the basic molecular mechanisms that occur 
within, providing a foundation for applied biomedical research, with a particular focus on drug 
discovery. SG programs have included international consortiums and large projects in the 
USA, Europe and Japan (Anderson, 2009; Grabowski et al., 2016; Weigelt, 2010). These have 
so far contributed approximately 12% of all structures deposited in the Protein Data Bank 
(PDB) (Grabowski et al., 2016), with SG projects accounting for nearly a quarter of novel 
structures of human proteins currently available (Weigelt, 2010). 
The general approach taken by a SG program involves first the selection of a large number of 
protein targets that will be studied in parallel, cloning of these into vectors for heterologous 
expression, small-scale testing for soluble protein, large scale protein expression and 
purification, followed by crystallisation, X-ray diffraction, and finally structure solution. For 
proteins for which structures can be solved, enzyme assays or other biochemical studies are 
established, and the molecular mechanisms that underlie their functions are characterised at 
an atomic level by co-crystallisation and structure solution with natural ligands. Following 
this, co-crystallisation with known inhibitors or those identified by screening facilitates the 
identification and optimisation of lead compounds for novel drugs.  
A structure-guided approach to drug discovery is particularly valuable for optimisation of lead 
compounds to increase affinity and specificity for a target, leading to the development of 
antimicrobial drugs against specific pathogenic organisms. Even though the proteins selected 
for characterisation in a SG project are often not validated drug targets, the approach makes 
available structures for many proteins that can then be further studied to validate them as 
potential drug targets, and also increases the knowledge of the pathogen under investigation. 
Many pathogens have been the subject of SG projects, including viruses, pathogenic protozoa, 
bacteria and malaria (Anderson, 2009; Li et al., 2014; Musa et al., 2009; Weigelt, 2010).  
An example of a large and successful SG project is the Tuberculosis Structural Genomics 
Consortium (TBSGC ‒ http://www.webtb.org), which commenced in 2000 and is the subject 
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of numerous reviews (Arora et al., 2011; Chim et al., 2011; Ehebauer and Wilmanns, 2011; 
Ioerger and Sacchettini, 2009; Musa et al., 2009). This collaboration includes approximately 
100 different research groups in 15 countries and its focus is to solve the structures of 
biologically important Mycobacterium tuberculosis proteins, with a strong emphasis on 
providing a foundation for structure-based drug discovery efforts. So far over one third of M. 
tuberculosis protein structures currently deposited in the PDB are attributed to members of the 
TBSGC – equal to over 250 structures. This has led to an enhanced understanding of proteins 
involved in important metabolic pathways and those associated with virulence, pathogenesis 
and persistent infection. In addition, misannotations in the genome have been corrected, and 
new potential drug targets have been identified and structurally characterised, allowing for 
screening of inhibitors and identification of potential drug leads (Lin et al., 2006). 
The sequence of the entire Aspergillus fumigatus genome has been made publicly available 
(Nierman et al., 2005), making possible the cloning of any particular gene of interest for 
heterologous expression. At the commencement of the current project, there were 91 structures 
of A. fumigatus proteins deposited in the PDB, representing only 36 unique proteins – a very 
small number compared to other important human pathogens. Applying a SG approach to the 
study of this important opportunistic pathogen would provide valuable structural information 
and is expected to uncover avenues for the development of drugs that exploit new targets. The 
SG projects discussed above are often multidisciplinary and involve large laboratories or 
consortiums of many different laboratories in addition to well established processes for large-
scale parallel screening of targets followed by structure solution. This kind of project 
obviously falls outside the scope of a single PhD project. Despite this, it is possible to use the 
same approach on a much smaller scale.  
 
2.2. Aims and Scope of the Current Project 
The current project therefore applies the same structure-based approach with the aim of 
characterising important proteins from A. fumigatus, beginning with a pilot set of proteins that 
have a broad range of functions and are of particular importance to the survival and growth of 
the organism within the human host. Specifically, a list of almost twenty proteins involved in 
essential cellular processes were selected for parallel investigation, with the aim of solving 
crystal structures and performing further biochemical characterisation of two or three of these. 
Parallel cloning and screening of a large number of protein targets for expression, solubility 
and crystallisation at the outset pre-empts the bottleneck that often occurs at the crystallisation 
step, and is an efficient way to ensure that useful structural information, with supporting 
biochemical data, is gained within the timeframe of a single PhD project. This information 
will be valuable for gaining a better understanding of the fundamental biochemistry that 
governs essential processes within this important opportunistic pathogen, and provide a 
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3.1. Target Selection 
The genome of A. fumigatus consists of eight chromosomes and contains 9,926 predicted 
genes (Nierman et al., 2005). An initial set of eighteen proteins were selected for this study 
(Table 1). These are all involved in essential processes such as stress response, synthesis of 
cell wall or membrane components, cellular metabolism, or DNA replication, and each fulfil 
at least two of the following criteria:  
• Essential for growth and/or virulence  
• Has prior validation as a drug target or predicted ‘druggable’ potential  
• Lacks a human homologue  
• Structures of homologues are unavailable  
• Is predicted to be soluble  
These criteria are similar to those used by the Center for Structural Genomics of Infectious 
Diseases (Anderson, 2009). 
To increase the probability of successfully obtaining soluble recombinant protein, truncations 
of all eight chitin synthases (ChS) contained in the A. fumigatus genome were constructed to 
include only the putative catalytic ChS domain; that is, all predicted transmembrane regions 
and other domains (such as the myosin motor-like domains of CSMA and CSMB) were 
excluded (see Table 1 for truncations). Protein secondary structure predictions (Phyre2 server 
(Kelley and Sternberg, 2009)) and alignment to previous truncations of a fungal ChS 
successfully expressed in E. coli (Magellan et al., 2010) were used as guides for designing 
appropriate truncations. Two truncations of the endoplasmic reticulum stress sensor, IreA, 
were designed to include either the core ER luminal domain or the dual catalytic cytosolic 
domain. The positions of these truncations were informed by previously solved S. cerevisiae 
and human Ire1 crystal structures (Ali et al., 2011; Credle et al., 2005; Lee et al., 2008; Zhou 
et al., 2006). All other targets were cloned as full length wild type proteins. 
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Protein name(s) and function Essential? References 




Protein kinase and ribonuclease Ire1/IreA. 
Endoplasmic reticulum stress sensor and 










GFA1 XM_745432.1 None. (Full length 
protein) 
Glutamine-fructose-6-phosphate amino-
transferase. First step in chitin biosynthetic 
pathway. 
Yes (Hu et al., 
2007) 
ERG10 XM_742114.1 None. Type II thiolase/acetyl-CoA acetyl-
transferase/acetoacetyl-CoA thiolase. First 
step in mevalonate pathway. 
Yes (Hiser et al., 





None. Thioredoxin reductase. Cell redox 
homeostasis. 
Yes (Hu et al., 
2007) 
HEM15 XM_748768.1 None.  Mitochondrial ferrochelatase. Heme 
biosynthesis. 
Yes (Hu et al., 
2007) 
ChSA XM_744229.1 H163-S545 Chitin synthase A. Synthesis of chitin – a 
major structural component of the fungal cell 
wall. 
No (Muszkieta et 
al., 2014) 
ChSB XM_741511.1 A281-S703 Chitin synthase B. Synthesis of chitin. No (Muszkieta et 
al., 2014) 
ChSC XM_743170.1 H160-S525 Chitin synthase C. Synthesis of chitin. No (Muszkieta et 
al., 2014) 
ChSD XM_747537.1 T100-R396 Chitin synthase D. Synthesis of chitin. No (Muszkieta et 
al., 2014) 
ChSF XM_742271.1 H635-T1019 Chitin synthase F. Synthesis of chitin. No (Muszkieta et 
al., 2014) 
ChSG XM_749091.1 A141-G562 Chitin synthase G. Synthesis of chitin. No (Muszkieta et 
al., 2014) 
CSMA XM_750584.1 L1231-S1564 Chitin synthase E/Myosin motor-like domain-
containing chitin synthase A. Synthesis of 
chitin. 
No (Muszkieta et 
al., 2014) 
CSMB XM_750583.1 Q1054-G1405 Myosin motor-like domain-containing chitin 
synthase B. Synthesis of chitin. 
No (Muszkieta et 
al., 2014) 
ACD XM_747761.1 None.  Acyl-CoA dehydrogenase. Catalyses 1st step in 
β-oxidation pathway (fatty acid catabolism). 
unknown (Kretschmer 
et al., 2012) 
ECH XM_750305.1 None.  Enoyl-CoA hydratase. Catalyses 2nd step in β-
oxidation pathway. 
unknown (Kretschmer 
et al., 2012) 
3HACD XM_743258.2 None.  3-hydroxyacyl-CoA dehydrogenase. Catalyses 
3rd step in β-oxidation pathway. 
unknown (Kretschmer 
et al., 2012) 
KAT1 XM_747542.1 None.  3-ketoacyl-CoA thiolase. Catalyses 4th step in 
β-oxidation pathway. 
unknown (Kretschmer 
et al., 2012) 
PCNA XM_745146.1 
(┼afu1g04900) 
None.  Proliferating Cell Nuclear Antigen/Sliding 
clamp. Hub protein for DNA replication/repair 





*See Chapter 6, Materials and methods.  
┼Updated sequence available at www.aspergillusgenome.org. See Chapter 5, Materials and methods. 
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3.2. Parallel Cloning and Screening for Heterologous Expression and Solubility 
The protein coding sequence for each target was PCR amplified from A. fumigatus strain af293 
(Nierman et al., 2005) cDNA (a gift from Assoc. Prof. James Fraser, School of Chemistry and 
Molecular Biosciences, University of Queensland) and cloned into Gateway® pDONR™221 
Vector (Invitrogen™) with a Tobacco Etch Virus (TEV) protease cleavage site at the 5’ end 
to facilitate proteolytic removal of any N-terminal tag used during protein purification (see 
Appendix 1).  These open reading frames (ORFs) were then subcloned via Gateway® 
recombination sites into vectors of choice for expression of protein in Escherichia coli, and 
confirmed using the Sanger sequencing service provided by the Australian Genome Research 
Facility (Plant Genomics Centre, Urrbrae, SA). The pVP16 vector (Center for Eukaryotic 
Structural Genomics) was used as a default first choice for expression of recombinant protein 
with an N-terminal maltose binding protein (MBP) and hexahistidine tag to enhance solubility 
and facilitate purification by affinity chromatography. These constructs were then tested for 
protein expression in BL21(λDE3) E. coli cells, solubility, and binding to Ni2+-NTA resin on 
a small scale (10 mL cultures; see Appendix 2 for protocol), before selecting those for which 
the highest yield of soluble protein was obtained for large scale culture (3 - 10 L). This follows 
a similar standard approach as that taken by the TBSGC (Chim et al., 2011; Ioerger and 
Sacchettini, 2009).  
All targets were successfully over-expressed as MBP-fusion proteins (Figure 5), with the 
exception of the IreA cytosolic domain (IreA.CD), which, when over-expressed, may have 
been toxic to the cells, as indicated by their highly reduced growth rate (observed in two 
separate experiments). CSMB, ChSA, ChSB, ChSC, ChSG, GFA1 and HEM15 all exhibited 
low solubility or appeared to be degraded easily. ChSD appeared to be partially soluble, but 
at least 50% degraded. CSMA and ChSF showed the greatest solubility and stability of all the 
ChS catalytic domains, albeit with some observable degradation. The IreA luminal domain 
(IreA.LD), TRR1, ERG10, 3HACD, ACD, ECH and KAT1 were all highly soluble and bound 
well to the Ni-NTA resin. Due to time constraints, it was not feasible to pursue structural 
analyses of all of these soluble targets within the current project. It is unknown which, if any, 
of the four enzymes of the β-oxidation pathway (ACD, ECH, 3HACD and KAT1; see Table 
1) are important for fungal pathogenesis. This is further complicated by the multiplicity of β-
oxidation genes contained in the A. fumigatus genome, as illustrated by the multiple putative 
KATs annotated (see Chapter 4, Figure S1), posing the possibility of functional redundancy. 
Indeed, previous genomic analyses have indicated that A. fumigatus possesses complete β-
oxidation pathways in both mitochondria and peroxisomes (Shen and Burger, 2009). It was 
therefore concluded that a structural and biochemical analysis of the complete β-oxidation 
pathway of A. fumigatus constitutes a separate study, which is discussed further in Chapter 
7, but is outside of the scope of the current study. 
Therefore, following from positive results for the small-scale tests, the IreA luminal domain 
(IreA), thioredoxin reductase (TRR1) and cytosolic thiolase (ERG10) were selected, in 
addition to PCNA (PCNA), for large scale protein purification and crystallisation screening. 
All of these proteins have been shown to be, or are very likely to be, essential for A. fumigatus 
growth or virulence (see Table 1). For A. fumigatus PCNA, a well-established protocol for the 
purification of human PCNA (previously developed by Dr. John Bruning) was used (see 
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Figure 5. SDS-PAGE analysis of small-scale E. coli expression, solubility and Ni-NTA resin binding tests 
for preliminary 6xhis-MBP tagged A. fumigatus targets. (-), whole cell sample taken pre-induction; (+), whole 
cell sample taken post-induction; FT, unbound fraction; W, 10 mM imidazole wash; E, elution (500 mM 
imidazole); M, protein size standards. Expected protein molecular weight (including 6xhis-MBP tag) is 
indicated above each gel. The molecular weight of the protein standards is indicated in kDa. 
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Chapter 5, Materials and methods), bypassing any small-scale testing. All four of these 
proteins were successfully purified to homogeneity from E. coli culture, with sufficient yields 
to facilitate extensive crystallisation screening. Crystal structures were solved and supporting 
biochemical and/or biophysical data were collected for cytosolic thiolase (afCT; see Chapter 
4), PCNA (AfumPCNA; see Chapter 5) and thioredoxin reductase (AfTrxR; see Chapter 6). 
A large (12 mg) homogenous IreA.LD protein sample was also successfully obtained. 












Chapter 4 (Publication): 
Structure of Aspergillus fumigatus 
Cytosolic Thiolase: Trapped Tetrahedral 
Reaction Intermediates and Activation 
by Monovalent Cations 
  

Structure of Aspergillus fumigatus Cytosolic Thiolase: Trapped
Tetrahedral Reaction Intermediates and Activation by Monovalent
Cations
Andrew C. Marshall,† Charles S. Bond,‡ and John B. Bruning*,†
†Institute for Photonics and Advanced Sensing (IPAS), School of Biological Sciences, The University of Adelaide, Adelaide, South
Australia 5005, Australia
‡School of Molecular Sciences, The University of Western Australia, Crawley, Western Australia 6009, Australia
*S Supporting Information
ABSTRACT: Cytosolic thiolase (CT) catalyzes the reversible
Claisen condensation of two molecules of acetyl-CoA to
produce acetoacetyl-CoA. The reaction cycle proceeds via a
ping-pong mechanism involving an acetylated enzyme
intermediate and two separate oxyanion holes which stabilize
negatively charged reaction intermediates. This is the initial
step in the synthesis of ergosterol in the prominent fungal
pathogen Aspergillus fumigatus and is essential for the growth
and survival of the organism. Here, we present crystal
structures of A. fumigatus CT in liganded and apo forms and
in a complex with different monovalent cations. Careful
observation of the electron density at the active sites of two
different afCT structures crystallized in the presence of acetyl-
CoA shows that our crystals have trapped various stages of the
thiolase catalytic cycle, including two tetrahedral reaction intermediates that have previously eluded structural characterization.
Unexpectedly, we have also shown that afCT is activated by monovalent cations, a biochemical property previously thought to
apply only to the mitochondrial biosynthetic thiolase, with a preference for potassium ions. Structures of fungal CT provide
valuable insight into the thiolase reaction cycle and allosteric activation of members of this class of enzymes by monovalent
cations.
KEYWORDS: biosynthetic thiolase, acetoacetyl-CoA, Claisen condensation, tetrahedral reaction intermediate,
monovalent cation activation
■ INTRODUCTION
Ergosterol is the main fungal cell-membrane sterol; it is
essential for fungal cell viability and survival and is lacking in
host cell membranes, making it an attractive antifungal target.
Antifungals targeting ergosterol are central to the treatment of
invasive aspergillosis (IA), a debilitating condition caused by
Aspergillus spp. associated with high morbidity and mortality
rates and has had an increasing incidence in recent decades.1−5
First-line anti-Aspergillus drugs target ergosterol, either directly
in the membrane or by inhibiting its synthesis. Amphotericin B
binds ergosterol directly, disrupting membrane function.6−8
Although it has been used to treat IA for over four decades, it
has largely been superseded by the azole class of antifungals due
to its poor side-effect profile.9 Triazole antifungals target 14-α-
lanosterol demethylase (ERG11), inhibiting ergosterol syn-
thesis at the conversion of lanosterol to C14-demethyl-
lanosterol. Voriconazole is currently recommended for first-
line treatment of IA in most cases.10 Unfortunately, triazole
antifungals are also associated with significant side effects,
including liver toxicity, psychosis, and visual disturbances.9,11
More importantly, the past two decades have seen an alarming
increase in the incidence of azole-resistant isolates of A.
fumigatusthe main causative agent of IAworldwide. Azole-
resistant strains of A. fumigatus have emerged both in the clinic
and in the environment and are associated with poorer
treatment outcomes.12−14
Because of its essential role in fungal growth and relevance to
the action of currently available antifungals, the biosynthesis of
ergosterol is an essential area of study to improve current
antifungals or uncover new targets in the synthetic pathway. In
A. fumigatus, squalene is converted to ergosterol via
approximately 12 distinct enzymes.15 Squalene is produced
from mevalonate, the precursor for all isoprenoids, which
include many important organic molecules such as sterols
(including ergosterol), quinones, polyprenyl alcohols, heme A,
and the post-translational prosthetic groups farnesyl and
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geranylgeranyl.16,17 Mevalonate is produced in the cytosol from
acetyl-CoA (Ac-CoA) via three catalytically independent steps
(Figure 1). The first step is catalyzed by an acetoacetyl-CoA
(AcAc-CoA) thiolase (ACAT). Therefore, synthesis of
ergosterol, and all other sterols, starts with cytosolic ACAT.
Thiolases are ubiquitous enzymes involved in the transfer of
acyl groups between acyl-CoA derivatives. There are two
functional classes: type I thiolases, referred to as 3-ketoacyl-
CoA thiolases (KAT), and type II thiolases, which are referred
to as acetoacetyl-CoA thiolases (ACAT) or acetyl-CoA acetyl-
transferases.18,19 ACATs studied thus far are typically
homotetramers, while KATs are homotetramers or homo-
dimers. KATs can accept acyl-CoA derivatives with a variety of
chain lengths and are localized to mitochondria or peroxisomes,
where they are involved in β-oxidation of fatty acids.18 ACATs
are cytosolic, mitochondrial, or peroxisomal20 and are specific
for short-chain acyl-CoA substrates (C2−C4), catalyzing the
formation or degradation of AcAc-CoA from Ac-CoA. Although
the degradative reaction is entropically favored, high cellular
concentrations of Ac-CoA derived from cellular catabolism
along with rapid turnover of AcAc-CoA by the next enzyme in
the pathway are postulated to drive the reaction in the
biosynthetic direction.21−25 ACATs are therefore often referred
to as biosynthetic thiolases. While cytosolic ACAT is essential
for sterol synthesis, mitochondrial ACAT is essential for ketone
body metabolism.26−28 In addition, mammalian mitochondrial
ACAT (referred to in the literature as T2) differs from its
cytosolic counterpart (referred to simply as cytosolic thiolase,
CT) with regard to its substrate specificity and dependence on
ions for activity. Unlike CT, T2 has been shown to turn over 2-
methylacetoactyl-CoA, implicating it in isoleucine catabo-
lism.27,28 Also, T2 has K+ and Cl− ion binding sites near its
active site and its catalytic activity is increased severalfold in the
presence of K+ ions, whereas the activities of bacterial and
mammalian CTs studied thus far are ion independent.29,30 K+-
dependent stimulation of thiolase activity is used as a tool for
diagnosis of human T2 deficiency, a well-characterized disorder
presenting with episodes of acute ketoacidosis, caused by
mutations in the gene encoding for T2.27,31,32
The cytosolic ACAT catalytic cycle has been studied in detail
in the bacterium Zoogloea ramigera22,24,33−37 and involves the
sequential binding of two Ac-CoA molecules to a single
catalytic pocket (Figure 2). Upon binding of the first Ac-CoA,
the acetyl group is transferred from the CoA to the catalytic
cysteine, Cys89, forming an acetylated protein intermediate
(Figure 2, stages 1−4). His348 is postulated to deprotonate
Cys89, activating it for nucleophilic attack on the carbonyl of
the acetyl moiety. Another Ac-CoA then binds and a Claisen
condensation reaction occurs, involving transfer of the acetyl
group from the enzyme, forming AcAc-CoA (Figure 2, stages
5−8). Cys378 is the active site base, abstracting a proton from
C2 of the second acetyl moiety, activating it for nucleophilic
attack on the carbonyl of the first acetyl moiety.34,37 In both
acetyl-transfer reactions, the reaction must proceed via a
tetrahedral intermediate associated with a negative charge on
the acetyl oxygen atom, which is stabilized by two separate
oxyanion holes (OAH). OAH1 is formed by Nε2 of His348
and a conserved catalytic water molecule and is involved in
both steps of the catalytic cycle, while OAH2 is formed by
peptide backbone nitrogen atoms of Cys89 and Gly380 and is
only involved in the second step. The catalytic water is involved
in forming OAH1 stabilized by a hydrogen bond to Asn316, an
interaction shown to be essential for efficient catalysis.37
The Claisen condensation reaction catalyzed by ACATs is a
fundamental first step in the construction of carbon skeletal
frameworks, essential for energy storage and normal cellular
function in both prokaryotes and eukaryotes. There is also
evidence to suggest that ACATs play a central role in cellular
stress response. Bacterial ACAT catalyzes the first step in the
synthesis of polyhydroxyalkanoates (PHA), the major energy
and carbon storage molecules in many bacteria, important for
survival under conditions of nutrient limitation or stress.25,38
Bacterial ACAT activity is inhibited by CoA, a negative
feedback loop that is hypothesized to sense the metabolic state
Figure 1. Production of mevalonate in the cytosol, involving three
steps starting with the condensation of two molecules of acetyl-CoA
by acetoacetyl-CoA thiolase (ACAT). Mevalonate is the precursor for
all isoprenoids, including ergosterol, for which the chemical structure
is shown (bottom).
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of the cell.39 Soto et al.40 showed that expression of alfalfa
cytosolic ACAT is upregulated under conditions of cold or
salinity stress and also that overexpression of alfalfa cytosolic
ACAT in bacteria increased bacterial stress resistance.
Importantly, they showed that plant ACAT is also inhibited
by CoA. It therefore follows that isoprenoid production is
dependent on intracellular CoA concentrations. CoA is released
from the citric acid cycle under optimal growth conditions, but
this pathway is inhibited under conditions of oxidative
stress.39,41,42 It has therefore been suggested that, when CoA
concentrations are high (during optimal conditions), thiolase
activity is low and so the rate-limiting step is the third step in
the pathway, catalyzed by HMG-CoA reductase (Figure 1);
however, when CoA concentrations are low, thiolase activity is
high and the first step, catalyzed by cytosolic ACAT, becomes
the rate-limiting step.40 Thus, it has been proposed that, upon
encountering conditions of stress, many organisms alter their
metabolism from the TCA cycle to the PHA or mevalonate
pathways to provide highly reduced molecules for the
antioxidant response.40,43 In agreement with this, in eukaryotes,
consumption of Ac-CoA for lipogenesis is inhibited when the
intracellular ATP concentration is low (cAMP concentration is
high)44as would be the case when the citric acid cycle is
inhibited. Under these conditions, conversion of Ac-CoA to
malonyl-CoAthe rate-limiting step in lipogenesisis in-
hibited by AMP-activated protein kinase (AMPK). This would
increase the Ac-CoA concentration, increasing thiolase activity
in the synthetic direction. Indeed, inactivation of the AMPK
homologue in yeast resulted in decreased cytosolic Ac-CoA
concentrations and reduced overall fitness and resistance to
stress.45 All of these observations suggest that cytosolic ACAT
plays a key role in the cellular response to environmental stress
in both prokaryotes and eukaryotes.
In fungi, S. cerevisiae cytosolic ACAT is the product of a
single gene, ERG10, and is essential for viability in the absence
of exogenous mevalonate.46 Similarly, Candida tropicalis
cytosolic ACAT null mutant is auxotrophic for mevalonate.20
Unsurprisingly, ERG10 has also been shown to be essential for
growth in A. fumigatus,47 presenting cytosolic ACAT as a
potential target for novel antifungals. Despite its importance to
fungal cell growth and survival, there have been no structural
studies on a fungal ACAT until now. Here, we present the X-
ray crystal structure of cytosolic ACAT from A. fumigatus
(afCT), representing the first structure of a fungal type II
thiolase. To our surprise, afCT is more similar to human
mitochondrial ACAT (hT2) than to human cytosolic ACAT
(hCT) with regard to its primary sequence, substrate binding
pocket, accommodation of K+ and Cl− ions, and dependence
on K+ for activity. We have also investigated the enzyme’s
monovalent cation preference, with observations that challenge
the current paradigm regarding activation of T2 by K+ but not
Na+. Perhaps most importantly, our crystals have trapped
several different catalytic site configurations, including both
tetrahedral reaction intermediates of the thiolase reaction cycle,
allowing us to clearly interpret the reaction mechanism of this
enzyme for the first time in A. fumigatus, with implications for
all members of the thiolase family.
■ EXPERIMENTAL SECTION
Reagents. Dithiothreitol was purchased from Apollo
Scientific Ltd.; all other reagents were purchased from Sigma-
Aldrich. CoA and AcAc-CoA stock concentrations were
determined using Ellman’s test48 in 0.1 mM EDTA and 100
mM potassium phosphate pH 7.0. Protein purification columns
were purchased from Bio-Rad Laboratories Pty., Ltd.
Sequence Analysis. A phylogenetic tree was generated by
the “Simple Phylogeny” tool on the EMBL-EBI Web site using
a Clustal omega multiple sequence alignment of ACATs from a
range of species; the Interactive Tree of Life web-based tool49
was used to generate Figure S1. Peroxisomal target signal
sequences were predicted using the “Target Signal Predictor”
web-based program.50 Mitochondrial targeting peptide sequen-
ces were predicted using TargetP.51 A Clustal omega multiple
sequence alignment of select ACATs was uploaded to the
ESPript 3.0 server52 to produce Figure S2.
Figure 2. Catalytic cycle of ACAT. Residue numbers refer to A.
fumigatus cytosolic ACAT (afCT). Cys92, His354, Cys384, and
Gly386 of afCT correspond to Cys89, His348, Cys378, and Gly380 of
Z. ramigera cytosolic ACAT (bCT), respectively (see text). Arrows
indicate the progress of the reaction in the biosynthetic direction.
Oxyanion hole 1 (OAH1) is formed by the side chain of His354 and a
water molecule (referred to as Watcat1 herein); OAH2 is formed by
backbone N atoms of Cys92 and Gly386. Note that the thioester
oxygen atom of the tetrahedral intermediate formed at stage 3 is drawn
occupying OAH2. This is consistent with the structural evidence
contained herein and challenges the previous understanding of the
reaction mechanism, where it was thought that this tetrahedral
intermediate was stabilized by OAH1.36
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Protein Purification. The A. fumigatus cytosolic ACAT
(afCT) DNA sequence (NCBI accession: XM_742114.1) was
amplified from af293 cDNA (a generous gift from Dr. James
Fraser, University of Queensland), cloned into pET-57-DEST
via Gateway technology (Invitrogen), and recombinant afCT
was then overexpressed in a 3 L culture of E. coli BL21(λDE3)
overnight at 16 °C in shake flasks. Cells were then resuspended
in buffer (20 mM Tris pH 8.0, 0.5 M NaCl, 10% glycerol, 10
mM imidazole, 5 mM β-mercaptoethanol) and lysed by
mechanical disruption. Clarified cell lysate was subjected to
Ni2+-affinity chromatography twice, with a TEV digest in
between to remove the hexahistidine and NusA tags. afCT
protein was then purified to >95% (as assessed by SDS-PAGE)
by anion-exchange chromatography (using an ENrich Q 5 × 50
Column; Bio-Rad) and dialyzed overnight at 4 °C to 10 mM
NaCl, 1 mM DTT, and 10 mM Tris pH 8.0. Protein was
concentrated to approximately 8 mg/mL, flash-cooled in liquid
nitrogen, and stored at −80 °C.
Enzyme Assays. The activity of the purified enzyme in the
degradative direction was assessed in vitro at 25 °C by the Mg2+
assay essentially as described53 (Table 1). In the standard assay,
the reaction was started by the addition of 300 ng of afCT to 50
mM Tris-HCl pH 8.1, 20 mM MgCl2, 42 μM CoA, and 7.5 μM
AcAc-CoA. The initial decrease in absorbance at 303 nm was
then used to determine the rate of conversion of AcAc-CoA to
Ac-CoA. The extinction coefficient for the Mg2+-AcAc-CoA
enolate complex under these conditions was determined to be
16000 M−1 cm−1, similar to that previously reported.29,54 The
kcat and apparent Km values for AcAc-CoA were determined by
varying the concentration of AcAc-CoA from 0 to 38 μM. The
addition of either NaCl or KCl substantially increased the
reaction rate, with maximum activity achieved at approximately
100 mM KCl. Therefore, Km and kcat values were also
determined in the presence of 100 mM NaCl or 100 mM
KCl, with the addition of 200 or 100 ng of afCT, respectively,
to commence the reaction. To investigate the relationship
between monovalent cation (MVC) ionic radius and activation
of thiolase, chloride salts of other group I cations (Li, Rb, and
Cs), as well as ammonium, were also tested at 100 mM in the
standard assay, with the addition of 200 ng of afCT to
commence the reaction. All data were collected in triplicate,
unless otherwise indicated, and fit in GraphPad Prism (v7).
Protein Crystallization. All protein crystallization experi-
ments were performed at 16 °C using the vapor-diffusion
method. afCT apo crystals grew as plates in 20% polyethylene
glycol 3350 and 0.2 M KF to a maximum size of approximately
400 × 400 μm in 3 days in hanging drop format, with 4 μL
drops (2 μL of the protein sample plus 2 μL of the reservoir
solution) and 0.5 mL reservoir volume. In the same way,
crystals of afCT in complex with rubidium or cesium were
grown in 20% polyethylene glycol 3350 and 0.15 M RbCl or
20% polyethylene glycol 3350 and 0.15 M CsCl, respectively.
Crystals of afCT in complex with substrate were obtained by
the addition of 5 mM Ac-CoA to 8 mg/mL purified protein
immediately prior to setting up crystallization screens. Crystals
grew as approximately 200−300 μm rods after 3 days under
two different conditions: 23% polyethylene glycol 3350, 0.2 M
(NH4)2SO4, 0.1 M Bis-Tris pH 6.5, and 0.2 M KCl in hanging
drop format, with 2 μL drops (1 μL protein plus 1 μL
reservoir) and 0.5 mL reservoir volume; 25% polyethylene
glycol 3350, 0.2 M (NH4)2SO4, and 0.1 M Bis-Tris pH 6.5 in
sitting drop format, with 2 μL drops and 75 μL reservoir
volume.
Data Collection and Refinement. Data collection and
refinement statistics are presented in Table S1 in the
Supporting Information. Diffraction data were collected at
100 K at the Australian Synchrotron (MX1 beamline),55 using
mother liquor supplemented with 16% glycerol as cryopro-
tectant. Each data set consists of 360 frames collected at 1°
intervals with 1° oscillation. All data were collected at an X-ray
energy of 13000 eV, except for additional data sets collected at
8500 or 15350 eV for Cs+- and Rb+-containing crystals,
respectively, to maximize anomalous signals. Data sets were
processed using iMosflm,56 and structures were solved by
molecular replacement (MR) using phaserMR.57 Human
mitochondrial ACAT (hT2) (PDB code: 2IBY) was used as
the initial search model for MR; the first afCT structure was
then used as the search model for subsequent afCT structures.
Atomic coordinates were refined using phenix.refine58 with
iterative cycles of rebuilding in Coot,59 with anisotropic B-
factor refinement restricted to automatically defined torsion-
liberation-screw (TLS) groups60 and Rb+ and Cs+ ions
individually, where applicable. The final models have good
geometry statistics, with greater than 97% of peptide bonds
within the favored region of the Ramachandran plot. The only
Ramachandran outlier occurs at Val91 of all apo afCT
structures and subunit C of afCT+AcCoA+NH4
+. phenix.-
maps61 was used to calculate anomalous difference maps, using
data to 3.0 or 3.3 Å for afCT+Cs+anom and afCT+Rb
+
anom data
sets, respectively. Anomalous difference Fourier maps for Rb+
and Cs+ ions, in addition to isomorphous difference maps
derived from comparisons between data from crystals grown in
the presence of KCl and those grown in the presence of RbCl
or CsCl, were used to identify MVC binding sites. Atomic
coordinates and structure factors for all models have been
deposited in the RCSB Protein Data Bank (https://www.rcsb.
org/) with the accession codes 6ARF, 6ARG, 6ARL, 6ARR,
6ART, 6AQP, and 6ARE (see Table S1).
Molecular Docking. Docking of (2S)-methylacetoacetyl-
CoA and (2R)-methylacetoacetyl-CoA separately to the
substrate binding site of the D subunit of afCT + AcCoA +
K+ was performed manually, guided by the bound CoA
Table 1. Kinetic Parameters of A. fumigatus Cytosolic ACAT
(afCT) (This Study), Human Cytosolic ACAT (hCT),74 Rat
Liver Cytosolic ACAT (rCT),53 Human Mitochondrial
ACAT (hT2),30 and Z. ramigera Cytosolic ACAT (bCT)37
with Acetoacetyl-CoA as the Substrate
enzyme conditionsb Km (μM) kcat (s
−1) kcat/Km (s
−1 μM−1)
afCTa low saltc 42 ± 19 7 ± 2 0.17
100 mM NaCl 8 ± 2 33 ± 3 4.1
100 mM KCl 8 ± 2 100 ± 10 13
hCT74 low salt NDd ∼170 ND
rCT53 50 mM KCl 33 ND ND
hT230 40 mM NaCl 8 ± 2 7.4 ± 0.2 0.93
40 mM KCl 4 ± 0.6 21 ± 1 5.3
bCT37 low salt 24 ± 5 813 ± 125 34
aAll data for the current study were collected in triplicate, with
uncertainty expressed as standard error. bAll assays were done in the
thiolytic direction using the Mg2+ method under similar conditions,
but with various [salt]. cSalts included in the standard conditions for
the current study are 20 mM MgCl2, 50 mM Tris-HCl (pH 8.1), and
approximately 0.08 mM NaCl (from protein storage buffer). dNot
determined.
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molecule in the crystal structure. This was then followed by
global optimization of side chains and annealing of the peptide
backbone (20 iterations) using ICM Molsoft (v3.8-6a).62
Structure Visualization. Electrostatic surface representa-
tions were colored using electrostatic potential maps calculated
by the APBS tool63 in UCSF Chimera.64 Atomic charges were
first assigned using PDB 2PQR.65 All other molecular graphics
images were produced using PyMOL (v1.8.6.0) with all
stereoviews produced using cross-eye stereo mode.66 All
chemical diagrams were drawn using ChemDraw Ultra (v12.0).
■ RESULTS
Sequence Analysis. Protein sequences of animal, plant,
fungal, and bacterial thiolases were compared to provide insight
into the evolution and function of A. fumigatus thiolases. A
phylogenetic analysis can be found in Figure S1. A. fumigatus
has genome annotations for four putative KATs and two
putative ACATs.67 Previous comparative genomic analyses of
fungal species, along with Aspergillus nidulans gene deletion
studies, have shown that, while yeasts such as Saccharomyces
spp. and Candida spp. appear to have lost a mitochondrial β-
oxidation pathway, retaining only a peroxisomal pathway, most
fungi (including Aspergillus spp.) possess both mitochondrial
and peroxisomal pathways.68−70 Shen et al.70 showed that two
of the four KATs in the A. fumigatus genome are likely localized
to the mitochondria and the other two to the mitochondria or
peroxisome. Interestingly, all four KATs from A. fumigatus
cluster with plant, yeast, and human peroxisomal KATs, while
human and fly mitochondrial KATs cluster separately. This
suggests differences in the evolution of thiolase subcellular
localization between lower eukaryotes and higher eukaryotes
and is also consistent with the fact that fungi lack a
mitochondrial trifunctional enzyme (TFE) homologue, in-
volved in the type II β-oxidation pathway in higher
eukaryotes.70
ACATs from all species cluster together, separate from the
KATs. Both A. fumigatus ACAT sequences were analyzed for
predicted mitochondrial targeting peptide (mTP) and perox-
isomal targeting signal (PTS) sequences. One ACAT possesses
neither a predicted PTS nor mTP, and the other contains an N-
terminal mTP, consistent with their respective clustering with
yeast and plant cytosolic ACATs or human and fly
mitochondrial ACATs (Figure S1). A. fumigatus cytosolic
ACAT is homologous to S. cerevisiae cytosolic ACAT (NCBI
accession: NP_015297.1), the product of the ERG10 gene
(NCBI Gene ID: 856079).46 Intriguingly, in comparison to
ACATs from higher eukaryotes, cytosolic ACATs from plant
and fungi are more similar in terms of amino acid sequence to
mitochondrial ACATs than to cytosolic ACATs. The crystal
structure of human mitochondrial ACAT (hT2) revealed a K+
binding site that stabilizes the substrate binding pocket and the
catalytic histidine, providing a structural basis for its activation
by K+ ions.30 In addition, a Cl− ion was observed at the dimer
interface, also stabilizing active site residues. A. fumigatus
cytosolic ACATreferred to simply as cytosolic thiolase
(afCT) hereinhas a higher sequence identity to hT2
(49.6%) than it does to human cytosolic ACAT (hCT)
(44.3%). Upon closer inspection of the multiple sequence
alignment of fungal, human, and bacterial ACATs (Figure S2),
all the residues that differentiate hT2 from hCT (and bacterial
ACAT (bCT)) with regard to Cl− binding are conserved in
afCT (Lys90, Asn385, and Gly389 with residue numbers
referring to afCT), and most of the residues involved in
coordination of the K+ in hT2 are well conserved in afCT
(most notably, Tyr187). In addition, Phe325 of hT2, which has
been suggested to be a key determinant for the broader
substrate specificity of T2 over CT, is also conserved in afCT
(Phe294). Interestingly, most of these residues are also
conserved in yeast and A. thaliana cytosolic ACATs, consistent
with the clustering of ACATs from fungi and plant with hT2,
separately from hCT and bCT (Figure S1).
Enzyme Kinetics. Recombinant afCT was purified to
homogeneity and assessed for AcAc-CoA thiolase activity in the
degradative direction using the Mg2+ method (see the
Experimental Section). When the assay was performed in the
standard protein buffer (low [salt]), thiolase activity was very
low, with a turnover rate much lower than for mammalian and
bacterial ACATs, and a higher Km for AcAc-CoA (Table 1).
The high sequence similarity between afCT and hT2,
particularly in regions associated with ion binding, prompted
us to determine whether the catalytic activity of afCT is
modulated by K+ ions in the same way as for hT2. afCT activity
was markedly increased in the presence of KCl, with maximum
activity achieved at a KCl concentration of approximately 100
mM. Addition of 100 mM KCl caused a 5-fold decrease in the
Km value for AcAc-CoA and increased the kcat value by 14-fold.
afCT catalytic efficiency was also enhanced in the presence of
NaCl; addition of 100 mM NaCl resulted in the same decrease
in Km for AcAc-CoA and a 5-fold increase in kcat to a value
similar to the kcat value of hT2 in the presence of KCl, but still
3-fold lower than the kcat value of afCT in the presence of KCl
(Table 1). This was unexpected, as it is currently accepted that
T2 is activated by K+ but not Na+ ions.29,30 Addition of 100
mM choline chloride resulted in no increase in afCT activity in
the standard assay (Figure 3), showing that activation of afCT
Figure 3. Activation of afCT by monovalent cations (MVC). Addition
of 100 mM chloride salts of ammonium or all common alkali-metal
ions (100 mM) increased afCT activity relative to the case when no
additional salt was added to the standard assay conditions (see
Experimental Section; “low salt” denotes approximately 0.08 mM
NaCl from protein storage buffer). Addition of 100 mM choline
chloride resulted in no increase in enzyme activity, showing that
activation cannot be attributed to an increase in the Cl− concentration
or an increase in the ionic strength. The ionic radius of each MVC
(coordination number 6) is shown (values are from the Database of
Ionic Radii (http://abulafia.mt.ic.ac.uk/shannon/);96 NH4
+ ionic
radius is from Sidey97). Enzyme activity values are the mean of four
separate experiments (except for NH4Cl; n = 3). Error bars represent
standard error of the mean.
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by NaCl is specific and is not simply a result of increasing ionic
strength. It also rules out the possibility that activation is due to
Cl− ions rather than Na+ ions. The MVC preference of afCT
was investigated further by testing the effect of other
monovalent cations (MVC) on afCT activity. Addition of
chloride salts of all five common alkali-metal ions, or
ammonium, increased the thiolytic reaction rate to some
degree (Figure 3). Li+ and Na+ increased afCT activity 4-fold
and 8-fold, whereas K+, NH4
+, Rb+, and Cs+ all increased afCT
activity greater than 20-fold relative to low salt conditions, with
the greatest activity observed in the presence of K+ (34-fold
increase). This suggests that afCT possesses a site(s) that
accommodates MVCs with an optimal ionic radius of that of K+
(1.38 Å, where the coordination number is 6) but is
promiscuous for other MVCs also.
Thiolase Structure. X-ray crystal structures of afCT were
solved by molecular replacement using data to resolutions of
1.70−2.25 Å. Structures were solved in apo and liganded forms
in complexes with different MVCs. Data processing and
refinement statistics can be accessed in Table S1 in the
Supporting Information. Occupancy refinement was performed
for all ions, ligands, and residues with alternate conformations.
For liganded structures, atoms of CoA were defined as a group
separate from each individual acetyl group for refinement of
group occupancies. Residues 1−398 could be confidently
modeled into the electron density for all subunits in all
structures (including Gly0the remnant of the TEV protease
cleavage site), except for N-terminal residues 1−3 for subunits
A of afCT+K+, afCT+Rb+, and afCT+Cs+ and residues 211−
214 of the cationic loop for most subunits across all structures.
afCT crystallized in space group P21 in all cases, with four
protein molecules per asymmetric unit, representing the
biological tetramer (Figure 4A). The tetramer exhibits
noncrystallographic 222 symmetry and is comprised of two
tight dimers arranged head to head, with one dimer rotated
approximately 45° with respect to the other, such that residues
of the cationic loop (including basic residues Arg212 and
Lys214) point toward the CoA binding pocket of the opposing
subunit (Figure 4A). Each subunit is essentially identical
(RMSD across all α-carbons is 0.15−0.29 Å) and is composed
of an N-terminal domain (NTD), a loop domain, and a C-
terminal domain (CTD) (Figure S2 and Figure 4B). Residues
of Nβ2 and Nα2, including their extended connecting loop
(Asn59 to Asn68), along with Nβ3 and Nα3 of the NTD,
contribute most of the interface between tight dimers. Lβ1 and
Lα1 of the loop domain and Cβ1 of the CTD make up the
remaining interface surface. The interface surface areas between
directly opposite subunits (i.e., A and C or B and D) and
diagonally opposite subunits (i.e., A and D or B and C) are
approximately 344 and 758 Å2, respectively. This is significantly
less than the dimer interface surface area (i.e., between A and B
or C and D), which is approximately 2494 Å2. For all afCT
structures, the average B factor of one dimer is approximately
double that of the opposing dimer (see Table S1), indicating
that the weaker tetramerization interaction allows for a degree
of flexibility between the two tight dimers. This has been
observed previously for other tetrameric thiolases,24,36,71 but its
functional significance remains unknown.
The cagelike tetramerization motif is typical of biosynthetic
thiolases and has been described in detail previously.24 It is
composed of residues His127 to Met148 of the loop domain
(Figure S2). This loop extends away from the subunit core,
allowing Tyr138, at the distal end of the loop, to form part of
the entrance to the pantetheine binding tunnel leading to the
thiolase active site of the diagonally opposite subunit and fill a
hydrophobic pocket on its surface formed by Ile147, Met148,
Leu152, and Leu255. Lβ1 (residues 127−129) and Lβ1′
(residues 141−144) form an antiparallel β-sheet that is partially
continuous with the equivalent β-sheet of both its dimeric
partner and of the subunit diagonally opposite, such that a small
Figure 4. Cartoon representations of the three-dimensional structure of afCT showing CoA (cyan sticks), K+ ion (purple spheres), and Cl− ion
(green spheres) binding sites: (A) tetrameric arrangement, with each subunit colored differently; (B) subunit tertiary structure, with α-helices (solid
cylinders) and β-strands (arrows) labeled according to Modis and Wierenga24 and the NTD, loop domain, and CTD colored red, green, and blue,
respectively. Other subunits are colored white.
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distorted β-barrel is formed. Twelve leucine residues, Leu129,
Leu132, and Leu143 from each subunit, point inwardly to form
the hydrophobic core of the cage. Four salt bridges formed
between Arg133 and Asp145 of dimeric partners at the top and
bottom of the cage stabilize the structure. Also contained within
the loop domain is the cationic loop (residues 203−221),
which extends into the intertetramer space toward the substrate
binding site of the opposing subunit (Figure 4). A highly
conserved arginine at the N-terminus (Arg14) appears to be
responsible for anchoring the cationic loop to the NTD via
electrostatic interactions with highly conserved acidic residues
at either end of the cationic loop sequence (Glu202 and
Asp222) (see Figure S2). The importance of these interactions
was highlighted by a deletion mutation of the residue preceding
Asp222 identified in hT2 from a T2-deficient patient.31
The NTD and CTD share a βαβαβαββ topology, with the
loop domain inserted between the final two β-strands of the
NTD, a secondary structural topology well conserved among
thiolases.19,24 Each terminal domain is composed of a central
mixed β-sheet, flanked by helices on either side. These domains
are rotated approximately 180° with respect to one another and
pack face to face such that Nα3 and Cα3 are at the center,
sandwiched between the β-sheets (Figure 4B).
Comparison to ACATs from Other Species. The afCT
monomer has a tertiary structure very similar to those of hCT,
hT2, and Z. ramigera ACAT (bCT), with average RMSD values
across all C-alphas of 1.20−1.34 Å, respectively (Figure S3A).
Superposition of dimers gives similar RMSD values (1.20−1.37
Å). Inclusion of the whole tetramer in this superposition
demonstrates a degree of variation regarding the relative
position of the second dimer (Figure S3B). This signifies a
departure from exact 222 symmetry, consistent with the flexible
nature of the tetramerization motif, and has been discussed in
detail previously.71
The main differences between afCT and the other cytosolic
ACATs (hCT and bCT) concern residues at the dimerization
interface and substrate binding pocket, corresponding to
regions that differentiate hCT from hT2, and have been
shown to be involved in binding of K+ and Cl− ions in hT2.30
Binding of Monovalent Cations near the Substrate
Binding Pocket. To probe for MVC binding sites, crystals of
afCT were grown in the presence of K+, Rb+, or Cs+ ions.
Anomalous difference Fourier maps for Rb+ and Cs+ ions
(Figure S4), in addition to isomorphous difference maps
derived from comparisons between data from crystals grown in
KCl and those grown in RbCl or CsCl, were used to identify
MVC binding sites. Average anomalous difference map peak
heights are given in Table 2 (Tables S2 and S3 give anomalous
and Fo − Fo peak heights for all Cs+ and Rb+ sites, respectively).
Thirteen binding sites were identified for Rb+ and 15 for Cs+.
All of the Rb+ binding sites correspond to Cs+ binding sites,
with the two extra Cs+ ions present at low occupancy
(approximately 50%) at sites distant from the active site,
implying that they are likely to be crystallization artifacts. Of the
13 MVC sites common to the Rb+ and Cs+ structures, one of
these is part of a crystal contact, consistently present at low
occupancy (approximately 50%), indicating that it is also likely
to be a crystallization artifact.
On the basis of these results, 13 K+ ions were modeled at the
sites common to the Rb+ and Cs+ structures, in both the apo
(afCT+K+) and liganded (afCT+AcCoA+K+) structures, for
which the crystallization conditions contained K+. The K+ ions
are in the same position in each subunit of the tetramer and
form similar coordination bonds. For the latter structure, K+
modeled into MVC binding sites refined to occupancies of
between 43 and 97%. The crystallization conditions for this
structure contained equal concentrations of K+ and NH4
+ ions;
therefore, given the high activity of afCT observed in the
presence of K+ or NH4
+ and their similar ionic radii (1.38 and
1.48 Å, respectively), it is likely that they would compete for the
same binding sites, explaining the lower occupancy of K+ at
MVC sites in this structure (Table S4). In addition, a structure
of liganded afCT in the presence of only NH4
+ (afCT+Ac-CoA
+NH4
+) was obtained, for which NH4
+ ions were modeled in all
cation binding sites for which there was appropriate electron
density (10 sites). Disregarding the MVC site that is part of a
crystal contact, each subunit has the same three MVC binding
sites (Figure 4). Two are positioned at the C-terminal ends of
separate surface-exposed helices and coordinated by three or
four water molecules and three carbonyl oxygens of adjacent
residues within surface-exposed loops. The other is situated
near the adenosine binding pocket (Figure 5). On the basis of
proximity to the substrate binding pocket, coordination by
protein atoms, and average occupancy and B factors for Cs+,
Rb+, K+, and NH4
+ in all structures (see Tables S2−S4), the last
of these three binding sites is most likely to be relevant to the
modulation of thiolase activity in vivo.
This site is homologous to the K+ binding site of hT2,30 with
approximate octahedral coordination by six oxygen atoms. The
K+ is coordinated by one water molecule (WatMVC; 2.7 Å) and
five protein atoms: the backbone carbonyl oxygens of Ala249
(3.3 Å), Pro250 (2.7 Å), Ser252 (2.6 Å), and Val350 (2.8 Å)
along with the hydroxyl oxygen of Tyr187 (2.8 Å) (Figure 5).
Ion coordination at this site is essentially identical in liganded
and apo afCT structures, aside from a small shift in WatMVC
(∼0.7 Å), facilitating the formation of a hydrogen bond (3.0 Å)
to the adenine base (N7) of CoA in the liganded structure.
Similarly, K+ coordinations at this site are essentially identical
for afCT and hT2, with the only significant difference being a
0.6 Å shift of the coordinated water closer to the position of the
bound CoA molecule, caused by the substitution of Pro254
(afCT) for Thr285 (hT2) (Figure S5). It has been previously
suggested that, for hT2, coordination of a K+ ion at this
position helps to rigidify the adenine binding pocket and
stabilize the Cβ3−Cα3 loop, which contains the catalytic
histidine.30 Ala249, Pro250, Ser252, and Tyr187 of afCT all
make direct contact with bound CoA substrate and are
contained within regions of the loop domain that contribute
most of the residues involved in substrate binding. Val350 is
part of a short helix (Cα2′) immediately preceding the loop
containing the catalytic histidine, His354 (Figure 5).
The mean length of coordination bonds (across all subunits)
for K+, Rb+, and Cs+ ions bound at this position are 2.86, 2.96,
and 3.12 Å, respectively. These values correspond very well to
mean six-coordinate M+−O2− complex bond lengths deter-
mined previously of 2.828, 2.989, and 3.124 Å, respectively.72
Table 2. Average Rb and Cs Anomalous Peak Heights
(RMSD Units, σ) for Data Collected at Different
Wavelengths
element 8500 eV data 13000 eV data 15350 eV data
Rb NAa 4.5 13.2
Cs 23.5 11.9 NA
aNot applicable.
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Superposition of these three apo structures shows that
substitution of K+ for Rb+ or Cs+ has no effect on the position
of any of the coordinating atoms except for WatMVC, which
shifts away from the MVC as the radius of the ion increases
(Figure S6). This increases the distance between the relative
positions of WatMVC in apo and liganded structures. For
example, in the Cs+-bound structure, WatMVC is shifted 2.0 Å
from the position it occupies when it forms a hydrogen bond
with the adenine (N7) in the liganded structure. K+ sits in the
same plane as the coordinating oxygens of Tyr187, Ala249,
Ser252, and Val350; however, due to their size, both Rb+ and
Cs+ shift out of this plane, such that Cs+ is positioned 0.5 Å
closer to the substrate binding site. This less ideal coordination
geometry, accompanied by the shift of WatMVC away from its
substrate-interacting position, provides a molecular explanation
for why K+ is better able to stimulate afCT activity in
comparison to these larger MVCs. Conversely, the planar
geometry of K+ with four coordinating ligands suggests that the
site is larger than ideal for smaller MVCs; Octahedral Li+−O2−
and Na+−O2− complexes have average bond lengths of 2.178
and 2.441 Å, respectively.72 Therefore, although the MVC site
of afCT can accommodate all common alkali-metal ions, its size
is ideal for coordination of K+.
Calculation of an electrostatic potential surface map shows a
strong negative charge at the MVC binding pocket, largely
contributed by Glu224 (Figure S7A). In the absence of MVCs,
electrostatic repulsion would exist between this negatively
charged region and the pyrophosphate of CoA. MVC binding
would increase the positive electrostatic potential of the
adenosine binding pocket, increasing its affinity for the
negatively charged phosphate groups of CoA. For hCT, a
water molecule occupies a position similar to the K+ of afCT
and hT2 (Figure S7C). This water molecule is coordinated by
only five oxygens: three backbone carbonyl oxygens (corre-
sponding to Ala249, Ser252, and Val350 of afCT) and two
other waters. The major differences between afCT and hCT
regarding this pocket are the substitution of Tyr187 for Gln186
and Glu224 for Phe221. The significance of Tyr187, which
provides a K+ coordinating oxygen, is highlighted by its
conservation across fungal ACATs and hT2 (Figure S2). A
glutamine is present at this position for both hCT and bCT,
which is too far from the K+ site to donate a coordinating
oxygen. Glu224, which carries the closest negative charge to the
Figure 5. Stereoview of the monovalent cation binding site adjacent to the substrate binding pocket of afCT. The K+ (purple sphere) is coordinated
by adenosine pocket residues and Val350 (marked with asterisks), which is in the loop preceding the catalytic histidine (His354). Coordination bond
(red dashes) lengths are shown (Å). apo (light green) and liganded afCT (dark green) are superposed, showing that the positions of the K+ and
surrounding residues are unaltered by ligand binding, but WatMVC (red sphere) shifts closer to CoA (cyan) in order to mediate hydrogen bonding
from K+ to CoA(N7A) (black dashes).
Figure 6. Stereoview of the Cl− binding site at the dimerization interface of afCT with key residues labeled. Catalytic residues are labeled in bold
type. Main chain atoms are hidden for all residues except Gly386 and Gly389. Opposing subunits of the tight dimer are colored different shades of
green. The Cl− ion (green sphere) is coordinated by three protein atoms and two waters (red spheres) near the thiolase catalytic site. Lengths of
coordination bonds (red dashes) and water-mediated hydrogen bonds (black dashes) to residues adjacent to the catalytic site are displayed in Å.
WatCL1, WatCL2, and WatCL3 are numbered. An anomalous difference map calculated from data collected at 8500 eV is shown for the Cl
− as a blue
mesh contoured at 3σ. Residues 85−86 were excluded from the foreground for clarity.
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K+ (4.4 Å), is conserved in hT2 but substituted for a
phenylalanine or tyrosine in hCT or bCT, respectively,
decreasing the negative electrostatic potential of the pocket
(Figure S7B).
Chloride Ion Binding Site. Residues that were identified to
make contacts with the Cl− ion in hT2 are conserved in afCT
(Figure S2). This prompted us to model Cl− ions at these sites
for afCT. In addition, small anomalous difference peaks for data
collected at 8500 eV (Table S1, afCT+Cs+anom data set)
provided further validation that these Cl− ions were modeled
correctly (Figure 6). There are two identical Cl− binding sites
at each dimer interface (one for every subunit), within
approximately 10 Å of the thiolase active site (Figure 6). The
Cl− is positioned between two basic residuesArg71 from one
monomer, and Lys90 from the dimeric partnerand is
coordinated by five atoms, Arg71 (Nε; 3.5 Å), Asn385 (Nδ2;
3.2 Å), Gly389 (N; 3.3 Å), WatCL1 (2.6 Å), and WatCL2 (2.7 Å),
consistent with a recent survey of PDB structures indicating
that 5 is the preferred coordination number for Cl− within
proteins.73 Even though it is not involved in catalysis directly,
this Cl− stabilizes the catalytic site via both direct and water-
mediated hydrogen bonds to catalytic residues and residues
adjacent. Aside from forming a coordination bond with
Asn385which is flanked on either side by catalytic residues
Cys384 and Gly386the Cl− interacts with Gly386(O) via
WatCL1, and Lys90(Nζ) via WatCL2 and WatCL3. Comparison
with the structure of hT2 shows that Ala102 and P118 of hT2
are substituted for Asn68 and Ile84 in afCT, respectively
(Figure S8A). The effect of these two substitutions is to widen
the afCT Cl− binding pocket slightly, allowing one extra water
molecule in comparison to hT2 and shifting the Cl− by 1.6 Å,
so that it is closer to Arg71 and the Cβ4−Cβ5 active site loop
(containing Cys384, Asn385, and Gly386). In addition, the
afCT site much more solvent accessible than the hT2 site. The
Cl− is connected to bulk solvent via a chain of waters leading to
Gly156 on the surface of the protein. For hT2, this residue is
Tyr188, which disrupts this chain of waters. Interestingly, of all
the ACAT sequences compared in Figure S2, afCT is the only
one without an aromatic residue at this position.
Regarding the region corresponding to the Cl− binding site,
the dimerization interfaces of hCT and bCT are much more
hydrophobic in comparison to afCT and hT2. Although Arg71
is highly conserved, Lys90, Asn385, and Gly389 are all
substituted for hydrophobic residues, Met90, Ile384, and
Met388 in hCT, with the last of these occupying the space of
the Cl− and WatCL2 in the afCT structure (Figure S8B).
Mode of CoA Binding. In addition to forming the
tetramerization motif, the loop domain contains most of the
residues that are important for substrate binding. Average B
factors for protein atoms of liganded structures are much lower
than for the apo structures (Table S1), indicating that substrate
binding stabilizes the polypeptide. The CoA binding site can be
conceptually divided into two pockets: the 3′-phosphoadeno-
sine binding pocket and the pantetheine binding pocket. Both
pockets open into the intertetramer space. Loop domain
residues 224−237 and 249 to 250, along with Tyr187, form the
3′-phosphoadenosine binding pocket (Figure 7A). Of note are
five basic residues within 10 Å of the phosphate groups of CoA:
Lys232 and Lys237 of the subunit in question, Lys137 of the
diagonally opposite subunit, and Arg212 and Lys214 of the
cationic loop (residues 203−221), which extend into the
intertetramer space from the opposing subunit (note that the
side chains of Arg212 and Lys214 are unstructured in almost all
structures; however, the proximity of the peptide backbone
affords the possibility that they interact with the 3′-phosphate
of CoA). Similar positioning of basic residues in tetrameric
ACATs from other species has been suggested to facilitate
electrostatic interactions with CoA to aid substrate capture.24,74
One of these basic residuesLys232forms a salt bridge with
the 3′-phosphate of CoA. Despite possessing numerous
hydrogen bond donors and acceptors, there are only three
other hydrogen bonds made directly between CoA and protein
atoms: Tyr187 (OH) to adenosine (N6) (2.9 Å), Asn229 (N)
to adenosine (N1) (3.2 Å), and Ser253 (O) to pantetheine
(N8) (2.8 Å) (Figure 7B). All other hydrogen bonds are
mediated by surrounding water molecules, including the
WatMVC-mediated interaction with K
+, mentioned previously.
A similar lack of direct bonding has been noted previously for
bCT, which possesses only one direct hydrogen bond between
protein and substrate.24 All residues that interact with bound
substrate are from the same subunit, with the exception of
Tyr138, which protrudes from the tetramerization loop of the
diagonally opposite subunit, forming part of the entrance of the
pantetheine binding tunnel and participating in a water-
mediated hydrogen bond with pantetheine (O9) (Figure 7).
Interestingly, of the ACAT sequences compared in Figure S2,
this tyrosine is only conserved in hT2. Ala249 and Pro250,
which both provide oxygen atoms for coordination of the K+,
Figure 7. Mode of CoA binding. (A) Stereoview of CoA substrate bound to afCT. Key residues are shown as sticks. A 2mFo-DFc composite omit
map (blue mesh) contoured at 1.0 σ is shown for the CoA molecule. The K+ is represented by a purple sphere. (B) Two-dimensional schematic of
interactions between afCT and bound CoA. Hydrogen bonds are indicated by dashed lines, and van der Waals contacts are indicated by solid curved
lines. Waters involved in water-mediated hydrogen bonds are shown as black circles. All interacting residues are from the same subunit, except for
Tyr138 (marked with an asterisk), which protrudes for the tetramerization loop of the diagonally opposite subunit.
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contact the adenosine of CoA. The pyrophosphate is less than
3.5 Å from Ala249, such that the CoA molecule bends around
Ala249 at this point. Pro250 packs against the adenine rings
(<3.7 Å). Leu233 and Ile236 also contribute van der Waals
interactions with the adenine and ribose groups, respectively.
For hT2, similar van der Waals interactions are facilitated by
corresponding residues: Ala280, Ala281, Val264, and Leu267.
Residues 227−230 of the Lβ3−Lα3 loop, which wrap around
the bound adenine in afCT, are shifted approximately 2 Å away
from the interdimer space relative to the same region of hT2
(Figure S9A). This is largely caused by the substitution of
Phe261 in hT2 for Pro230 in afCT and results in a similar small
shift in the adenosine (∼1 Å) deeper into the protein. Despite
this, the overall structure of the adenosine binding pocket and
key interactions are highly conserved between afCT and hT2.
Unlike hT2, the adenine binding pocket is much less
conserved between afCT and other cytosolic ACATs. hCT and
bCT contain a small uncharged residue (Ala230 of hCT) at the
position corresponding to Lys232 of afCT and therefore lack
this salt bridge to the 3′-phosphate of the adenosine. Both also
contain one extra residue in the Lβ3−Lα3 loop (220−229 of
afCT)His224 of hCT and His221 of bCTwhich packs
down against the surface of the protein away from the bound
CoA, resulting in a significant rearrangement of this loop
relative to the afCT structure (Figure S9B). This allows the
preceding arginine (hCT Arg223, bCT Arg220) to stack against
the adenine rings of CoAan interaction that is absent from
both afCT and hT2 structures.
Aside from Ser252 and Ser253, the pantetheine pocket
leading to the catalytic site is lined exclusively by hydrophobic
residues: Met122, Leu152, Met161, Gly162, Ala239, Phe240,
Pro254, and Leu255 of the loop domain and Phe294, Ala324,
Phe325, and Ile356 of the CTD. These residues are highly
conserved across fungal, bacterial, human, and plant ACATs
(Figure S2), with the notable exceptions of Ala239, Pro254, and
Phe294. In addition, Leu160, which is positioned approximately
7 Å away from the pantetheine at the tunnel entrance, is
substituted for a histidine in hT2 (His192), hCT (His159), and
bCT (His156), which contacts the pantetheine of the bound
substrate (Figure S9A,B). The area occupied by this histidine is
replaced by a water molecule in afCT, mediating a hydrogen-
bonding interaction between pantetheine (O5) and Gly162
(N) (Figure 7B). Ala239 is conserved for bCT but substituted
for Tyr237 in hCT (Figure S9B). This tyrosine provides more
surface area for van der Waals interaction with the pantetheine
moiety but does not appear to significantly alter the relative
position of the bound substrate. Pro254 is near the K+ binding
site and is substituted for a glycine in both hCT and bCT,
probably to allow for the extra bulk of the aromatic residue that
occupies the space of Glu224 near the K+ site mentioned
earlier.
Accommodation of 2-Methylacetoacetyl-CoA by
afCT. In addition to catalyzing the synthesis and degradation
of AcAc-CoA, T2 catalyzes the last reaction in the isoleucine
degradation pathway, where 2-methylacetoacetyl-CoA is
converted to propionyl-CoA and Ac-CoA in the mitochon-
dria.27 Human T2 deficiency results in accumulation of
isoleucine degradation metabolites. Substitution of afCT
Phe294 for methionine in both hCT and bCT is the only
major difference between these enzymes at their catalytic sites.
Phe294 is conserved in hT2 (Phe325) and has been linked to
the broader substrate specificity of hT2 in comparison to hCT.
The Phe325-Pro326 dipeptide of hT2 expands the catalytic
cavity relative to hCT (for which the corresponding sequence is
Met293-Gly294), allowing it to accommodate the larger
branched chain substrate, 2-methylacetoacetyl-CoA.30 bCT
has been shown to have no activity toward 2-methylacetoace-
tyl-CoA.25 Strikingly, Phe294 is conserved across all ACAT
sequences compared in Figure S2, except for hCT and bCT, for
which it is substituted for a methionine. Specifically, the Phe-
Pro dipeptide is conserved in both mitochondrial ACATs (A.
fumigatus mACAT and hT2); both hCT and bCT contain Met-
Gly, and all other cytosolic ACATs contain a Phe-Thr dipeptide
at this position. In addition, afCT Asn332 is conserved across
all these ACATs except for hCT and bCT, which both contain
an aliphatic residue at this position (Figure S2). The Nδ2 atom
of Asn332 (hT2 Asn363) forms a hydrogen bond (2.9 Å) with
the backbone O atom of Thr295 (hT2 Pro326) and is possibly
important for anchoring the preceding phenylalanine to allow
room for the extra methyl group of this branched chain
substrate.
Figure 8. afCT catalytic site shown in stereoview. Superposition of afCT liganded (dark green) and apo (light green) structures shows that ligand
binding induces changes in the side chain conformations of Cys92 and Met161. Cys92 is acetylated in the liganded structure. Key residues are
labeled and key waters represented by spheres: colored red in the liganded structure and light green in the apo structure. Positions of Watcat1, Watcat2,
and Watcat3 are labeled 1, 2, and 3. Watcat1 shifts into OAH1 in the absence of an occupying acetyl group (i.e., from Ac-CoA); this position is labeled
0. Asterisks indicate alternate conformations for waters modeled in the liganded structure (see text). OAHs 1 and 2 are indicated in the liganded
structure by hydrogen bonds (red dashes; measurements are in Å) to Watcat1 (position 0) and Ac-Cys92, respectively. When it occupies position 1,
Watcat1 is stabilized by a hydrogen bond from Asn322 (black dashes).
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A simple molecular docking experiment suggests that afCT
can indeed accommodate 2-methylacetoacetyl-CoA, requiring
only a minor (20°) rotation of Phe294 away from substrate.
This places Phe294 in a position almost identical with that
observed for the corresponding phenylalanine (Phe325) in the
structure of hT2 in complex with CoA (PDB: 2IBY).30 The
extra methyl group is in van der Waals contact with the phenyl
ring of Phe294, and the thioester and 3-keto O atoms are
positioned in OAHs 1 and 2, respectively (Figure S10). This is
consistent with the results of a similar docking experiment
performed for hT2.30 These results potentially implicate afCT
in isoleucine metabolism; however, further investigation is
needed to confirm this and clarify its biological significance.
Catalytic Site. The catalytic residuesCys92, His354,
Cys384 and Gly386are contained in three loops, Nβ3-Nα3,
Cβ3-Cα3, and Cβ4-Cβ5, in the interior of each subunit (Figure
8). Conserved glycines (95, 357, and 360) of the two central
helices (Nα3 and Cα3) allow them to pack very close to one
another, positioning the catalytic site at the N-terminal ends of
two long helices, taking advantage of helix dipoles to decrease
the pKa of active site cysteines and assist with stabilization of
negatively charged species formed during the thiolase catalytic
cycle (Figure 2).75 In addition, Asn322, which is part of the
signature NEAF motif of thiolases located in the Cβ2−Cα2
loop (corresponding to Asn316 of bCT), stabilizes a catalytic
water (Watcat1) via a hydrogen bond. Watcat1 and His354 (Nε2)
form OAH1. The peptide backbone nitrogens of Cys92 and
Gly386 form OAH2. Cys92, which serves as the nucleophile in
the first acetyl transfer (Figure 2, stage 2), is contained within a
310-helix at the N-terminal end of Nα3, a strained conformation
observed previously for other thiolases,36,74 stabilized by
hydrogen bonds between Ser94 (OH) and the peptide
backbone of Lys90 and Val91. Val91 is the only Ramachandran
outlier in any of the structures. It is only present consistently in
afCT apo structures, suggesting that this strained peptide
conformation is “relieved” during the thiolase reaction cycle.
For both liganded structures (afCT+AcCoA+K+ and afCT
+AcCoA+NH4
+), CoA could be modeled into all active sites
with an occupancy of 76% or greater. Ligand binding induces
no large conformational changes in protein structure; RMSD
values between apo and liganded afCT are 0.24 or 0.67 Å across
Cαs of a single subunit or the entire tetramer, respectively. The
only notable changes occur at the active site, regarding the side
chain conformations of Met161 and Cys92 (Figure 8). Sδ of
Met161 is shifted 2.6 Å away from the active site center upon
ligand binding to allow room for the pantetheine of CoA.
Binding of CoA also induces a small shift in the position of
Cys92 (Sγ), 1.4 Å toward the side chain of His354. It is
postulated that this shift facilitates the deprotonation of Cys92
(Sγ) by His354 (Nε2), allowing Cys92 to act as the nucleophile
in the first acetyl transfer.35 Once bound, the sulfur of CoA is
then positioned only 4.1 Å away from Met161 (Sδ), 4.0 Å from
Cys92 (Sγ), and 5.4 Å from Cys384 (Sγ). Positioning of CoA
(S) near sulfur atoms at the thiolase active site is important for
high affinity binding of substrate.76
Figure 9. Stages 2 and 4 of the thiolase reaction cycle trapped in afCT crystal structures. Images are shown in stereoview. Polder maps (blue mesh)
are shown for the Cys92 side chain, the sulfur and adjacent carbon of CoA, acetyl groups, and waters in position 0, 1, or 2 of the water trail. Maps are
contoured at 3.0σ. Waters with alternate conformations are marked with asterisks. Hydrogen bonds of OAHs are indicated by red dashes. The
hydrogen bond from Asn322 stabilizing Watcat1 is colored black. Units of measurement are Å. (A) Catalytic site of afCT+AcCoA+K
+ subunit D
demonstrates the conformation of Ac-Cys92 occupying OAH2 with CoA bound. Watcat1 partially occupies OAH1. (B) Catalytic site of afCT+AcCoA
+K+ subunit C shows the position of the acetyl group both before and after the first acetyl-transfer reaction as alternate conformations of Ac-CoA
(occupying OAH1) and Ac-Cys92 (occupying OAH2). His354 (foreground) is shown as transparent sticks.
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Approximately 15 ordered water molecules are displaced by
substrate binding; 9 from the adenosine pocket and 6 from the
pantetheine pocket. In addition, there is a chain of 3 water
molecules that begins at the active site and penetrates further
into the interior of the protein. This includes Watcat1, which,
along with His354 (Nε2), forms OAH1. In contrast, for both
hCT and bCT this chain of waters includes approximately 10
waters, forming a hydrogen-bonding network that extends
through a narrow cavity between Cβ2 and Cα2 through to
solvent at the back side of the protein.35,74 It has been
suggested that this water network may modulate the electro-
static environment of the catalytic site, promoting catalysis and
may explain the lower catalytic efficiency of T2 (which lacks
this network) in comparison to hCT and bCT.37 In both afCT
and hT2 structures, only the first two or three waters of the
network are present, closest to the catalytic site. Comparison of
the sequences and crystal structures of afCT and hT2 with hCT
and bCT indicates that substitution of several residues within
Cα2 may account for the narrowing of this cavity, disallowing
the presence of water molecules (Figure S11). Ser326, Val327,
and Leu330 of afCT pack against Lα1 and Lα2 and are all
larger than the equivalent residues of hCT, which are all alanine
residues. These three Cα2 residues are on the side of the helix
opposite to Cβ2, shifting the helix closer to Cβ2. Another Cα2
residue, Asn332, is conserved in all ACATs except hCT and
bCT (where it is substituted for an aliphatic residue; Figure S2)
and forms hydrogen bonds with backbone atoms of Cα1
(Thr295 and Ala299), also drawing Cα2 closer to Cβ2 (Figure
S11). In addition, Tyr182 occupies what would be the entrance
to the cavity at the surface of the protein.
Although both liganded structures share similar global folds
(Cα-RMSD of tetramers: 0.66 Å), notable differences in the
electron density present in the catalytic sites of the enzyme
prompted us to model the atomic composition at each active
site of the tetramer in both structures separately using Polder
maps to both reduce model bias and enhance weak density that
may be masked by bulk solvent.77 The observed density
indicates that Cys92 is modified such that OAH2 is occupied,
and at least one acetyl group is present in every active site.
Given that CoA occupies every active site, and there is density
for at least one acetyl group, there are seven different
configurations of atoms possible, corresponding to stages 2−8
of the reaction cycle shown in Figure 2. The electron density
suggests that we have trapped multiple reaction intermediates.
For five of the eight active sites, CoA and an acetylated
Cys92 (Ac-Cys92) corresponded to the electron density
(Figure 9A), with the occupancy of the acetyl group between
63 and 76%, in agreement with the occupancy of the
corresponding bound CoA molecule. OAH2 is occupied by
the acetyl carbonyl oxygen, with hydrogen bonds to Cys92 (N)
(2.9 Å) and Gly386 (N) (2.4 Å). This represents stage 4 of the
reaction cycle, after acetyl transfer from the first Ac-CoA to
Cys92. For biosynthetic thiolase, the rate-limiting steps in both
biosynthetic and degradative directions are those involving
Figure 10. Both tetrahedral reaction intermediates of the thiolase reaction cycle trapped in afCT crystal structures. Images are shown in stereoview.
Polder maps (blue mesh) are shown for the Cys92 side chain, the sulfur and adjacent carbon of CoA, acetyl groups, and waters in position 1 or 2 of
the water trail. Maps are contoured at 3.0σ and 2.5σ for (A) and (B), respectively. The hydrogen bond from Asn322 stabilizing Watcat1 is colored
black. Units of measurement are Å. (A) Catalytic site of afCT+AcCoA+NH4
+ subunit D shows the covalent tetrahedral intermediate formed during
the first acetyl-transfer step, stabilized by OAH2. Dashed sticks indicate bonds that are formed or broken during this stage of the thiolase reaction
cycle. (B) Catalytic site of afCT+AcCoA+NH4
+ subunit C shows the covalent tetrahedral intermediate formed during the second acetyl-transfer step.
The first acetyl group is stabilized by OAH2, and the second (Ac-CoA) occupies OAH1. Superposition with AcAc-CoA bound to bCT (Cys98Ala)
(narrow salmon sticks; PDB: 1M1O) shows that the intermediate is positioned in a way similar to that for AcAc-CoA, as expected.
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deacetylation of the active site cysteine;35 therefore, it is
unsurprising that this is the most commonly observed active
site configuration. In all these cases there is additional density
observed in OAH1. This space is occupied by a water molecule
in the apo structure (afCT+K+), in which the second water is
absent from the water chain that begins with Watcat1 (Figure 8).
This suggests that Watcat1 shifts forward into OAH1,
accompanied by a shift in the adjacent water (Watcat2) from
position 2 in the water chain to the original position of Watcat1
(position 1), leaving position 2 vacant, as observed for the apo
structure. To reflect this, for the liganded structure, a water
molecule was modeled with two alternate conformations: (1)
occupying position 2 of the water chain (Watcat2) or (2)
occupying OAH1 (Figures 8 and 9A). Subsequent refinement
resulted in occupancies of approximately 50% at both positions.
The position of the thioester O atom of Ac-Cys92 (occupying
OAH2) that we observe conflicts with previous structural
studies on bCT.24,35,36 This is discussed further in the
subsequent section.
Additional electron density present between the sulfur atoms
of CoA and Cys92 in one of the afCT+AcCoA+K+ active sites
promoted us to model a second acetyl group, as Ac-CoA
(Figure 9B). This clashed with Ac-Cys92 and therefore was
modeled as an alternate conformation, corresponding simulta-
neously to stages 2 and 4 of the reaction cycle (Figure 2)
immediately before and after the first acetyl transfer. For stage
2, the thioester O of Ac-CoA occupies OAH1, with hydrogen
bonds to Watcat1 (2.4 Å) and His354 (Nε2) (2.6 Å). This
stabilizes the partial negative charge present on this oxygen,
increasing the electrophilicity of the adjacent C1 atom. Cys92
(Sγ) is very close to C1 of the acetyl group (2.3 Å), poised for
nucleophilic attack. For stage 4, the carbonyl O of Ac-Cys92
occupies OAH2 in the same way as for the active sites with
CoA and Ac-Cys92 described above.
Tetrahedral Intermediates Trapped for Both Acetyl-
Transfer Reactions. For a single active site of the afCT
+AcCoA+NH4
+ structure, there is strong density connecting
C1 of Ac-Cys92 to the sulfur of CoA. The shape of the density
indicates that Cys92 (Sγ), the acetyl group, and CoA (S) adopt
a tetrahedral geometry (Figure 10A). Therefore, covalent bonds
were defined from the acetyl group C1 atom to both Cys92
(Sγ) and CoA (S). This represents the tetrahedral intermediate
formed during acetyl transfer from Ac-CoA to Cys92 (Figure 2,
stage 3). The negatively charged thioester O atom is positioned
in OAH2, stabilized by hydrogen bonds to Cys92 (N) (3.2 Å)
and Gly386 (N) (2.6 Å). While the conformation of this
Cys92-Ac-CoA tetrahedral intermediate is well justified by the
electron density, it is inconsistent with the previous suggestion
that the first acetyl transfer proceeds via a tetrahedral
intermediate stabilized by OAH1.36 No density is observed in
OAH1, suggesting that the S atom of CoAwhich is
approximately 0.6 Å closer to Cys92 (Sγ) than for the active
sites containing CoA and Ac-Cys92prevents Watcat1 from
shifting into OAH1, as observed for the CoA+Ac-Cys92 active
sites (Figure 9A).
For the remaining active site of afCT+AcCoA+NH4
+ there is
continuous density occupying both OAHs and connecting CoA
(S) to Cys92 (Sγ). This was explained well by modeling an
acetyl group in OAH2 covalently linked via C1 to both Cys92
(Sγ) and C2 of a bound Ac-CoA molecule (Figure 10B). This
configuration represents the tetrahedral intermediate that
occurs during the second acetyl transferfrom Cys92 to Ac-
CoAto form AcAc-CoA (Figure 2, stage 7). The negative
charge present at the thioester O atom of the first acetyl group
is stabilized by OAH2, with hydrogen bonds of 2.5 and 2.8 Å to
Cys92 (N) and Gly386 (N), respectively. The thioester O atom
of Ac-CoA partially occupies OAH1 but is farther away from
His354 (Nε2) (3.8 Å) and closer to Watcat1 (2.2 Å) in
comparison to its position immediately prior to the first acetyl
transfer (stage 2) shown in Figure 9B. Superposition of this
catalytic site with the structure of bCT in complex with AcAc-
CoA (the active site cysteineCys89was mutated to serine)
(PDB: 1M1O)36 shows that the acetyl groups of the tetrahedral
intermediate occupy positions similar to those of the reaction
product, AcAc-CoA, as expected (Figure 10B).
■ DISCUSSION
Implications for the Thiolase Catalytic Cycle. Crystal
structures representing all five different acetyl-group config-
urations of the catalytic site have been determined previously
for Z. ramigera ACAT (bCT) (stages 1,35 2,36 4,24 535 and 836
of the reaction cycle shown in Figure 2); however, a crystal
structure of an ACAT in complex with a tetrahedral reaction
intermediate (Figure 2; stage 3 or 7) has not been reported
until now. Here we present structures of A. fumigatus cytosolic
ACAT (afCT) in complex with both tetrahedral reaction
intermediates previously predicted to form during each of the
acetyl-transfer reactions. Different active sites of the crystallized
tetrameric enzyme trapped substrates/intermediates at different
stages of the reaction cycle are depicted in Figure 2, including
(1) Ac-Cys92+CoA (stage 4), (2) a site containing alternate
conformations of Cys92+Ac-CoA as well as Ac-Cys92+CoA
(stages 2 and 4, respectively), (3) Cys92-Ac-CoA tetrahedral
intermediate (stage 3), and (4) Cys92-Ac-Ac-CoA tetrahedral
intermediate (stage 7). These last two structures complete the
structural repertoire of all stable intermediates that occur
during the thiolase reaction cycle, allowing us to observe with
direct experimental structural evidence the full reaction
mechanism for the first time.
Regarding the first acetyl-transfer reaction (Figure 2; stages
1−4), our structural data show that Ac-CoA binds with the
thioester O atom occupying OAH1 (Figure 9B) and that, upon
nucleophilic attack of Cys92 (Sγ) on the electrophilic C1 atom,
the acetyl group rotates into OAH2, where the negative charge
on the thioester O atom of the tetrahedral intermediate is
stabilized by hydrogen bonds to the backbone N atoms of
Cys92 and Gly386 (Figure 10A). After acetyl transfer, the
thioester O of Ac-Cys92 remains in OAH2 (Figure 9A). This
sequence of events conflicts with previous studies which have
suggested that, during acetyl transfer, the thioester oxygen atom
of the acetyl group occupies OAH1 and only shifts to OAH2
upon binding of a second Ac-CoA.36 This previous conclusion
was based on the interpretation of four structures of bCT: (1) a
C89A mutant bCT in complex with Ac-CoA (stage 2) showing
that the acetyl group binds in OAH1 (PDB: 1M3Z),36 (2) the
acetylated enzyme (Ac-Cys89) in complex with CoA (stage 4)
showing that the thioester O atom points away from OAH2
and is positioned between CoA (S) and Cys378 (O) (PDB:
1QFL),24 (3) the unliganded acetylated enzyme (between
stages 4 and 5) showing that the thioester O atom partially
occupies OAH1 while the C2 atom occupies OAH2 (PDB:
1M4S),36 and (4) the acetylated enzyme in complex with Ac-
CoA (stage 5) showing that binding of the second Ac-CoA
shifts the thioester O atom of Ac-Cys89 into OAH2 (PDB:
1DM3).35 Of these structures, 1 and 4 are consistent with our
interpretation of afCT structures. We suggest that the electron
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density observed at the active sites of bCT structures 2 and 3
was insufficient to accurately interpret the orientation of the
acetyl group. Therefore, on the basis of the structures presented
herein, for which there is strong, readily interpretable density,
we propose that the tetrahedral intermediate formed during the
first acetyl-transfer reaction is stabilized by OAH2, as indicated
by the reaction scheme shown in Figure 2 (stage 3).
Regarding the Claisen condensation reaction represented by
the second tetrahedral intermediate (Figure 10B), the
nucleophilic character of C2 of the second acetyl group (Ac-
CoA) is imparted by proton abstraction by Cys384 (Sγ).34 This
C2 is 4.8 Å from Cys384 (Sγ): too far for proton abstraction,
suggesting that proton abstraction and nucleophilic attack are
discrete steps, consistent with previous biochemical studies
indicating that C−H bond cleavage is separate from C−C bond
formation25,34 and that OAH1 is critical for the stabilization of
the enolate ion formed after proton abstraction has occurred37
(Figure 2, stage 6).
Enzyme Activation by MVCs. We have shown that, like
hT2, the catalytic efficiency of afCT is greatly increased by K+.
Numerous examples of MVC-activated enzymes have been
documented; all those characterized thus far have a preference
for either Na+ or K+.78−80 Na+-activated enzymes, such as
thrombin81 and β-galactosidase, are generally poorly activated
by smaller (Li+) or larger (K+, Rb+, Cs+) MVCs. K+-activated
enzymes, such as kinases82−84 and molecular chaperones,85 are
generally also activated partially by NH4
+ and Rb+ but not by
Li+, Na+, or Cs+.78 MVC-activated enzymes are classified into
two broad categories.79 Type I MVC activation involves direct
contact between the MVC and substrate, and the requirement
for MVCs is usually absolute. This is typified by enzymes
involved in phosphoryl transfer reactions, such as kinases,
which require both a divalent metal ion and a MVC. The MVC
is required for ATP binding and polarization of phosphate
groups and sometimes stabilization of the active conformation
of the protein. Type II activated enzymes have a basal level of
activity that is enhanced by specific binding of MVC(s) to a
site(s) distal to the active site. For example, Na+ binding to
thrombin induces subtle conformational changes that propagate
through the protein to the active site to promote catalysis.86 A
contrasting example is the DNA mismatch repair protein MutL,
in which a MVC is bound very close to its substrate binding site
and forms a water-mediated hydrogen bond with the α-
phosphate of ATP.87 Like afCT, MutL also exhibits a broad
MVC specificity; although it has a preference for Na+, it is also
activated by K+, Rb+, and Cs+. Given that the MVC is not in
direct contact with substrate and the requirement for MVCs is
not absolute, afCT can be clearly classified as a type II activated
enzyme.
We suggest that the MVC bound by afCT activates the
enzyme in two ways: (1) by increasing affinity for substrate via
a water-mediated hydrogen bond and stabilization of the
adenosine binding loop and (2) by stabilization of the loop
containing the catalytic histidine (His354). Interestingly, the
kcat/Km value of afCT was markedly increased by addition of
either Na+ or K+. Both decreased the Km value for AcAc-CoA
equally, but the kcat value was 3-fold higher for K
+ than for Na+.
Assuming the rate of catalysis is much slower than that of
substrate binding, this indicates that both ions increase
substrate affinity similarly, but K+ is more effective at promoting
catalysis. Further biochemical studies are required to confirm
this. It is known that ACATs can turn over AcAc-pantetheine
with only slightly lower catalytic efficiency than for AcAc-
CoA,21,23 indicating that the adenosine part of CoA is not
required for substrate binding. Comparison of the kinetic
properties of afCT using CoA substrate versus pantetheine
substrate would be valuable for delineating relative contribu-
tions of effects 1 and 2 to enhancing its catalytic efficiency. In
addition, determination of the structure of the enzyme in the
absence of MVCs and in complex with Na+, followed up by
mutagenesis studies, is anticipated to provide further insight
into the allosteric activation of afCT (and T2) by MVCs.
To our knowledge, ACATs are a unique example of a class of
enzymes which includes members that are specifically activated
by MVCs and members that are ion independent, while
otherwise maintaining a highly conserved overall structure.
From our structural comparisons, we suggest that the structural
determinants which differentiate K+-activated ACATs (afCT
and hT2) from ion-independent ACATs (hCT and bCT)
involve very few residues. These include Tyr187 (afCT), which
is a glutamine in both hCT and bCT, and Glu224, which is an
aromatic residue in hCT and bCT. A previously reported
clinical mutation in hT2 indicates the importance of Tyr187
(hT2 Tyr219): biochemical characterization of hT2-
(Tyr219His) showed that this mutation abolished enzyme
activity.31 Glu224 confers a strong negative charge to facilitate
electrostatic attraction of K+ to the MVC coordination site
(Figure S7A). In addition to these two residues, the Lβ3−Lα3
loop, which forms the outside of the adenosine binding pocket,
is one residue longer in these ion-independent ACATs. This
additional histidine (hCT His224) causes a structural
rearrangement, allowing a cation−π interaction between the
preceding basic residue (hCT Arg223) and the adenine rings of
CoA (Figure S9B). It is interesting to note that this basic
residue is conserved in K+-activated ACATs (afCT Lys226),
but the conformation of the Lβ3−Lα3 loop precludes it from
contacting the substrate.
Insights into Other Species. Surprisingly, afCT is more
like hT2 than hCT or bCT in terms of primary sequence,
structure of key elements surrounding the active site, and
biochemical properties. Discrimination of mitochondrial ACAT
from cytosolic ACAT based on activation by K+as
demonstrated for mammalian tissues29clearly does not
apply for fungi. It is interesting to note that A. thaliana
cytosolic ACAT is also more similar to hT2 and afCT than to
hCT and bCT in terms of overall sequence identity (Figure S1)
and conservation of key residues involved in substrate
specificity and binding of K+ and Cl− (Figure S2). It is
therefore possible that the biochemical properties of plant
ACATs also conflict with the current paradigm differentiating
mitochondrial and cytosolic ACATs and that bacterial and
mammalian cytosolic ACATs are the exception regarding
nonactivation by K+. Further bioinformatic and biochemical
studies are anticipated to elucidate the extent to which MVC
activation of ACATs is conserved across all domains of life. To
our knowledge, there are no published data showing that the
activity of T2 is independent of Na+ ions. The similarity
between the ion binding sites of hT2 and afCT along with the
MVC promiscuity that afCT exhibits leads us to suggest that
the accepted notion that T2 is activated by K+ but not Na+29
may need to be revisited. That is, although K+ is the preferred
activating MVC, afCTand therefore probably T2are not
strictly selective for K+ and thus do not adhere to a strict
dichotomy of activation by K+ but not Na+.
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■ CONCLUDING REMARKS
We have solved the first structure of a fungal type II thiolase,
both in apo form and in complex with substrate. The different
catalytic site configurations trapped in the crystals of afCT
provide the first direct experimental observations of the
structures of the tetrahedral intermediates formed during the
thiolase reaction cycle. We have also shown that, unexpectedly,
afCT possesses specific ion binding sites and is activated by
MVCs in a way similar to that for hT2. Future work focusing
on the comparison of key structural features of ion-dependent
and ion-independent thiolases is anticipated to provide further
structural rationales for the allosteric ion activation of this class
of enzymes.
Biosynthetic thiolases catalyze the first step in the synthesis
of highly reduced organic molecules in both prokaryotes and
eukaryotes that are essential for energy storage and
maintenance of normal cellular function, presenting them as
potential drug targets. In addition, for many years much
biotechnological research has focused on microbial metabolic
engineering for the large-scale biosynthesis of biodegradable
plastics such as polyhydroxyalkanoates,88−91 high-value iso-
prenoid-based natural products,16 and production of biofuels
from renewable sources92−95all processes for which bio-
synthetic thiolases play a central role. Thus, the detailed
structural investigation of ACATs, such as presented herein, is
anticipated to inform both the rational design of antimicrobial
drugs and the advancement of biotechnological applications for
industrial, commercial, and biomedical fields in the future.
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Table S2. Cs+ sites. Anomalous (Anom) peak heights, isomorphous difference map (Fo-Fo) peak heights and atomic 
properties for all ordered Cs+ ions in the afCT+Cs+ structure. Listed values refer to subunits A, B, C and D, respectively. 
MVC binding sites are listed above each column, labeled as the closest coordinating residue (except for the site near the 
substrate binding pocket; labeled “CoA pocket”). 
 CoA pocket Val44 Asp200 Asn274c Asp314 
Anom @ 8500 eV (σ) 25, 29, 41, 43 15, 12, 23, 27 20, 20, 28, 36 nad, na, na, 16 na, na, 11, 8 
Anom @ 13000 eV (σ) 13, 14, 21, 22 7,  7,  13,  15 9,  9,  14,  17 na, na, na, 7 na, na,  8,  4 
Fo-Foa (σ) 25, 30, 59, 67 18,  9, 33, 35 18, 19, 35, 43 na, na, na, 23 na, na, 18, 11 
Occupancy (%)b 97, 99, 95, 99 84, 80, 66, 73 92, 91, 80, 79 na, na, na, 48 na, na, 55, 57 
B-factor (Å2)b 55, 46, 17, 15 75, 90, 26, 26 73, 66, 26, 21 na, na, na, 27 na, na, 43, 73 
Occupancy/B-factor b 1.8, 2.1, 5.7, 6.6 1.1, 0.9, 2.6, 2.8 1.3, 1.4, 3.1, 
3.9 
na, na, na, 1.8 na, na, 1.3, 0.8 
a Fo-Fo is Fo(afCT+Cs+) minus Fo(afCT+K+), with all data collected @ 13000 eV. b For data collected @ 13000 eV.  c At 




Table S3. Rb+ sites. Anomalous (Anom) peak heights, isomorphous difference map (Fo-Fo) peak heights and atomic 
properties for all ordered Rb+ ions in the afCT+Rb+ structure. Listed values refer to subunits A, B, C and D, respectively. 
MVC binding sites are listed above each column, labeled as the closest coordinating residue (except for the site near the 
substrate binding pocket; labeled “CoA pocket”). 
 CoA pocket Val44 Asp200 Asn274c 
Anom @ 15350 eV (σ) 15, 17, 20, 20 8, 7, 14, 13 11, 12, 14, 17 na, na, na, 6 
Anom @ 13000 eV (σ) 5,  4,  6,  6 3,  3,  5,  4 3,  4,  5,  6 na, na, na, 4 
Fo-Foa (σ) 16, 18, 28, 35 9, 6, 20, 18 11, 13, 23, 25 na, na, na, 9 
Occupancy (%)b 85, 96, 94, 97 82, 94, 69, 76 87, 90, 79, 85 na, na, na, 58 
B-factor (Å2)b 41, 41, 18, 17 66, 89, 20, 24 65, 52, 20, 20 na, na, na, 49 
Occupancy/B-factor b 2.1, 2.4, 5.1, 5.8 1.2, 1.1, 3.4, 3.2 1.3, 1.7, 4.0, 4.3 na, na, na, 1.2 
a Fo-Fo is Fo(afCT+Rb+) minus Fo(afCT+K+), with all data collected @ 13000 eV. b For data collected @ 13000 eV.  c 




Table S4. Atomic properties of all ordered K+ ions at MVC binding sites in afCT+K+ and afCT+AcCoA+K+ structures and 
NH4+ ions in the afCT+AcCoA+NH4+ structure. Listed values refer to subunits A, B, C and D, respectively. MVC binding 
sites are listed above each column, labeled as the closest coordinating residue (except for the site near the substrate binding 
pocket; labeled “CoA pocket”). 
afCT+K+ CoA pocket Val44 Asp200 Asn274b 
Occupancy (%) 76, 94, 100, 100 96, 100, 91, 82 100, 100, 91, 90 na, na, na, 50 
B-factor (Å2) 39, 43, 23, 19 69, 78, 24, 22 69, 58, 21, 21 na, na, na, 37 
Occupancy/B-factor  1.9, 2.2, 4.3, 5.3 1.4, 1.3, 3.8, 3.8 1.5, 1.7, 4.4, 4.3 na, na, na, 1.4 
afCT+AcCoA+K+ a     
Occupancy (%) 58, 49, 54, 43 84, 97, 70, 82 82, 84, 85, 77 na, na, na, na 
B-factor (Å2) 25, 29, 12, 10 25, 39, 12, 18 24, 26, 14, 10 na, na, na, na 
Occupancy/B-factor  2.3, 1.7, 4.4, 4.2 3.4, 3.1, 5.9, 7.8 3.4, 2.5, 5.7, 4.5 na, na, na, na 
afCT+AcCoA+NH4+     
Occupancy (%) 100, 100, 100, 90 na, 100, 100, na 100, 100, 88, 100 na, na, na, na 
B-factor (Å2) 9, 6, 15, 18 na, 33, 39, na 22, 19, 22, 32 na, na, na, na 
Occupancy/B-factor  11, 17, 6.8, 5.1 na, 3.0, 2.5, na 4.6, 5.3, 4.1, 3.2 na, na, na, na 
a Crystallization condition contained NH4+ ions also. b At interface with symmetry-mate. 
 
  




Figure S1. Phylogenetic tree of all thiolase protein sequences from Aspergillus fumigatus, Saccharomyces 
cerevisiae, Arabidopsis thaliana, Human, Drosophila melanogaster, Escherichia coli and Zoogloea ramigera. 
NCBI accession numbers are shown for all sequences except A. thaliana, for which sequences were obtained 
from The Arabidopsis Information Resource (TAIR, www.arabidopsis.org). The subcellular location of all A. 
thaliana thiolases has been experimentally determined 1; proteins with both cytosolic and peroxisomal isoforms 
are marked with an asterisk.  
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Figure S2. Multiple sequence alignment of cytosolic and mitochondrial acetoacetyl-CoA thiolases (cACAT and 
mACAT) from Aspergillus fumigatus (Af), Saccharomyces cerevisiae (Sc), Arabidopsis thaliana (At), Homo 
sapiens (Hs) and Zoogloea ramigera (Zr). Conserved sequences are outlined by blue boxes: Strictly conserved 
residues are white text on a red background, highly similar residues are red text. Catalytic residues are highlighted 
yellow. Residues of afCT or hT2 highlighted green or magenta are involved in binding Cl- or K+ ions, 
respectively. Phe294, involved in substrate specificity, is marked with an asterisk. Secondary structural elements 
of afCT (shown above the sequence - β-strands: arrows, α-helices: large coils, 310-helices: tight coils) are labeled 
according to the nomenclature adopted for the first crystal structure of a tetrameric ACAT 2. Element labels for 
the NTD, loop domain and CTD are colored red, green and blue, respectively. (Sequence accession numbers: Af 
cACAT - XP_747207.1, Af mACAT - XP_751294.1, Sc cACAT - NP_015297.1, At cACAT - AT5G48230.1, 
Hs cACAT - NP_005882.2, Hs mACAT - NP_000010.1, Zr cACAT - AAA27706.1) 
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Figure S3. Comparison of afCT (green – this study), hCT (yellow – 1WL4), hT2 (cyan – 2IBY) and bCT (salmon 
– 1QFL) structures. α-carbons are traced as ribbons and CoA molecules are shown as sticks. (A) Single subunit 
superposition. The N- and C-termini of afCT are labeled. (B) Tetramers. Only the top tight dimer of each was 
used for the superposition, showing the variation in orientation of the second tight dimer. 
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Figure S4. Monovalent cation binding sites of afCT. (A) Superposition of anomalous difference maps for 
afCT+Rb+anom (15350 eV) (blue mesh) and afCT+Cs+anom (8500 eV) (red mesh) datasets contoured at 4.5 and 5.5 
σ, respectively. afCT is shown as green ribbons. (B) Relationship of X-ray energy to theoretical anomalous signal 
strength (f") for Rb and Cs (data from http://skuld.bmsc.washington.edu/scatter 3, plotted using Gnuplot v5.0.6). 
Datasets were collected at X-ray energies indicated by the crosses; average anomalous peak heights for data 
collected at each wavelength are listed in Table 2. 
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Figure S5. Superposition of afCT+AcCoA+K+ (dark green) with hT2 (cyan; also bound to CoA; PDB: 2IBY) 
shows that their K+-binding sites are almost identical. The K+ of afCT (purple sphere) is shown with coordination 
bonds (red dashes, lengths in Å); WatMVC is shown as a red sphere. Both the K+ and coordinating water of hT2 
(large and small cyan spheres) are shifted only very slightly relative to those of the afCT structure. Residue labels 




Figure S6. The MVC binding site of afCT is an ideal size to accommodate K+ ions. Superposition of afCT+K+ 
(light green), afCT+Rb+ (red) and afCT+Cs+ (blue) (all elements for each individual structure are colored the 
same) shows that the larger the radius of the cation (K+ < Rb+ < Cs+; shown as tiny spheres for clarity), the further 
it shifts out of the plane formed by the coordinating oxygen atoms of Tyr187, Ala249, Ser252 and Val350, 
simultaneously pushing WatMVC (larger spheres) further away from its position in afCT+AcCoA+K+ (dark green).  
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Figure S7. Space-filling representations of afCT and hCT colored by electrostatic potential (gradient: -9 to +9, 
red to blue). CoA is shown as sticks. (A) afCT: The K+ ion (purple sphere) binding site is a pocket with a strong 
negative charge close to the adenosine of CoA. (B) hCT: The region surrounding the adenosine binding pocket 
is much less negatively charged than for afCT, largely due to the substitution of Glu224 (afCT) for Phe221 (hCT). 
(C) Superposition of afCT+AcCoA+K+ (dark green) with hCT (yellow; PDB: 1WL4) shows that, in the hCT 
structure, a water molecule (red spheres) is coordinated (red dashes) at the homologous site to the K+ (purple 
sphere) of afCT. WatMVC of afCT is shown as a dark green sphere. Residue labels refer to hCT, with those that 
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Figure S8. Comparison of the Cl- binding site of afCT with corresponding regions of hT2 and hCT shown in 
stereo view. (A) Superposition of afCT (green) and hT2 (cyan) Cl- binding sites. The hT2 site accommodates one 
less water (cyan spheres) and the Cl- (orange) is shifted further from the Cβ4-Cβ5 loop. Residues labels refer to 
hT2. (B) Superposition of afCT (green) with hCT (yellow). Met388 of hCT occupies the space corresponding to 
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Figure S9. Comparison of the substrate binding sites of afCT, hT2, hCT and bCT shown in stereo view. (A) 
Superposition of the adenosine binding pockets of afCT (green) and hT2 (cyan; PDB: 2IBY). Labels always refer 
to afCT residues discussed in the text, except for Phe261 of hT2 (marked with an asterisk), which shifts the 
position of the Lβ3-Lα3 loop relative to afCT. The K+ is represented by a purple sphere. (B) Superposition of the 
adenosine binding pockets of afCT (green), hCT (yellow; PDB: 1WL4) and bCT (salmon; PDB: 1QFL). Residues 
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Figure S10. Stereo view of 2-methylacetoacetyl-CoA (sticks: carbon atoms of S-enantiomer are magenta; for 
clarity, all atoms of R-enantiomer are grey) docked in silico to the active site of afCT. Key residues are shown as 
sticks, and waters as red spheres. The 2-methyl moiety of both enantiomers make van der Waals contact with the 
phenyl ring of Phe294. Thioester and 3-keto oxygens of the substrate occupy oxyanion holes formed by His354 
(Nε2) and Watcat1 (OAH1), and Cys92 (N) and Gly386 (N) (OAH2). Red dashes indicate hydrogen bonds; 




Figure S11. Superposition of hCT (yellow; PDB: 1WL4) and afCT (dark green) shows that afCT possesses only 
the first three waters (red spheres) of the water trail present in hCT (yellow spheres). Waters with alternate 
locations are marked with asterisks. Lα1, Lα2, Cβ2 and Cα2 are labeled in italics. Residues discussed in the text 
are labeled, with catalytic residues in bold; all labels refer to afCT residues. Cys92 is acetylated for afCT and 
oxidized for hCT. Hydrogen bonds (dashes) are shown for the hCT water trial (yellow), OAH1 (red), stabilization 
of Watcat1 by Asn322 (black) and the sidechain of Asn322 with backbone atoms of Cα1 (black). Note that, for 
clarity, Cα2' was omitted from the models shown (dashed cartoon representation; foreground). Figure shown in 
cross-eye stereo view. 
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The fungal pathogen Aspergillus fumigatus has been implicated in a drastic
increase in life-threatening infections over the past decade. However, com-
pared to other microbial pathogens, little is known about the essential
molecular processes of this organism. One such fundamental process is
DNA replication. The protein responsible for ensuring processive DNA
replication is PCNA (proliferating cell nuclear antigen, also known as the
sliding clamp), which clamps the replicative polymerase to DNA. Here we
present the first crystal structure of a sliding clamp from a pathogenic fun-
gus (A. fumigatus), at 2.6A. Surprisingly, the structure bears more similar-
ity to the human sliding clamp than other available fungal sliding clamps.
Reflecting this, fluorescence polarization experiments demonstrated that
AfumPCNA interacts with the PCNA-interacting protein (PIP-box) motif
of human p21 with an affinity (Kd) of 3.1 lM. Molecular dynamics simula-
tions were carried out to better understand how AfumPCNA interacts with
human p21. These simulations revealed that the PIP-box bound to
AfuPCNA forms a secondary structure similar to that observed in the
human complex, with a central 310 helix contacting the hydrophobic sur-
face pocket of AfumPCNA as well as a b-strand that forms an antiparallel
sheet with the AfumPCNA surface. Differences in the 310 helix interaction
with PCNA, attributed to residue Thr131 of AfumPCNA, and a less stable
b-strand formation, attributed to residues Gln123 and His125 of
AfumPCNA, are likely causes of the over 10-fold lower affinity of the p21
PIP-box for AfumPCNA as compared to hPCNA.
Database
The atomic coordinates and structure factors for the Aspergillus fumigatus sliding clamp can be
found in the RCSB Protein Data Bank (http://www.rcsb.org) under the accession code 5TUP.
Introduction
In recent decades, an increase in the number of treat-
ment regimens involving immunosuppressant therapies
has been associated with a rise in the incidence of
invasive nosocomial fungal infections worldwide [1–3].
Aside from transplant failure or cancer relapse, the
primary cause of death for immunocompromised
patients is infection, and various species of fungi, par-
ticularly Candida and Aspergillus spp., play a major
role [4]. The saprophytic filamentous fungus Aspergil-
lus fumigatus is abundant in the environment, and the
Abbreviations
Afum, Aspergillus fumigatus; IDCL, interdomain connector loop; PCNA, proliferating cell nuclear antigen; PIP, PCNA-interacting protein.
985The FEBS Journal 284 (2017) 985–1002 ª 2017 Federation of European Biochemical Societies
most common cause of invasive fungal infection in
immunocompromised patients [5,6]. Typically found
feeding on decaying organic matter, it plays a crucial
role in the recycling of carbon and nitrogen [7,8].
Aspergillus fumigatus spores, called conidia, are ubiqui-
tous and thus inhaled on a daily basis [9]. Conidia are
usually cleared efficiently from the lungs by the innate
immune system, but in specific cases they may germi-
nate and cause infection [10]. Infection is most often
pulmonary, but infections of the bronchi, sinus, and
dissemination to the brain and other organs are also
common. Susceptibility to invasive infection is closely
linked to the immune status of the host; individuals at
highest risk are those with hematological malignancies,
particularly acute leukemia, and transplant patients
[7,11]. Although morbidity and mortality are usually
associated with invasive aspergillosis (IA) in immuno-
compromised patients, an even larger number of
patients are affected by chronic or allergic conditions
caused by Aspergillus spp. [12]. Occurrence of IA in
otherwise immunocompetent patients is atypical, but
has been reported following influenza [13,14] in ICU
patients without hematological malignancy [15] and in
otherwise healthy individuals [16,17]. Aspergillus fumi-
gatus conidia are small enough to reach the lower air-
ways and are readily internalized by alveolar epithelial
cells, where they are able to evade host immune cells
and to initiate systemic infection [18]. The low sensitiv-
ity of current microbiological and histopathological
methods, along with a lack of consistency in surveil-
lance and case definition, has made estimation of the
incidence of IA in the past difficult and has probably
lead to an underestimation of the true disease burden
[19,20]. However, it is generally recognized that the
incidence of invasive fungal infections is increasing,
with the major contributors shifting from Candida spp.
to Aspergillus spp. [19,21]. Central nervous system
aspergillosis is a particularly devastating condition
associated with a very poor prognosis and mortality
rates of approximately 90% [11,12,17,22,23]. In addi-
tion, IA is the most common cause of death due to
lung infection in hematopoietic stem cell transplant
(HSCT) patients [23]. A multicenter prospective survey
of 23 institutions in the US reported an incidence of
invasive fungal infections in HSCT patients of 0.9%–
13.2%. IA was the most common condition, with
A. fumigatus by far the most prevalent species impli-
cated. Overall 1-year survival rates for all autologous
and allogeneic HSCT patients included in the study
were 87% and 64%, respectively, but dropped to
25.4% when including only those who contracted
aspergillosis [19]. IA is also common in solid organ
transplant recipients, with an associated mortality of
approximately 22% [12]. In particular, lung transplant
recipients exhibit invasive fungal infections in up to
19% of cases, with the majority of infections caused
by A. fumigatus [24–26].
Despite the availability and widespread use of anti-
fungals active against A. fumigatus for many years, the
mortality rate remains unacceptably high. The major
drugs approved for the treatment of IA target compo-
nents of the cell membrane: amphotericin B, and azole
antifungals including voriconazole, itraconazole,
posaconazole, and more recently, isavuconazole [27].
Amphotericin B is associated with severe side effects,
the most notable being severe kidney and liver toxicity,
and has been largely superseded by the azole antifun-
gals, although these are also often associated with sig-
nificant side effects [28,29]. Current aspergillosis
management guidelines from the Infectious Diseases
Society of America recommend voriconazole for pri-
mary therapy in almost all cases, and posaconazole for
prophylaxis [12]. The last 15 years or so have seen an
alarming increase in the incidence of azole-resistant
A. fumigatus strains that appear to have originated
both in the environment—due to the widespread use
of azole antifungals in agriculture—and in the clinic.
Azole resistance is a major cause of treatment failure
[30–34]. In addition, as the incidence of Aspergillus
infection increases and species identification methods
advance, more related species are added to the list that
cause disease. These have differing antifungal suscepti-
bilities and have been associated with negative clinical
outcomes, highlighting the need for improved diagnos-
tic protocols and a broader range of antifungal options
[6,35]. Expanding our basic knowledge of the essential
biological processes of this important fungal pathogen
is crucial to further advances in medical treatment,
and the development of new antifungal drugs with
novel targets. One process that presents as a therapeu-
tic target for many diseases is DNA replication and
repair.
Proliferating cell nuclear antigen (PCNA) tethers
proteins to DNA in cellular processes including DNA
replication, DNA repair, and cell cycle control [36]. It
is a member of the sliding clamp family of proteins,
found in all three domains of life. Despite a lack of
sequence homology between them [37], all sliding
clamps share a pseudo sixfold symmetry arising from
six structurally similar domains [38,39], and have a
high level of structural conservation. In archaea and
eukaryotes, the sliding clamp is trimeric [37,39,40].
PCNA subunits from different species are able to
interact to form a trimer; the PCNA subunit from
Saccharomyces pombe is able to interact with both
Drosophila melanogaster and human PCNA subunits,
986 The FEBS Journal 284 (2017) 985–1002 ª 2017 Federation of European Biochemical Societies
X-ray crystal structure of AfumPCNA A. C. Marshall et al.
suggesting that interactions between PCNA subunits,
and important residues in the interaction interface, are
evolutionarily conserved [41]. PCNA alone has no
intrinsic enzymatic activity but functions by fully
encircling DNA and sliding freely. Through this topo-
logical interaction it is able to control and coordinate
the access of proteins to DNA, particularly at the
DNA replication fork. PCNA has been described as a
‘tool belt’, referring to its ability to interact with
numerous and varied proteins [42,43]. These proteins
are interchangeable, allowing for the ‘belt’ to hold dif-
ferent ‘tools’ depending on its current role within the
cell. The majority of proteins that interact with PCNA
contain a PCNA-interacting protein (PIP)-box peptide
motif [36] which binds a hydrophobic cavity present
on each monomer in the trimeric ring and forms an
antiparallel b-sheet with the interdomain connector
loop (IDCL) of PCNA. This allows for the binding of
up to three such proteins to PCNA at one time [44].
This hydrophobic PIP-box-binding pocket is present in
all eukaryotic sliding clamps; a comparable pocket is
also present in bacterial sliding clamps, although there
are significant differences in the pockets and binding
peptides between eukaryotes and bacteria [45]. The
PIP-box was first defined by Warbrick et al., using a
yeast two-hybrid screen followed by alanine scanning
to identify key residues involved in the interaction of
the tumor-suppressor protein p21 with PCNA, and its
ability to inhibit SV40 DNA replication. It has been
suggested that drugs based on the PIP-box of p21,
either as derivatives or peptide mimetics, could have
therapeutic uses in down-regulating DNA replication
[41,44]. Small molecules that act as competitive inhibi-
tors of the PCNA–PIP-box interaction have also been
identified and proposed as novel anticancer therapeu-
tics [46]. In addition, small molecules [47–49], natural
compound derivatives [50], peptides [51], peptide
mimetics [45,52], and cyclic peptides [53] that target
the function of the bacterial sliding clamp have all
been presented as novel antimicrobials. Despite its
integral role in cell growth and survival, PCNA has
not yet been investigated as a target for novel antifun-
gal drugs.
Here we present the first crystal structure of a sliding
clamp from a pathogenic fungus. We have solved the
X-ray crystal structure of PCNA from A. fumigatus
(AfumPCNA) to 2.6A resolution. The structure reveals
a trimeric ring-shaped fold similar to other eukaryotic
sliding clamps. Interestingly, the overall structure is
more similar to the human sliding clamp than that
from Saccharomyces cerevisiae (yPCNA). Fluorescence
polarization experiments with AfumPCNA and the
PIP-box from human p21 demonstrate a Kd of 3 lM,
providing evidence that AfumPCNA interacts with pro-
teins at the replication fork though a conserved PIP-
box mechanism similar to the human system, rather
than the prokaryotic systems which do not employ use
of the PIP-box system for protein–protein interactions.
We have employed molecular dynamics simulations
with AfumPCNA and the human p21 PIP-box to better
understand the interactions. This revealed that the sec-
ondary structure of the PIP-box motif is similar in its
interactions with AfumPCNA as with hPCNA. How-
ever, differences in the 310 helix interaction cavity and
the IDCL as well as a decreased ability to form a beta-
strand conformation are likely to contribute to the
lower affinity of p21 for AfumPCNA rather than
hPCNA.
Results
Identification of PCNA from Aspergillus
fumigatus
The A. fumigatus protein sequence was identified using
the Aspergillus Genome Database and confirmed by
means of multiple sequence alignment with PCNA
from other species, as shown in Fig. 1. Analysis of the
amino acid sequence of PCNA from several different
sequences, as shown in Table 1, reveals that PCNA
from A. fumigatus is most similar to A. thaliana
(56.9%) and D. melanogaster (56.6%), followed very
closely by human PCNA (53.9%). It is interesting to
note that, in terms of PCNA sequence, the fungus
A. fumigatus is more closely related to the higher order
eukaryotes than to the yeast S. cerevisiae (49.6%). Pre-
vious studies have shown evolutionary drift of PCNA
between the yeast and pathogenic fungi such as
AfumPCNA. In eukaryotic species, the N- and C-
terminal domains of each subunit are connected via an
extended loop (residues 118 to 134) known as the
interdomain connector loop (IDCL), which is neces-
sary for interaction with the PIP-box-containing pep-
tides [44]. Evolutionary drift among the PCNA
molecules of Fungi is perhaps most notable in the
IDCL. Zamir et al. [54] compared the IDCL of PCNA
from numerous different fungal species and found that
variation in just 4 of the 12 IDCL residues analyzed
appeared to allow segregation of the different species
into two distinct groups, as indicated in Fig. 1. Chi-
mera-based protein–protein binding experiments in
which the IDCL of fungal species were interchanged
among the PCNA molecules and affinity for PIP-box-
containing proteins was measured, demonstrated that
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the IDCLs of the two groups of fungi could not be
interchanged without significant loss of affinity. IDCL
sequences from Group 1 fungal species (including
S. cerevisiae) were incompatible with IDCL sequences
from Group II species (including A. fumigatus) sug-
gesting large evolutionary drift among the fungal spe-
cies. However, to date no structural information has
been available to explain these differences.
X-ray crystal structure of PCNA from Aspergillus
fumigatus
To gain a better understanding of AfumPCNA struc-
ture and mechanism, AfumPCNA was purified and
crystallized in space group P21. The AfumPCNA
structure was solved to a resolution of 2.6A by means
of molecular replacement. Data processing and
Fig. 1. Sequence alignment of the PCNA protein sequence from six different organisms. Residues are colored according to the following
scheme [54]; nonpolar residues are yellow (GAST), polar residues are magenta (NQH), hydrophobic residues are green (CVILPFYMW),
negatively charged residues are red (DE), positively charged residues are blue (KR). a-helices and b-sheets are labeled as they were
described for the structure of Saccharomyces cerevisiae PCNA [37]. The IDCL is labeled as defined by Gulbis et al. [44]. The four residues
within the IDCL identified by Zamir et al. [54] as segregating fungal species into two distinct groups are marked above by asterisks. The
IDCL from Pyrococcus furiosus does not clearly belong to either group, as indicated.
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refinement statistics can be found in Table 2 and a
reduced model bias stereo figure of representative elec-
tron density can be seen in Fig. 2. The asymmetric
unit is composed of three subunits that form a ring-
shaped trimer that is representative of DNA sliding
clamps from other species (Fig. 3). Subunits of the tri-
mer show high structural similarity, with RMSD values
between subunits ranging from 0.89A to 0.97A (calcu-
lated over 254 Ca atoms) and total surface areas of
12375 A2, 12297 A2, and 12446 A2, giving an average
surface area per subunit of 12373 A2. Subunits are
composed of four a-helices and 18 b-strands arranged
into two domains of nearly identical topology, con-
nected by an IDCL (Fig. 3A). Each domain consists of
two adjacent a-helices covered on one side by two
antiparallel b-sheets of four or five strands each. Each
b-sheet is continuous with the b-sheet of the adjacent
domain, such that six, nine-stranded b-sheets surround
the trimeric ring: three cross the domain interface
within each subunit and three cross the interface
between each subunit (Fig. 3B). The AfumPCNA tri-
mer therefore has a pseudo sixfold rotational symmetry,
with the axis of symmetry running through the center
of the ring. The subunits pack to form the trimer leav-
ing a central cavity of approximately 30A—a diameter
which would allow nonspecific interactions with DNA.
Atomic interactions of the AfumPCNA subunit
interface
Proliferating cell nuclear antigen oligomerizes via an
interface that is conserved among all three subunit–
subunit interfaces (Figs 3B and 4). The subunit–
subunit interfaces involve the interaction of bI1 and
aB1 of the N-terminal domain with bD2 and aA2 of
the C-terminal domain. The peripheral b-strands of
each domain (bI1 and bD2) form an antiparallel b-
sheet such that the b-sheet is continuous across the
subunit interface. For the following discussion, we
refer to the interface between subunits A and C, unless
otherwise specified.
The interface surface area is 687.2 A2; similar to the
corresponding interfaces of both hPCNA and yPCNA
(697.6 A2 and 654.1 A2, respectively), and involving 11
hydrogen bonds (Fig. 4A) and one salt bridge
(Fig. 4B). Eight hydrogen bonds between peptide
backbone atoms of residues 109 to 117 (bI1) and 175
to 183 (bD2) have distances ranging from 2.28A to
3.40A, and define the antiparallel b-sheet (Fig. 4A).
The remaining three hydrogen bonds are weak (dis-
tance > 3.6A) and are between Lys77 (NZ) and
Ala153 (O), Thr108 (N) and Gln193 (OE1), and
Asp115 (OD2) and Ser177 (OG). Arg110, contained in











P. furiosus 100.00 26.11 23.45 24.34 25.99 25.55
S. cerevisiae 26.11 100.00 49.61 40.00 35.66 36.05
A. fumigatus 23.45 49.61 100.00 56.86 53.88 56.59
A. thaliana 24.34 40.00 56.86 100.00 65.23 62.11
Human 25.99 35.66 53.88 65.23 100.00 71.04
D.
melanogaster
25.55 36.05 56.59 62.11 71.04 100.00
Table 2. Data collection and refinement statistics.
AfumPCNAa
Data collection
Space group P 21
Cell dimensions
a, b, c (A) 56.95, 103.37, 79.2
a, b, c (°) 90.00, 96.60, 90.00




I / rI 7.2 (1.0)




No. reflections 28 050








Bond lengths (A) 0.004
Bond angles (°) 0.978
aData collected from 1 crystal.
bValues in parentheses are for highest-resolution shell.
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bI1, forms a salt bridge with Glu143 from aA2
(Fig. 4B). The core of the interface is hydrophobic,
centered around Tyr114, and is composed of aB1 resi-
dues Val78 and Ala81, bI1 residues Tyr114 and Ile116,
aA2 residues Leu151 and Leu154, and bD2 residues
Ile175 and Val180 (Fig. 4B).
The subunit interface is highly conserved among
species, with comparisons to hPCNA and yPCNA
revealing very similar surface areas and interacting
residues. All of the hydrophobic residues at the inter-
face core are conserved in human and yeast PCNA,
and each interface involves a similar number of hydro-
gen bonds. The most conspicuous nonconservative
substitution is at position 153 of aA2, which is an ala-
nine, histidine, or glutamine in AfumPCNA, hPCNA,
and yPCNA, respectively. However, this substitution
for bulkier residues in both hPCNA and yPCNA
appears to have very little effect on the conformation
of other interface residues, but may contribute to a
slightly larger interaction surface. The only other sig-
nificant nonconservative substitution at the subunit
interface is a glutamine residue in AfumPCNA
(Gln83), which is glycine in hPCNA. This permits the
side chain of Arg146, which points to solvent in
AfumPCNA (Fig. 4B), to contact aB1 of the opposing
subunit of hPCNA, forming a hydrogen bond with
Lys80 (O) (2.97A). The hPCNA interface includes a
salt bridge at the end of the b-strand, involving
Lys117 and Glu174, which is absent in both
AfumPCNA and yPCNA. Lys117 is conserved in fun-
gal PCNA, but residue 174 is an aspartate residue,
which lacks the conformational flexibility required to
form an electrostatic interaction with Lys117. The salt
bridge between residues 110 and 143 is conserved in
AfumPCNA, with the variation that 110 is an arginine
rather that a lysine. In yPCNA, Arg110 also forms a
salt bridge, but partners with Asp150 rather than
Glu143. Interestingly, both Glu143 and Asp150 are
conserved and in similar positions in both fungal
PCNA structures, suggesting that Arg110 may be able
to form a salt bridge with either of these residues. This
is confirmed in AfumPCNA upon inspection of the
interface between subunits B and C, where indeed an
Fig. 2. Representative electron density. Wall-eye stereo image of a
reduced model bias feature-enhanced map [68] contoured at 1.5r
encompassing residues Gly244 to Lys253 of AfumPCNA.
Fig. 3. Structure of the AfumPCNA.
Depicted are ribbon diagrams of
AfumPCNA. (A) Single subunit of
AfumPCNA. (B) AfumPCNA trimer colored
by subunit.
990 The FEBS Journal 284 (2017) 985–1002 ª 2017 Federation of European Biochemical Societies
X-ray crystal structure of AfumPCNA A. C. Marshall et al.
Arg110–Asp150 salt bridge is present, rather than the
Arg110–Glu143 salt bridge of the interface between
subunits A and C. Furthermore, at the remaining
interface (A–B), the side chain of Arg110 is disordered
in the electron density, consistent with conformational
flexibility at this position. In contrast, the shorter side
chain of Lys110 of hPCNA precludes it from forming
a salt bridge with Asp150, limiting interaction to
Glu143.
Comparison of AfumPCNA to the yeast and
human PCNA
AfumPCNA shows high overall structural similarity to
both the human and yeast PCNA crystal structures
(Fig. 5), with average RMSD values across all sub-
units of 1.51A and 1.53A, respectively. Despite this,
variation in the sequence of the IDCL results in struc-
tural changes that may affect interactions with binding
partners. Interestingly, the IDCL of AfumPCNA
showed more similarity to the human IDCL rather
than the yeast IDCL, implying the AfumPCNA sur-
face may interact with interacting partners by means
of a human type PIP-box. The IDCL (residues 118–
134) stretches across the outside of seven of the nine
strands of the core b-sheet in each subunit (Fig. 6A).
It is stabilized by a number of interactions with both
backbone atoms and side chains protruding from the
underlying sheet, including hydrogen bonds between
Met119 (N) and Gly69 (O) (2.94A), Gln123 (NE2) and
Asp29 (OD2) (2.70A), and Leu126 (O) and Gln38
(NE2) (3.32A). The hydroxyl group of Tyr133 also
forms two separate water-mediated hydrogen bonds
with Pro234 (O) and Try249 (OH). In addition, Ile128
packs against hydrophobic residues Leu47 and Tyr249,
and Tyr133 sits in a hydrophobic pocket formed by
Cys228, Val233, Leu236, and Tyr249.
These interactions are conserved in hPCNA, with
the notable exception of Gln123. A valine is present at
this position of the IDCL in hPCNA, precluding any
hydrogen bonding interaction with Asp29. This aspar-
tate residue has been shown to be involved in binding
p21 (and other PIP-box peptides with antiparallel b-
strand interaction) [44,55]. Therefore, the sequestering
of this hydrogen bond acceptor by Gln123 in
AfumPCNA may result in differences in binding speci-
ficity and affinity for PIP-box-containing peptides.
This difference at position 123 is accompanied by the
most evident conformational difference in the IDCL
Fig. 4. Subunit–subunit interface of
AfumPCNA. AfumPCNA is shown in ribbons
with interacting residues shown as sticks.
Subunit A is shown in magenta, while
subunit B is shown in green. (A) Subunit–
subunit interface of the b-sheet region. (B)
Subunit–subunit interface of the a-helix
region.
Fig. 5. Superimposition of PCNA subunits from different species.
PCNA subunits are depicted in wire format. AfumPCNA is depicted
in green (5TUP), hPCNA is depicted in magenta (PDB: 1AXC), and
yPCNA is depicted in yellow (PDB: 1PLQ) [37,44].
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between human and AfumPCNA; relative to Val123
of unliganded hPCNA (PDB: 1W60) [56], Gln123(Ca)
is shifted 4.14A toward the surface of PCNA and
results in a concomitant shift of adjacent residues
Asp122 and Glu124 in the same direction (Fig. 6B).
Inspection of the IDCL from S. cerevisiae PCNA
(yPCNA) [37] reveals conformational differences with
AfumPCNA (Fig. 6C). These differences are due to
substitutions at His125 and Pro129, two of the four
IDCL residue positions that have been used to sepa-
rate fungal species into two separate evolutionary fam-
ilies (Fig. 1) [54]. However, this region of the yPCNA
structure is involved in a number of crystal contacts,
which may also contribute to conformational differ-
ences in the IDCL. Interestingly, despite the presence
of a hydrophobic residue at position Ala123, similar to
hPCNA, the position of the IDCL in this region (122
to 124) is more similar to that of AfumPCNA, which
contains a glutamine residue at this position (Gln123),
as shown in Fig. 6C. Phe125 of yPCNA participates in
hydrophobic interactions that have a similar effect on
the position of IDCL residues 122 to 124 as the hydro-
gen bond between the side chains of Gln123 and
Asp29 of AfumPCNA. The side chain of Phe125
packs onto the underlying b-sheet via hydrophobic
interaction with Ile36 (Ala36 in AfumPCNA), drawing
residues 124 to 127 of the IDCL an average of ~ 1.1A
closer to the underlying b-sheet (Fig. 6C). Phe125 of
yPCNA partially occupies the space of Asp29 of both
AfumPCNA and hPCNA. This is reflected by the con-
formation of the side chain of Gln29 of yPCNA,
which is shifted ~ 3.8 A away from the IDCL back-
bone relative to Asp29 of AfumPCNA, potentially pre-
cluding it from acting as a hydrogen-bonding partner
for PIP-box-containing peptides. The proline at posi-
tion 129 in AfumPCNA is Glu129 in yPCNA
(Fig. 6C). This substitution induces a different confor-
mation of the IDCL and markedly alters the position
of this residue, allowing it to pack ~ 3.7A closer to the
underlying b-sheet, facilitated by an additional weak
hydrogen bond between Glu129 (OE1) and Gln247
(NE2) (3.5A). This increased flexibility also allows
Glu130 to occupy the space of Gln131 in hPCNA,
which has been shown to form a hydrogen bond with
the Tyr151 side chain hydroxyl group of the p21 pep-
tide [44]. AfumPCNA contains a Thr (Thr131) at this
position, a considerably shorter side chain which
would require extension of PCNA toward the PIP-box
for hydrogen bond formation as compared to the
human structure.
Fig. 6. Details of the AfumPCNA IDCL. (A)
Interactions of the AfumPCNA IDCL.
AfumPCNA is shown in green ribbons with
the IDCL highlighted as magenta sticks. (B)
Superimposition of AfumPCNA (green) with
unliganded hPCNA (magenta; PDB: 1W60)
[56]. (C) Superimposition of AfumPCNA
(green) with yPCNA (yellow; PDB: 1PLQ)
[37].
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Proliferating cell nuclear antigen residues
(AfumPCNA residue numbers) Met40, Val45, Leu47,
Leu126, Ile128, Pro129, Tyr133, Pro234, Tyr249,
Ala251, and Pro252 form a hydrophobic pocket that is
‘plugged’ by the conserved 310 helix of the PIP-box.
This interaction has been shown to be essential for
high-affinity binding of PIP-box-containing peptides
[55]. Strikingly, these residues are 100% conserved
between hPCNA and AfumPCNA highlighting the
conserved nature of this interaction. Comparison of
these with the hydrophobic pocket of yPCNA reveals
only minor differences, with the only nonconserved
substitution being position 129 in the IDCL, as previ-
ously mentioned.
Proliferating cell nuclear antigen residues of the C
terminus that have been shown to interact with PIP-
box peptides include Ala252, Pro253, and Ile255 of
hPCNA and Ala251, Pro252, Lys253, and Phe254 of
yPCNA [37,44]. These are conserved in AfumPCNA,
suggesting their importance in mediating PCNA–PIP
interactions across fungi and mammals. The six C-
terminal residues of hPCNA (256 to 261) are disor-
dered in the PCNA:p21-peptide structure. This
includes four charged residues which have been sug-
gested to closely associate with the charged residues at
the N terminus of the p21 peptide via poorly ordered
ionic interactions. The final four residues of
AfumPCNA and yPCNA (both 255 to 258) are unde-
fined in the electron density of these structures and
include three charged residues, one aspartate and two
glutamine residues, suggesting the conservation of this
poorly ordered ionic interaction with binding peptides.
AfumPCNA binds p21 peptide with high affinity
To determine if the AfumPCNA interacts with its
partners by means of a PIP-box, we determined the
affinity of AfumPCNA for a peptide derived from the
cyclin-dependent kinase inhibitor protein p21, previ-
ously shown to have the highest known affinity for
hPCNA [55]. AfumPCNA binding to a canonical
human p21 PIP-box motif was determined by incubat-
ing FITC-labeled p21 peptide (N-139 GRKRRQTSM
TDFYHSKRRLIFS 160-C) with increasing concentra-
tions of AfumPCNA, and measuring the changes in
fluorescence polarization. Figure 7 contains the dose–
response curves for the fluorescence binding. A Kd
value of 3.1  0.1 lM was determined in PBS using
similar conditions to Bozza et al. [57] (Fig. 7B). These
authors determined the affinity of hPCNA to the same
peptide in these conditions to be 342 nM. Thus, using
similar buffer conditions, the p21 interaction for
hPCNA is only 10-fold higher in affinity than the
interaction with AfumPCNA. In experiments using
Tris buffer (Fig. 7A), the Kd was determined to be
1.0  0.1 lM, indicating that removal of salt strength-
ens the AfumPCNA/p21 interaction. Electrostatic con-
tacts play a role in hPCNA/p21 complex formation,
with salt bridges stabilizing the intermolecular b-sheet
(hPCNA Asp29 to p21 Arg154, and hPCNA residues
Asp122 and Glu124, to p21 Arg155). These hPCNA
residues are conserved in AfumPCNA suggesting the
intermolecular electrostatic interactions may be main-
tained, consistent with the FP data.
Deciphering the interaction of p21 with
AfumPCNA by molecular dynamics simulation
Given our finding that AfumPCNA interacts with the
human p21 peptide with high affinity, we performed
Fig. 7. Fluorescence polarization binding curves. Determination of
the binding affinity of AfuPCNA for N-terminally FITC-labeled
human p21 peptide in (A) 20 mM Tris with 10% glycerol and (B)
PBS, pH 7.4 (full details of buffer conditions are giving in the
Materials and methods). Curves represent single experiments,
where each data point is the mean of triplicate samples and error
bars represent the standard deviation. Each experiment was
repeated three times.
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molecular dynamics simulations to better define the
interactions of AfumPCNA with p21 as well as iden-
tify the structural basis for the lower affinity interac-
tion with AfumPCNA versus hPCNA. The molecular
dynamics simulation was carried out for a total of 50 ns
using the AfumPCNA trimer bound to one p21 peptide
per subunit. The simulation was stable over the entire
time frame as indicated by the RMSD versus time (plot-
ted by secondary structure) depicted in Fig. 8, and the
overall structural trajectory is shown in Fig. 9. Two
movies of the simulation can be found in the Support-
ing Information section (Movies S1 and S2).
The molecular dynamics simulation revealed that,
although the core binding mode of the p21 peptide to
PCNA is largely conserved between human and A. fu-
migatus, a number of differences are present that may
contribute to a lower peptide-protein affinity for the
A. fumigatus protein. The interaction of p21 with
AfumPCNA, much like with hPCNA, can be concep-
tually divided into interactions of the p21 N terminus,
310 helix, and C terminus, the latter of which forms an
antiparallel b-sheet with the IDCL of PCNA.
The interaction of the p21 peptide N-terminal resi-
dues with the AfumPCNA C terminus was maintained
throughout the simulation. Similar to the interactions
of p21 with hPCNA, interactions of the N terminus of
p21 include a system of hydrogen bonds: a hydrogen
bond from p21 Arg143 main chain oxygen atom to
Ile255 main chain nitrogen atom and from Gln144 side
chain to Ser44 main chain oxygen atom (Fig. 10A).
Unlike the p21 interaction with hPCNA, the side chain
of Thr145 does not make a hydrogen bond with
AfumPCNA and is instead rotated away from the sur-
face of AfumPCNA making no intermolecular con-
tacts by means of the side chain atoms.
The p21 310 helix that plugs a hydrophobic pocket
on PCNA was stable throughout the duration of the
simulation, reflecting the high conservation of residues
that form the pocket (including residues Met40, Val45,
Leu47, Leu126, Ile128, Pro129, Tyr133, Pro234,
Tyr249, Ala251, and Pro252). Tyr151 is one of the key
residues for high-affinity interaction of p21 with
hPCNA [58], due to the side chain hydroxyl proton
forming a hydrogen bond to the side chain nitrogen
atom of Gln131. This interaction was predicted to be
lost in AfumPCNA, due to the substitution of Gln for
Thr at this position (Thr131 of AfumPCNA). The sim-
ulations showed this held true for two of the three
peptide–PCNA interactions, but interestingly, a hydro-
gen bond between Thr131 (side chain hydroxyl) and
p21 peptide Tyr151 (side chain hydroxyl) is present in
the remaining peptide interaction, but requires Tyr151
to shift approximately 2.7A toward the core of the
protein. Of the three p21 peptides bound to the PCNA
trimer, the peptide which forms the hydrogen bond
between Thr131 and Tyr151 also adheres to a well-
formed antiparallel b-strand, while the two peptides
with unstable b-strand formation are correlated with a
loss of hydrogen bonding capacity between these resi-
dues (Fig. 10B). From this it can be deduced that at
least part of the lower affinity of p21 for AfumPCNA
can be attributed to the lessened ability of p21 to
hydrogen bond with AfumPCNA residue Thr131,
which is intricately linked to the b-strand conforma-
tion of the peptide. In addition, AfumPCNA contains
a larger and less hydrophobic surface cavity (124 A3 in
hPCNA/p21 versus 235 A3 in AfumPCNA/p21) cap-
able of promoting interaction with the 310 helix
(Fig. 10C,D); both of these effects can partly be attrib-
uted to the presence of Thr131 in the AfumPCNA
structure rather than Gln131 as seen in the hPCNA
structure.
The antiparallel b-sheet formed between the p21
peptide C terminus and residues 121–127 of the
AfumPCNA IDCL is maintained throughout the simu-
lation for one of the three peptides, partially main-
tained for another, but has completely dissociated in
the case of the remaining peptide (Figs 9 and 10B).
The formation of the b-strand conformation of p21 in
the AfumPCNA-bound simulation only occurs with
significant rearrangement of the IDCL as compared to
the human p21-bound IDCL. The disruption of this
interaction is consistent with the observation that
Asp123 of the IDCL sequesters the electrostatic inter-
action to Arg156 in the AfumPCNA crystal structure,
precluding the formation of hydrogen bonds to Asp29
from Arg156 of p21 that aid in anchoring the C-term-
inal half of the peptide to the surface of hPCNA
Fig. 8. Molecular dynamics RMSD versus time binned by
secondary structure. AfumPCNA is shown as blue, while the p21
peptides are shown in green, red, and brown.
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(Fig. 10E). Furthermore, His125 of AfumPCNA
obstructs b-sheet by formation of a favorable side
chain hydrogen bond with the His152 side chain of
p21, forcing the peptide in a conformation that is too
distant from the surface of AfumPCNA to form the
tight hydrogen bonds of a b-sheet as seen in the
human structure (Fig. 10E).
It is interesting to note that, while the interaction
between the central 310-helical plug and the
AfumPCNA hydrophobic pocket is very stable, the
polar interactions between the N-terminal and C-terminal
peptide residues and the PCNA C terminus and IDCL,
respectively, appear to be mutually exclusive. This is
shown by the observation that the loss of intermolecu-
lar hydrogen bonding at the C-terminal half of the p21
peptide is accompanied by an increase in the number
of hydrogen bonds between the N terminus of the pep-
tide and C terminus of AfumPCNA (Fig. 11C). In
fact, the only peptide for which the conformation of
the peptide’s N terminus and 310 helix (residues 143 to
151) is almost identical to that of the hPCNA–p21
peptide structure is the one that has completely lost
the b-sheet interaction at the C-terminal end of the
peptide. On the other hand, extensive hydrogen bond-
ing involving the C-terminal region of the peptide is
accompanied by a decrease in hydrogen bonding at
the N terminus of the peptide (Fig. 11A,B). Regarding
the peptide for which the b-strand in the C-terminal
region of the peptide is well maintained, the 310 helix
is forced into a more a-helical conformation by inter-
action with Thr131; a peptide conformation which
favors C-terminal b-strand formation, but disfavors
interactions between the N-terminal region and the C
terminus of AfumPCNA.
Discussion
Here we present the first crystal structure of PCNA
from A. fumigatus as well as the first crystal structure
of PCNA from a pathogenic fungus. Interestingly, the
structure of the AfumPCNA is more structurally
related to human PCNA than the previously reported
S. cerevisiae PCNA. Furthermore, we also demon-
strated that AfumPCNA interacts with high affinity
with a human PIP-box, implying that PCNA-interacting
proteins from the pathogen A. fumigatus are likely to
interact with AfumPCNA by means of a conserved
PIP-box similar to that of the human sequence. Given
that p21 interacts with AfumPCNA with 10-fold lower
affinity than its human counterpart, we performed
Fig. 9. Molecular dynamics simulation trajectory over time at 10-ns intervals. Displayed is a ribbon diagram of AfumPCNA (colored by
secondary structure) with p21 peptides shown as sticks (green, red, and brown).
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molecular dynamics simulations to uncover fundamen-
tal structural differences in the AfumPCNA surface
that can account for these differences in affinity. Our
MD revealed differences in the IDCL of AfumPCNA
that likely contribute to this difference in affinity,
including residues Asp29, His125, Asp123, and
Thr131.
Previous studies focusing on human PCNA have
suggested that a key factor for determining the affin-
ity of a protein for PCNA is the primary sequence of
its PIP-box [55,59]. Therefore, further investigation
into native partners of A. fumigatus PCNA, with a
focus on their PIP-box sequences, could uncover
determinants of high-affinity binding. It has also been
suggested that, evolutionarily speaking, natural
PCNA-interacting proteins are not optimized for high
affinity, but rather that affinity is finely tuned to
allow for rapid and appropriate exchange of partners
to allow the cell to adapt promptly to changing envi-
ronmental conditions [55,60]. This affords the possi-
bility that artificial PIP-box sequences could be
designed that have a greater affinity for PCNA than
the highest affinity native PIP-box-containing pro-
teins. Indeed, using the p21 PIP-box sequence to
Fig. 10. Interactions of AfumPCNA with the
p21 peptide as determined by molecular
dynamics. (A) Interactions of the p21 N
terminus (magenta) with PCNA (green). (B)
Interactions of the conserved Tyr151 of p21
with Thr131 of AfumPCNA. Shown is a
superimposition of each PCNA subunit
(differentiated by color: cyan, green, and
magenta) bound to p21. (C) Surface
representation of AfumPCNA (green) bound
to p21 (magenta sticks). (D) Surface
representation of hPCNA (yellow) [44]
bound to p21 (magenta) (PDB: 1AXC). (E)
Interactions of the C terminus of p21
(magenta) with AfumPCNA (green).
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guide the design of high-affinity peptide mimetics that
target hPCNA for the treatment of cancer is the sub-
ject of ongoing investigation. In the same way, we
expect that the details of the PCNA–peptide interac-
tion interface presented in the current study will be
useful for guiding the synthesis of high-affinity pep-
tides which could, in turn, guide the design of stable,
high-affinity peptide mimetics that bind tightly to
AfumPCNA, halting DNA replication, thereby pre-
venting fungal cell growth. In addition, the differ-
ences between the peptide interaction surfaces of
hPCNA and AfumPCNA highlighted here may afford
specificity of antifungal peptides toward the fungal
PCNA over its human homolog.
Fig. 11. Frequency of intermolecular
hydrogen bonds between residues of the
p21 peptide and AfumPCNA during the MD
trajectory. ‘Collective % H-bond occupancy’
(y-axis) denotes the proportion of time that
a hydrogen bond exists between a specific
p21 peptide residue and PCNA over the
course of the MD simulation. Note that this
value may be > 100% if there are multiple
hydrogen bond donors or acceptors
implicated in either the peptide residue or
PCNA. (A) Hydrogen bonds of subunit A. (B)
Hydrogen bonds of subunit B. (C) Hydrogen
bonds of subunit C.
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Materials and methods
Protein expression and purification
The AfumPCNA coding sequence was PCR amplified from
A. fumigatus strain af293 cDNA using primers (a) 50-CCC
GGGCATATGTTGGAAGCACGACTAG-30 and (b) 50-GG
GCCCGGATCCTTACTCCTCATCTCCGATC-30 and
cloned into the pMCSG19 vector using BamHI and NdeI
restriction sites. Sequencing revealed that the sequence cod-
ing for AfumPCNA included 117 extra nucleotides at the 50
end when compared to the sequence deposited in the NCBI
database (Accession XM_745146) [61] but was identical to
the ORF sequence available at www.aspergillusgenome.org
(afu1g04900) (accessed 23 May 2016), indicating an error in
the original annotation. AfumPCNA was overexpressed in
Escherichia coli BL21(DE3) shake-flask culture by the addi-
tion of 0.5 mM IPTG when the culture reached log-phase,
and incubated at 16 °C for approximately 18 h. Cell pellets
were resuspended in 20 mM Tris pH 7.5, 20 mM NaCl,
0.5 mM EDTA, 2 mM DTT, and stored at 80 °C until
required.
Cells were lysed by high-pressure disruption and insoluble
debris was removed by centrifugation before purification of
the protein from the crude lysate, as follows. Lysate was
loaded onto a 5 mL Unosphere Q column (Bio-Rad, Her-
cules, CA, USA) and eluted using a linear NaCl gradient
(20 to 700 mM). Fractions containing AfumPCNA were
pooled and brought up to 1.5M (NH4)2SO4 by the dropwise
addition of 3 M (NH4)2SO4 before incubating overnight at
4 °C with gentle stirring. Precipitate was then cleared by
centrifugation; supernatant was loaded onto a 5 mL HiTrap
Phenyl FF column (GE) and eluted using a reverse linear
salt gradient (1.5 to 0M (NH4)2SO4, 20 to 0 mM NaCl).
AfumPCNA fractions were pooled and dialyzed with 20 mM
Tris pH 7.5, 50 mM NaCl, and 2 mM DTT overnight at
4 °C. Dialyzed protein was concentrated to 10 mL and
passed through a HiPrep Sephacryl 26/60 S-300 column
(GE) equilibrated in 20 mM Tris pH 7.5, 50 mM NaCl, and
2 mM DTT. AfumPCNA fractions were then pooled and
dialyzed against 20 mM Tris pH 7.5, 20 mM NaCl, and
2 mM DTT overnight at 4 °C. Dialyzed protein was loaded
onto a 1 mL Enrich Q column (Bio-Rad) and eluted using a
linear NaCl gradient (20 to 500 mM). AfumPCNA fractions
were pooled and dialyzed with 20 mM Tris pH 7.5, 2 mM
DTT, and 10% glycerol overnight at 4 °C, concentrated to
approximately 10 mgmL1 and subjected to crystallization
trials immediately.
Crystallization, data collection, and structure
determination
Protein crystallization was carried out by vapor diffusion in
sitting-drop format at 16 °C. Crystals grew as small plates
in 0.2 M KCl, 20% PEG 3350, and diffracted X-rays to
2.6A using the MX-1 beamline at the Australian Syn-
chrotron [62]. Data were collected at 100 K using 1o oscil-
lations at a wavelength of 0.9537A. The AfumPCNA data
were processed in space group P21 using iMosflm and
solved by molecular replacement using phaserMR [63] with
a homology model built using chainsaw [23]. The Litope-
naeus vannamei PCNA crystal structure (PDB: 4CS5) [64]
was used as a template for the homology model. The struc-
ture was refined by iterations of manual rebuilding using
Coot [65] and refinement using phenix.refine [66]. Groups
for TLS parameterization [67] were defined automatically
using phenix.refine and used for refinement as this
improved refinement statistics. For the final rounds of
refinement, NCS restraints were imposed along with opti-
mization of X-ray/stereochemistry weight to improve the
stereochemistry of the final model. The final rebuild was
performed using a feature-enhanced map (FEM) generated
using phenix [68]. The final structure contained 0.66%
Ramachandran outliers with 99.34% of the residues con-
tained in the most favored and allowed regions. Coordi-
nates were deposited in the PDB, accession code 5TUP.
P21 peptide binding assay using fluorescence
polarization
Fluorescence polarization assays were carried out on a Per-
kinElmer Victor X5 2030 Multilabel Reader, using 100 nM
N-terminally FITC-labeled human P21 peptide (N-139
GRKRRQTSMTDFYHSKRRLIFS 160-C) as the labeled
ligand, and increasing concentrations of AfumPCNA (0.2–
26 lM). Experiments were performed at room temperature,
in either buffer 1: 20 mM Tris (pH 7.5) with 10% glycerol,
or buffer 2: phosphate-buffered saline (137 mM NaCl,
2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4).
Each buffer also contained 2 mM DTT, 0.01% triton, 1 mM
EDTA, and 1xCOMPLETE protease inhibitors.
Data were fit to the following equation:
DFP ¼ FPmax  ðLT þ Kd þ RTÞ

ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðLT þ Kd þ RTÞ2  4LTRT
2LT
s
where DFP is the measured change in fluorescence
polarization, FPmax is the maximum change in polar-
ization of the labeled ligand upon saturation, LT is the
ligand concentration, RT is the protein concentration,
and Kd is the dissociation constant for the interaction.
Each experiment consisted of triplicate samples, and
experiments were repeated three times to obtain a
mean Kd value, and standard deviation.
Molecular dynamics simulations
The p21 peptide was docked onto the AfumPCNA-binding
surface of one subunit using the ICMPRO (Molsoft) software
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suite [69]. The trimeric complex of AfumPCNA–p21 was
constructed using hPCNA as a guide after aligning individ-
ual AfumPCNA–p21 complexes with the hPCNA trimer.
Molecular dynamics simulation of p21 peptide bound to
the AfumPCNA was conducted using NAMD 2.9 [70].
PCNA and peptide complex was parameterized with the
CHARMM27 force field [71] and solvated using the solvate
plugin of VMD [72]. After neutralization, 150 mM NaCl
was added to the solvated system using the autoionize plu-
gin of VMD. Prior to the simulation, the system was equili-
brated to NPT ensemble for a period of 2 ns. Then the
production simulation was carried out for a period of
50 ns. During the simulation, a 12A cutoff was used for
nonbonded short-range interactions, and long-range elec-
trostatics were treated with the particle-mesh Ewald
method [73]. Temperature and pressure were maintained at
310K and 101.3 kPa using Langevin thermostat and the
Langevin piston. The time step used was 1 fs. Trajectories
were saved at every 20 ps. Data analysis and the visualiza-
tion of the simulation were carried out by the VISUAL
MOLECULAR DYNAMICS package [72].
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ABSTRACT: Aspergillus fumigatus infections are associated with high mortality rates and 
high treatment costs. Limitations of available antifungals and increasing antifungal resistance 
highlight the need for new antifungals. Thioredoxin reductase (TrxR) is essential for 
maintaining redox homeostasis and presents as a promising target for novel antifungals. We 
show that ebselen (2-phenyl-1,2-benzoselenazol-3(2H)-one) is a potent inhibitor of A. 
fumigatus TrxR (Ki = 0.22 μM) and inhibits growth of the fungus with an MIC of 1-2 µg/mL. 
Mass spectrometry analysis demonstrates that ebselen interacts covalently with a catalytic 
cysteine of TrxR, Cys148. We also present the X-ray crystal structure of A. fumigatus TrxR, 
and use in silico modeling of the enzyme-inhibitor complex to outline key molecular 
interactions, providing a scaffold for future design of specific and potent anti-Aspergillus 
drugs that target TrxR. 
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In recent years, considerable progress in the areas of cancer treatment and transplantation, with 
a concomitant rise in the number of immunocompromised patients, has been accompanied by 
an increased incidence of invasive fungal infections (2-5). The main contributors are Candida 
spp. and Aspergillus spp., with a recent trend towards the latter as the most common cause of 
invasive fungal infection (6, 7). Aspergillus fumigatus is one of the most prevalent airborne 
fungal species in the environment; spores are ubiquitous and constantly inhaled by humans 
(2). Normally spores are cleared easily by the innate immune system; however, in the case of 
an immunocompromised host they can germinate and cause infection (8). A. fumigatus is by 
far the most common etiologic agent of invasive aspergillosis (IA), frequently causing life-
threatening infections in immunocompromised patients such as transplant recipients, those 
with hematological malignancies, particularly acute leukemia, and AIDS patients (2, 3, 9). IA 
is now the main contributor to mortality due to lung infection in bone-marrow transplant 
patients (10). A. fumigatus infection is difficult to diagnose early and accurately, and 
knowledge of the details of its growth, host-interactions and pathogenesis is lacking. In 
addition, the number of antifungals effective against it is limited and resistance is on the rise 
(11-14).  
There are three classes of antifungals used to treat A. fumigatus infections: azoles, polyenes 
and echinocandins, all targeting components of the cell wall or cell membrane (15). All three 
drug classes are associated with significant side-effects (11). Amphotericin B, a polyene, has 
been used to treat IA for over four decades, but has been largely superseded by azole 
antifungals due its poor side-effect profile (11, 16). In particular, acute renal failure associated 
with amphotericin B treatment has contributed to longer hospital stays and higher mortality 
rates (17). Current practice guidelines by the Infectious Diseases Society of America for the 
management of IA recommend the azole drugs voriconazole and posaconazole for first-line 
treatment and prophylaxis, respectively, in most cases (18). Despite being the preferred 
therapeutic option, azoles are also associated with serious side-effects, such as hepatotoxicity, 
visual disturbances, rash, photosensitivity, psychosis and prolonged QT interval – and are 
susceptible to a number of clinically significant drug-drug interactions involving cytochrome 
P450 metabolism (11, 15, 16, 19). Most alarming is the emergence of resistance to azole 
antifungals.  
Azole-resistant A. fumigatus isolates have now been reported worldwide and have been 
correlated with treatment failure and high mortality rates (50 to 100%) (14). Ongoing 
monitoring in the Netherlands has shown a rapid increase in the prevalence of azole-resistant 
A. fumigatus, with the first examples emerging in 2000, growing to a prevalence of 10.1% in 
2010 (20, 21). A more recent survey of 16 Dutch hospitals reported azole resistance rates of 5 
to 10%, with rates up to 30% in particular hematology wards (22). Similarly, a UK study of 
clinical A. fumigatus isolates spanning 1997 to 2007 reported a rapid rise in the frequency of 
resistance to azoles after 2004; up to 17% in 2007 (23). This rapid emergence in resistance to 
the main class of drugs used to treat Aspergillus infections, increasing incidence of infection, 
and limitations of currently available antifungals, all highlight the need for the development 
of new antifungals with novel targets. This requires a detailed knowledge of the basic biology 
of the organism and the intracellular systems that are essential for its growth and survival in 
the human host. One such system is the maintenance of intracellular redox homeostasis. 
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The two main antioxidant systems that are responsible for maintaining cellular redox 
homeostasis, the glutathione (GSH) and thioredoxin (Trx) systems, are essential for cellular 
viability (24, 25). The Trx system is present in all domains of life and has a diverse range of 
functions including: maintaining the intracellular environment in a reducing state to prevent 
protein aggregation or inactivation due to the formation of deleterious disulfide bonds, acting 
as an electron donor for various biosynthetic enzymes (for example, ribonucleotide reductase; 
responsible for production of deoxyribonucleotides for DNA synthesis (26)) or enzymes that 
catalyze the reduction of reactive oxygen species, the redox regulation of many transcription 
factors, and allowing correct insertion of native disulfide bonds in proteins entering the 
endoplasmic reticulum (27-29). These functions are mediated by Trx, a small single domain 
protein with two adjacent redox-active cysteines that provide the electrons required for 
reduction of substrate (30, 31). The reducing activity of Trx is dependent on Trx reductase 
(TrxR), which catalyzes the transfer of electrons from NADPH to the redox active dithiol of 
Trx (30) (Fig. 1a). TrxRs (EC 1.8.1.9) are dimeric flavoenzymes and can be divided into two 
broad classes: high molecular weight (MW) TrxR and low MW TrxR (28).  
High MW TrxRs are present in animals and have a typical subunit MW >55 kDa. In addition 
to endogenous Trx, mammalian TrxR can efficiently reduce a range of substrates including 
Trxs from other species, a number of other disulfide and selenocysteine-containing proteins, 
and also a variety of small molecules such 
as peroxides, selenite, selenodiglutathione, 
vitamin K and 5,5’-dithiobis(2-nitrobenzoic 
acid) (DTNB) (32). They are structurally 
homologous to glutathione reductases, with 
a similar arrangement of FAD and NADPH 
binding domains, but with an additional 
flexible C-terminal extension containing a 
redox-active cysteine-selenocysteine pair 
(33, 34). The increased reactivity of this 
selenocysteine at the active site is believed 
to confer the higher substrate promiscuity of 
high MW TrxR as compared to low MW 
TrxR (35). 
Low MW TrxRs are present in prokaryotes, 
plants and fungi and show specificity for 
their endogenous Trx substrate (36-38), 
with an overall structure and molecular 
mechanism that differs considerably from 
high MW TrxRs. A single subunit is 
typically 35-40 kDa and is composed of an 
NADPH domain, a FAD domain, and a 
CA[T/V]C active site contained within the 
NADPH domain (39). These active-site 
cysteine residues provide the redox-active 
dithiol from which reducing equivalents are 
transferred to Trx in a thiol-disulfide 
Figure 1 | TrxR reaction mechanism and 
inhibition by EbSe. (a) TrxR catalyzes the NADPH-
dependent reduction of Trx via a dithiol-exchange 
reaction. (b) Proposed mechanism by which EbSe 
(bottom left) inhibits low MW TrxR (1). 
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exchange reaction (40). Two distinct enzyme conformations are required to complete the 
catalytic cycle, referred to as flavin-oxidizing (FO) or flavin-reducing (FR) conformations (40, 
41). A 66° rotation of the NADPH domain relative to the FAD domain is required to alternate 
between these two conformations (40, 41). In the FR conformation, the bound NADPH 
molecule is aligned with the embedded FAD cofactor to allow for electron transfer from its 
nicotinamide group to the flavin group (41). Concurrently, the active site dithiol is exposed to 
allow for reduction of Trx. In the FO conformation, the flavin group is aligned with the active 
site to allow reduction of the disulfide to regenerate the active site dithiol (39, 40). 
The central role of the Trx system in cellular redox homeostasis, anti-oxidant defense and 
DNA synthesis has led to the investigation of TrxR as a target for antimicrobials (1, 42-44) as 
well as drugs for the treatment of cancer (45, 46) and rheumatoid arthritis (47). In addition, 
the differing structures and molecular mechanisms of high and low MW TrxRs affords the 
possibility of selectively inhibiting the Trx system of bacterial and fungal pathogens over the 
human system (1). In fungi, the essential role of TrxR (low MW) has been shown by genetic 
studies (37, 48-50). The Saccharomyces cerevisiae genome contains two TrxR genes, TRR1 
and TRR2, encoding for cytosolic and mitochondrial enzymes, respectively (51). Disruption 
of TRR1 results in poor viability, hypersensitivity to H2O2, methionine auxotrophy, and growth 
that is slow and temperature-sensitive (49, 50). Similarly, a TRR2 knockout strain was twice 
as sensitive to oxidative stress caused by H2O2 exposure than wildtype (37). More 
significantly, a conditional mutant strain of A. fumigatus in which TRR1 expression was 
repressed exhibited a severe growth defect under normal growth conditions (48), presenting 
TrxR as a potential target for novel antifungals. 
Ebselen (2-phenyl-1,2-benzoselenazol-3(2H)-one; EbSe), a small selenium-containing redox 
active molecule (Fig. 1b), has shown potential as a drug that can target TrxR (1). In humans, 
EbSe has antioxidant, anti-inflammatory and cytoprotective properties, and a favorable 
toxicological profile, and is being investigated for the treatment of a range of clinical 
presentations including stroke (52), bipolar disorder (53), type II diabetes (54), osteoporosis 
(55) and noise-induced hearing loss (56). In contrast, EbSe has been shown to have 
antimicrobial activity against a range of bacterial and yeast pathogens (57-60), and is a potent 
inhibitor of E. coli TrxR in vitro (1). 
Here, we show that EbSe is a nanomolar inhibitor of A. fumigatus TrxR (AfTrxR), and verified 
that EbSe has potent antifungal activity against A. fumigatus in culture. Inhibition of TrxR is 
mediated via formation of a covalent complex with a specific active-site cysteine. We also 
present the crystal structure of AfTrxR at 3.2 Å and have used this structural information, along 
with MS/MS data confirming the EbSe-TrxR interaction, to inform molecular modeling of the 
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RESULTS 
AfTrxR enzyme kinetics and inhibition by ebselen. Recombinant AfTrxR, purified to 
homogeneity, was assessed for its ability to reduce A. fumigatus Trx (AfTrx) using the DTNB 
assay, essentially as described (30, 32, 36, 61). The kinetic parameters of AfTrxR were 
determined to be comparable to those of low MW TrxRs from other species, with an apparent 
KM for AfTrx of 1.2 ± 0.1 µM and kcat of 8.6 ± 0.2 sec
-1 (Table 1). Others have shown that 
EbSe is a potent inhibitor of E. coli TrxR in vitro, with a Ki of 0.52 ± 0.13 µM (1). Upon 
addition of EbSe to our assay, we also observed a significant decrease in AfTrxR activity. At 
concentrations of EbSe from zero to 0.90 µM, the data fit a standard model of competitive 
inhibition (Supplementary Fig. 1) and show that EbSe is an even more potent inhibitor of 
AfTrxR than for E. coli TrxR, with a Ki of 0.22 ± 0.01 µM (Table 1). AfTrxR activity was 
completely abolished in the presence of 4 µM EbSe (data not shown).  
Ebselen interacts covalently with a catalytic cysteine. EbSe reacts with exposed cysteines 
to form covalent selenosulfide adducts (63, 64). This is the proposed mechanism by which 
EbSe inhibits bacterial TrxR, and involves the formation of a covalent bond between the Se 
atom and the Sγ of one of the active site cysteines (1) (Fig. 1b). This is accompanied by the 
cleavage of the Se-N bond, resulting in the opening of the 1,2-selenazolidin-3-one ring. In 
contrast, EbSe is efficiently turned over by mammalian (high MW) TrxR to produce EbSe 
selenol (65). This incongruence can be explained by observing that for high MW TrxR, the 
increased reactivity of the selenocysteine at the active site results in the formation of a 
diselenide bond, which is non-polar and therefore attacked readily by the nucleophilic 
resolving cysteine, allowing for the efficient turnover of EbSe, whereas the selenosulfide bond 
formed between low MW TrxR and EbSe is polar with a partial negative charge on the S atom, 
hindering nucleophilic attack by the resolving cysteine. To investigate whether this is the 
mechanism of inhibition of AfTrxR by EbSe, AfTrxR was subjected to MS/MS analysis after 
incubation with excess EbSe. The experiment was performed for wild-type AfTrxR and two 
mutants, AfTrxR(C145S) and AfTrxR(C148S). Peptides covering the active site were detected 
for all three proteins (Fig. 2; Supplementary Figs. 2 and 3). Only one of these was modified 
by EbSe, AfTrxR(C145S). The MS/MS data indicate that this peptide was modified at Cys148, 
with a mass increase corresponding to one EbSe molecule (Fig. 2; Supplementary Fig. 2). 
The corresponding cysteine residue of E. coli TrxR (Cys138) has been shown by biochemical 
(66) and structural (41) studies to be the attacking thiolate on the redox-active disulfide of Trx. 
In addition, EbSe was shown to modify Cys138 of E. coli TrxR previously (1), consistent with 
our results. 
Table 1. Kinetic parameters of TrxRs from A. fumigatus, S. cerevisiae and E. coli, with endogenous Trx as 
substrate. Inhibition constants for EbSe have been determined for AfTrxR and EcTrxR only. 
Enzyme KM (µM) kcat (sec–1) EbSe Ki (µM) 
AfTrxRa 1.2 ± 0.1 8.6 ± 0.2 0.22 ± 0.01 
ScTrxR 1.3b 43.7b ND 
EcTrxR 2.89c 22c 0.52 ± 0.13d 
a Data for the current study were collected in triplicate, with uncertainty expressed as standard error. b Data 
obtained from Oliveira et al, 2010 (36). c Prongay et al, 1989 (62). d Lu et al, 2013 (1). ND = Not determined. 
All data were collected using the DTNB assay under similar experimental conditions. 
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Ebselen has potent antifungal activity against A. fumigatus. To assess whether the observed 
in vitro inhibition of TrxR by EbSe translates to inhibition of fungal growth, the antifungal 
activity of EbSe against A. fumigatus was determined on solid and in liquid media according 
to Clinical & Laboratory Standards Institute 
methods. In broth microdilution, EbSe inhibited 
growth of A. fumigatus with an MIC of 1-2 
µg/mL, comparable to or better than that of 
other currently available non-azole antifungal 
drugs (Table 2). Similarly, on solid media, a 
clear zone of inhibition was evident that 
demonstrated the inhibition of A. fumigatus 
growth by EbSe (Supplementary Fig. 4). 
Crystal Structure of A. fumigatus TrxR. The crystal structure of AfTrxR in complex with 
NADPH and FAD was solved in space group P3221 by molecular replacement using data to a 
resolution of 3.2 Å. Data processing and refinement statistics are listed in Supplementary 
Table 1. The asymmetric unit contains two protein subunits, representing a head-to-tail 
homodimer (Fig. 3a). The tertiary structure of each AfTrxR subunit is homologous to yeast, 
bacteria and plant TrxRs solved previously; when superposed with E. coli, S. cerevisiae and 
A. thaliana TrxR crystal structures, the resulting RMSD values across all Cαs are 2.28 Å, 0.83 
Å and 1.35 Å, respectively (Supplementary Fig. 5). Electron density allowed model building 
Table 2. Antifungal activity of EbSe and other 
non-azole antifungal drugs against A. fumigatus 
(ATCC MYA 3626) by broth microdilution 
method after 48 hr incubation. 




Amphotericin B 4-8 
Figure 2 | MS/MS data shows that EbSe forms a covalent bond with Cys148 of AfTrxR. Displayed 
above is the MS/MS data of a peptide with m/z 1642.74 derived from AfTrxR(C145S) after incubation 
with excess EbSe. A mass shift at Cys148 equal to the addition of one EbSe molecule (MW = 274.18) 
confirms the formation of a covalent bond between EbSe and Cys148. The peptide sequence modified at 
Cys148 is shown, with the C145S mutation marked by an asterisk. Full peptide annotation along with 
equivalent non-modified peptides derived from AfTrxR wildtype, C145S and C148S proteins is provided 
in Supplementary Figs. 2 and 3. 
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of residues 1 through 326 of both polypeptide chains, with the exceptions of Met1 and Gly39 
of subunit A, and Ala37 through Gly43 of subunit B. The density is poor for the β2-η1 loop 
(residues 34 to 44) relative to the rest of the structure, suggestive of flexibility in this region. 
This loop forms a ‘cap’ over the FAD binding pocket, shielding the adenosine rings of FAD 
from solvent. This FAD cap is conserved in yeast and plant TrxRs, but consists of five fewer 
residues in the E. coli TrxR (Supplementary Fig. 6). Its structure has been observed 
previously for Entamoeba histolytica TrxR (44), and, given its position at the Trx binding site, 
it is very likely to contribute to the species-specific recognition of Trx by low MW TrxRs. The 
C-terminal 47 residues (327 to 373) of both subunits are unstructured, representing a 
disordered region. The crystal lattice (not shown) contains wide solvent channels, consistent 
with the high solvent content and fragility of the crystals, which are probably necessary to 
accommodate this flexible C-terminus. Interestingly, this C-terminal extension is absent from 
E. coli, S. cerevisiae and A. thaliana TrxRs (Supplementary Fig. 6), and its functional 
significance is unknown. 
Each subunit of AfTrxR consists of two domains: an FAD domain and an NADPH domain 
(Fig. 3a). Both domains form Rossmann folds, typical of nucleotide binding domains, with a 
central five-stranded parallel β-sheet sandwiched between an anti-parallel β-sheet on one side 
and three α-helices on the other. Regarding both dinucleotides and their respective domains, 
the adenosine nucleoside is positioned at the C-terminal end of the central parallel β-sheet, and 
Figure 3 | Crystal structure of AfTrxR in flavin-oxidizing conformation at 3.2 Å. The NADPH molecule 
(cyan), the FAD molecule (magenta) and key residues are shown as sticks. The polypeptide backbone is 
shown in cartoon representation. A 2mFo-DFc composite omit electron density map for the bound 
dinucleotides and active site cysteines (Cys145 and Cys148) is contoured at 1.0 (blue mesh) and 3.0 (pink 
mesh) rmsd (right panels only). Lengths of hydrogen bonds (dashes) are shown in Å. (a) The AfTrxR 
homodimer. α-helices (cylinders) and β-stands (arrows) are labeled for one subunit. Each subunit (colored 
different shades of green) contains an NADPH domain connected to an FAD domain via a short two-stranded 
‘hinge’. Each domain is composed of a central parallel β-sheet sandwiched between an antiparallel β-sheet 
and three α-helices (note that β1 and β6 contribute to both β-sheets of the FAD domain). (b) Stereo view of 
the adenosine of NADPH with key binding site residues. Electron density was insufficient to model the 
nicotinamide riboside. (c) Stereo view of the bound FAD cofactor and key residues. The flavin moiety is 
poised for electron transfer to the Sγ atom of Cys148. 
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the bridging pyrophosphate is positioned at the N-terminus of the central α-helix. The two 
domains are connected by a short two-stranded antiparallel β-sheet that serves as the hinge, 
allowing the domain rotation necessary for completion of the catalytic cycle (41). The 
dimerization interface area is 2,096 Å2, involving 34 hydrogen bonds (2.4 – 3.8 Å) and seven 
salt-bridges. The three α-helices (α1, α2 and α7) of the FAD domain along with the η1-α2 loop 
contribute most of the residues at the dimer interface. A number of solvent molecules are 
present at or near the interface. 
The adenosine nucleotide of NADPH, including the 3’-phosphate and bridging pyrophosphate, 
could be modeled in the NADPH binding site of both subunits; however, the nicotinamide 
riboside was not well ordered and therefore was excluded from the model (Fig. 3a,b). The 
bound NADPH is largely solvent exposed, allowing for rapid exchange of NADP+ for NADPH 
after transfer of reducing equivalents to FAD. Three conserved arginine residues of the β10-
α6 loop interact favorably with the 3’-phosphoadenosine of the NADPH: Arg189 and Arg193 
both form salt-bridges (2.9 Å) to the 3’-phosphate, and Arg188 packs against the adenine rings 
(~ 3.2 Å). The importance of these electrostatic interactions is highlighted by the strict 
conservation of these basic residues (Supplementary Fig. 6) and the high specificity of TrxR 
for NADPH over NADH, which lacks the 3’-phosphate (38). The opposite face of the adenine 
base packs against hydrophobic sidechains of Leu129, Ile163 and Val254. The pyrophosphate 
is bound at the N-terminus of α5, with hydrogen bonds to Asp167 (N) (2.9 Å) and Ser168 
(OH) (2.7 Å). Modeling of the nicotinamide riboside using the structure of TrxR from H. 
pylori as a template – for which the entire NADPH molecule is well defined (PDB: 2Q0K) – 
results in a distance of >15 Å between the nicotinamide and the flavin of FAD (not shown). A 
large domain rotation would thus be required to bring the nicotinamide of the NADPH into 
proximity to reduce the flavin (and simultaneously expose the active site cysteines – which 
are buried in the interior of the protein), as previously shown by structural studies on E. coli 
TrxR (41). 
Although no exogenous FAD was added during the protein purification or crystallization, 
electron density at the FAD binding site indicates that it is bound tightly and co-purified; an 
FAD molecule modeled at this site refined to an occupancy of greater than 85% in each 
subunit. The FAD is in an extended conformation, with one end (the flavin group) bound near 
the dimer interface and the other (the adenine base) partially exposed to solvent on the opposite 
side of the FAD domain (Fig. 3a,c). The adenosine is bound in a pocket at the C-terminal ends 
of β1, β2, and β6. Five hydrogen bonds (2.9–3.2 Å) to peptide backbone atoms of Tyr32, 
Glu33 and Ile87, and the sidechain hydroxyl of Thr122 stabilize the adenine base, and three 
hydrogen bonds (2.8–3.0 Å) to peptide backbone atoms of Ser11, Thr40 and Ala41 stabilize 
the ribose sugar. The negatively charged pyrophosphate is located immediately at N-terminal 
end of α1, interacting favorably with the helix dipole, and stabilized by three hydrogen bonds 
(2.7 – 3.1 Å) to backbone nitrogen atoms of Ala14, Gln45 and Asp294. The flavin moiety is 
positioned in the interior of the protein at the N-terminal end of α7. Here, the flavin is very 
close to the active site disulfide formed by Cys145 and Cys148. This is the flavin-oxidizing 
conformation of TrxR, with the flavin group poised for electron transfer to the active site 
cysteines. The C4 atom of the flavin group and the Sγ atom of Cys148 are positioned only 3.3 
Å from one another, consistent with the reaction cycle proceeding via a covalent adduct 
formed between these two atoms (39, 62). In contrast, the distance between this C4 atom and 
Cys145 (Sγ) is 5.3 Å. The positive charge provided by the helix dipole of α7, a very long helix, 
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would help to stabilize the negatively charged species that occur during electron transfer from 
the flavin group to Cys148. A hydrogen bond is formed between the O2 carbonyl of the flavin 
and the backbone nitrogen of Ala303 (2.9 Å), which is the first residue of α7. 
The active site cysteine residues, Cys145 and Cys148, are part of a short helix (α4) in the 
NADPH domain, and are positioned favorably to form a disulfide bond. Indeed, despite the 
presence of reducing agent (DTT) in the protein buffer, the electron density indicates that they 
do form a disulfide bond (Fig. 3c), with a distance of 2.03 Å between the Sγ atoms of each 
cysteine. This has been observed previously (44) and suggests that the active site cysteines are 
readily oxidized during crystallization and/or upon exposure to X-ray radiation. 
Modeling the Ebselen-AfTrxR Interaction. To investigate the interactions involved in the 
inhibition of AfTrxR by EbSe, the crystal structure of AfTrxR along with MS/MS data showing 
the covalent interaction of EbSe with Cys148 were used to inform in silico modeling of the 
complex. As discussed above, AfTrxR crystallized in the FO conformation, with the active site 
cysteines buried in the core of the protein close to the flavin group. In this conformation, there 
is a narrow cavity between the NADPH domain and FAD domain, leading from the NADPH 
binding site to the active site. In silico docking of EbSe to the AfTrxR crystal structure showed 
that, although an EbSe molecule can occupy this cavity, access to Cys148 is precluded as the 
cavity narrows to < 3 Å in diameter, too narrow to allow EbSe to react with Cys148 (not 
shown).  
The FR conformation of AfTrxR was therefore modeled by rotating the NADPH domain ~66° 
relative to the FAD domain, and modifying the active site to its reduced, dithiol configuration 
(Fig. 4a). This was guided by the structure of E. coli TrxR in the FR conformation (41) (PDB 
ID 1F6M), and followed by global model optimization (see Online Methods). Superposition 
of the final model on crystal structures of E. coli (1F6M) and Entamoeba histolytica (4CCQ) 
TrxRs in FR conformation gives RMSD values across Cαs of 1.65 and 2.48 Å, respectively. 
In this conformation, both active site cysteines are at the protein surface, with Cys145 
positioned away from the bulk solvent and Cys148 positioned towards the bulk solvent, 
consistent with the preferential modification of Cys148 as suggested by the MS/MS analysis.  
Docking of EbSe to this model was performed with inclusion of the proposed reaction 
mechanism (Fig. 1b) in the simulation. This involves breaking of the five-membered 1,2-
selenazolidin-3-one ring and formation of a covalent bond between the Se atom of EbSe and 
the Sγ atom of Cys148. The ten top docked conformations (poses) could be divided into three 
groups – A, B and C – based on their general positioning on the surface of the protein 
(Supplementary Fig. 7). A representative example from each group is shown in Fig. 4b. 
Group A includes five of the ten top poses, all with the EbSe molecule positioned in a narrow 
groove formed by residues 36 to 42 of the β2-η1 loop on one side and α4 (residues 146 to 149) 
on the other. A single hydrogen bond is formed between the carbonyl oxygen of the bridging 
amide and backbone nitrogen of Ala41. For the example shown in Fig. 4b (wheat color), the 
aniline ring is positioned at the entrance to the large cavity occupied by the FAD and packs 
against the Sγ atom of Cys145. The ortho-selenobenzamide ring at the other end of the 
molecule makes contacts with Thr47 and Thr48. Group B includes three poses in which EbSe 
packs exclusively against the NADPH domain. Each pose involves formation of a hydrogen 
bond via the N atom of the amide group to the sidechain of either Gln139 or Asp149. For one 
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of these poses (Fig. 4b, pink), the 
EbSe molecule extends up towards a 
pocket at the surface of the NADPH 
domain, approximately 7 Å from the 
active site. One side of the pocket is 
mostly hydrophobic, formed by 
sidechain atoms of Asp149, Val152, 
Ile154 and Phe155; the other side is 
formed by Gln139 and backbone 
atoms of residues 141 through 143. 
The aniline ring of EbSe is positioned 
at the entrance to this amphipathic 
pocket, forming extensive van der 
Waal contacts with Val152. Group C, 
which includes only two of the top ten 
poses, has EbSe packing down almost 
exclusively on the FAD domain, 
contacting a conserved string of four 
threonine residues: Thr47 through 
Thr50 (Fig. 4b, cyan). 
The docking results demonstrate 
several insights into the binding mode 
of EbSe with TrxR. Aside from the 
newly formed covalent bond, 
restraining the molecule to the 
vicinity of the active site, numerous 
potential interactions are presented by 
the range of conformations sampled 
by the molecule. These specific 
interactions could be exploited in 
future drug discovery efforts, 
enhancing its specificity and 
increasing its potency as a TrxR 
inhibitor. For example, the amide of 
Group A invariably forms a hydrogen 
bond with Ala41 (N), and the aniline 
ring is positioned at the entrance to the FAD cavity, which could be exploited by adding 
substitutions to the ring, filling the cavity. Group B conformations involve a hydrogen bond 
to either Gln139 or Asp149 and extend the aniline ring to the entrance of the pocket above the 
active site. Specific interactions could be engineered by addition of substitutions to ortho- or 
meta- positions of this aromatic ring to fill this pocket. In addition, for most of the docked 
conformations, the sidechain of Cys148 is rotated away from Cys145, an unfavorable 
conformation for nucleophilic attack on the selenosulfide bond by Cys145 (Sγ). It is 
anticipated that these considerations will be useful for informing design of drugs that inhibit 
AfTrxR via this mechanism. 
Figure 4 | Modeling of the EbSe–AfTrxR interaction. (a) 
The flavin-reducing (FR) conformation of AfTrxR was 
modeled by rotating the NADPH domain by ~66°, exposing 
the active site cysteines. Cys145 and Cys148 (yellow), FAD 
(magenta) and NADPH (cyan) are shown as sticks. (b) The 
reaction of EbSe with Cys148 was performed in silico using 
the FR conformation of AfTrxR. The results are shown in 
stereo view. Representative examples of group A (wheat 
carbons), group B (pink carbons) and group C (cyan carbons) 
poses are shown as sticks. Key interacting residues are also 
shown. A transparent molecular surface representation is 
shown for the protein, colored by electrostatic potential, -5 
kT/e (red) to +5 kT/e (blue). The Sγ atom of Cys148 is 
colored yellow and the Se atom of EbSe is orange. All 
hydrogen bonds (dashes) are 2.9-3.0 Å in length. The FAD 
cofactor (magenta) can be seen in the background (bottom of 
view).  
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DISCUSSION 
The development of new antimicrobials via traditional drug discovery pathways is time and 
resource expensive, making drug repurposing an attractive option (67, 68). Despite being 
initially described as a mimic of glutathione peroxidase (69), EbSe has since been shown to 
strongly stimulate the activity of the mammalian Trx system towards hydrogen peroxide via 
its ability to act as an efficient substrate for both TrxR (high MW) and Trx, suggesting that its 
antioxidant activity in mammalian cells is mediated predominantly through its interactions 
with the Trx system (65, 70). In contrast, EbSe is a potent inhibitor of E. coli TrxR (1) and A. 
fumigatus TrxR (this study) – both low MW TrxRs. We also show that EbSe inhibits growth 
of A. fumigatus on solid and in liquid media, with activity comparable to or better than a 
number of currently available non-azole antifungals (Table 2). 
The antifungal activity of EbSe against several yeast species has been reported previously (57, 
58), and a number of different targets have been proposed. Chan et al (58) attributed the 
fungicidal activity of EbSe against S. cerevisiae to its direct inhibition of the plasma membrane 
H+-ATPase, Pma1. The authors also observed, however, that the concentration of EbSe 
required to inhibit Pma1 was much higher than the concentration at which yeast growth was 
significantly inhibited, suggesting that the antifungal activity of EbSe may be predominantly 
mediated by its interaction with a different target. A more recent study by Thangamani et al 
(57) showed that EbSe disrupted redox homeostasis in yeast. Although their study focused on 
the EbSe-mediated depletion of GSH and increased sensitivity of GSH1 and GSH2 deletion 
mutants to EbSe, TRR1 and TRR2 mutants also showed increased sensitivity, suggesting that 
EbSe probably disrupts redox homeostasis via both GSH and Trx systems. In addition, 
depletion of intracellular GSH by EbSe has been similarly observed in mammalian cells (71). 
Therefore, while it is a likely contributor to EbSe toxicity, it does not explain the marked 
increase in sensitivity of fungal cells to EbSe over mammalian cells. 
EbSe reacts with thiol groups (63, 72). It has thus been shown to modulate a range of biological 
systems, largely via its ability to both inhibit various cysteine-containing enzymes (73) and 
potentiate cellular antioxidant systems by acting as a mimic of glutathione peroxidase (69) and 
peroxiredoxin (65) in mammalian cells. The complex interplay between the myriad of 
pathways that are affected by exposure to EbSe makes it difficult to delineate its major 
functional targets; however, the stark difference in physiological outcomes on mammalian 
versus microbial cells provides insight. The fact that EbSe is an efficient substrate for 
mammalian TrxR (facilitating its antioxidant activity as a peroxiredoxin mimic), but is an 
inhibitor of bacterial and fungal TrxRs, presents an effective basis for drug selectivity, 
providing an explanation for why EbSe displays relatively low toxicity to mammalian cells (1, 
60) while being a potent inhibitor of fungal cell growth. In addition, there is strong evidence 
to suggest that inhibition of TrxR by EbSe is a major contributor to its antibacterial activity 
(1). In light of these observations and the potent inhibition of AfTrxR we observe in vitro 
(Table 1; Supplementary Fig. 1), we suspect that targeting of TrxR is central to the antifungal 
activity of EbSe. Significantly, the MIC of EbSe against A. fumigatus of 1-2 μg/mL (≈ 4-7 
μM) (Table 2) corresponds very closely to the concentration that completely inhibited AfTrxR 
activity in vitro (~4 μM), consistent with TrxR being a major target. 
Our in silico analyses suggest that EbSe binds to Cys148, locking AfTrxR in a catalytically 
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non-productive FR conformation. Simulation of the EbSe-Cys148 reaction shows EbSe 
binding to the surface of AfTrxR in an array of conformations, consistent with the binding of 
a small molecule to the protein surface in a largely non-specific manner while being 
constrained to the same site by the covalent selenosulfide bond (Fig. 4b; Supplementary Fig. 
7). Categorizing the different docked conformations into groups highlighted potential specific 
interactions that could facilitate efficient packing of EbSe, and potential EbSe analogs, onto 
the surface of the protein. Half of the top ten poses showed the EbSe molecule positioned 
between the β2-η1 loop of the FAD domain and α4 of the NADPH domain, suggesting 
preferential binding to this groove (Supplementary Fig. 7, wheat color). Notably, residues 36 
through 40 of the β2-η1 loop, which form one side of this groove, are absent from EcTrxR. It 
is tempting to speculate that this may contribute to the enhanced inhibition of AfTrxR over 
EcTrxR by EbSe.  
Rational design of analogs to exploit specific TrxR-inhibitor interactions, while also 
positioning Cys148 in an unfavorable conformation for nucleophilic attack by Cys145 (Sγ), is 
expected to increase the specificity and potency of the inhibitor. In particular, the amphipathic 
pocket near the active site as well as the groove leading to the FAD cavity present as potential 
inhibitor binding sites, warranting investigation of EbSe analogs that extend into these spaces 
by the addition of pharmacophores that facilitate specific interactions. In parallel, a detailed 
description of the AfTrxR-AfTrx interaction is expected to provide insights useful for inhibitor 
design. For example, based on observation of the homologous E. coli TrxR-Trx complex (PDB 
ID 1F6M) we hypothesize that a conserved arginine residue of Trx (AfTrx Arg76) inserts into 
the amphipathic pocket above the active site. Addition of similar pharmacophores to the ortho- 
or meta- positions of the aniline ring (see Fig. 4b, pink) could enhance binding of the inhibitor, 
improving specificity and potency.  
During infection of the human host, opportunistic fungal pathogens such as A. fumigatus must 
contend with conditions of high oxidative stress (74, 75). Therefore, given that the Trx system 
is central to antioxidant defense, it is expected the antifungal activity of EbSe (and analogs) 
may be enhanced in the context of the host environment. In addition, EbSe can cross the blood-
brain barrier (76), making it an attractive option for the treatment of cerebral aspergillosis – a 
condition associated with particularly high mortality rates (3). The fungicidal activity of EbSe 
against Candida and Cryptococcus clinical isolates has been confirmed recently, 
demonstrating MIC values of 0.5 to 2 μg/mL (57); concentrations that are in the same range 
as we have determined here for A. fumigatus, warranting further investigation into EbSe and 







T h i o r e d o x i n  R e d u c t a s e  | 91 
 
MATERIALS AND METHODS 
Reagents. All reagents were purchased from Sigma-Aldrich™. PCR primers were from 
GeneWorks (Thebarton, SA, Australia). NADPH (50 mM) and FAD (10 mM) aqueous stocks 
were stored at -20°C until required. Ebselen was stored at 4°C in powder form until required. 
A 9 mM working stock of EbSe was made up fresh in 100% DMSO. 
Cloning of A. fumigatus TRR1. The entire TRR1 coding sequence was amplified by PCR 
from A. fumigatus strain Af293 (77) cDNA (a generous gift from Dr. James Fraser, University 
of Queensland) using primers:  
(1) 5’ GGGGACAAGTTTGTACAAAAAAGCAGGCTACGAAAACCTGTATTTTCAGG 
GAATGGTGCACACAAAAGTTACCA 3’ and,  
(2) 5’ GGGGACCACTTTGTACAAGAAAGCTGGGTATTAGAGAAGAGGGTTCGACT 
TGTATT 3’,  
and cloned into Gateway® pDONR™221 Vector (Invitrogen™) with a Tobacco Etch Virus 
(TEV) protease cleavage site upstream of the ORF (underlined in primer (1) sequence). This 
TEV-TRR1 construct was then subcloned via Gateway® recombination sites into Gateway® 
Nova pET-57-DEST™ vector for expression of recombinant protein in E. coli with an N-
terminal NusA and hexahistidine tag and confirmed by sequencing. Here, the TRR1 transcript 
we have identified (GenBank accession MG551986) is shorter than the putative sequence 
previously deposited (GenBank accession XM_746439) (77). The resulting protein product is 
shorter by 17 amino acids near the N-terminus, with the replacement of 19 amino acids (Thr7 
through Val27) with 2 amino acids (Val7-Ile8). Alignment of this protein sequence with 
thioredoxin reductase sequences from other fungal species including Aspergillus, Penicillium, 
Blastomyces and Saccharomyces spp. provides strong support for our new annotation.  
AfTrxR protein expression and purification. Expression of AfTrxR was induced in 2.5 L E. 
coli BL21(λDE3) shake-flask culture for 20 hours at 16°C. Cells were lysed by mechanical 
disruption in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 10 mM imidazole (pH 8.0), 10% 
glycerol and purified by using two Ni2+-NTA columns (Bio-Rad) with a TEV protease digest 
in between to remove the NusA and his-tag. The protein solution was then made up to 1 M 
(NH4)2SO4, passed through a HiTrap™ Phenyl FF HS column (GE Healthcare Life Sciences) 
and eluted using a 1 to 0 M (NH4)2SO4 gradient. Final protein purity was > 95%, as assessed 
by SDS-PAGE. Protein was dialyzed to 20 mM Tris-HCl (pH 7.5), 50 mM NaCl before being 
concentrated to ~ 6 mg/mL, flash frozen in liquid nitrogen and stored at -80°C. 
AfTrxR extinction coefficient determination. The extinction coefficient of AfTrxR at 280 
nm was calculated by determining the concentration of liberated FAD cofactor as described 
(78). Briefly, purified protein was incubated with excess FAD before removing unbound FAD 
by gel filtration. Absorbance at 280 nm was measured prior to liberating bound FAD by 
incubation with 0.2% SDS for 15 min at room temperature. Following this, the concentration 
of FAD was determined by measuring the absorbance at 450 nm, using the extinction 
coefficient of 11300 M−1.cm−1 for FAD. Assuming a ratio of one FAD molecule per protein 
subunit, the extinction coefficient of AfTrxR at 280nm was determined to be 1.57 (mg/mL)-1 
using measurements at three different concentrations. This value was used for all further 
protein concentration determinations, and subsequently validated by comparison with protein 
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concentration values determined by infrared absorbance using a Direct Detect® spectrometer 
(Merck).  
AfTrxA protein expression and purification. A pET-45b(+) vector containing the coding 
sequence for A. fumigatus thioredoxin, TrxA (GenBank accession XM_748424) with an N-
terminal hexahistidine tag was purchased from GenScript® (Piscataway, NJ, USA). Protein 
expression was induced in 2 L shake-flask culture of E. coli BL21(λDE3) for 20 hours at 16°C. 
Cells were lysed by mechanical disruption in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 10 
mM imidazole (pH 8.0), 5 mM β-mercaptoethanol, 10% glycerol. His-tagged AfTrxA was 
purified from lysate using a Ni2+-NTA column (Bio-Rad) followed by a HiPrep™ 26/60 
Sephacryl™ S-300 HR column (GE) pre-equilibrated in phosphate buffered saline (without 
reducing agent), flash-frozen in liquid nitrogen and stored at -80°C until required. 
Enzyme assay. AfTrxR activity was determined in the absence and presence of EbSe using 
the DTNB assay, as described (30, 32, 36, 61). Assays were performed in triplicate in 96-well 
plate format and optimized for buffer pH, salt and NADPH concentration. AfTrxR was first 
incubated with excess FAD and passed through a size-exclusion column to remove unbound 
FAD. The reaction was started by addition of 30nM AfTrxR to 100 mM potassium phosphate 
(pH 7.5), 2 mM EDTA, 1 mM DTNB, 0.2 mM NADPH and 0–10 μM AfTrxA in a final volume 
of 200 μL. Absorbance at 414 nm was monitored for 20min at 25°C using a Multiskan Ascent 
spectrophotometer (Thermo Scientific™). Inhibition by EbSe was determined by addition of 
EbSe at final concentrations 0–0.90 μM to the assay prior to addition of AfTrxR. The final 
DMSO concentration was 0.5% in all experiments and had no effect on AfTrxR activity. Data 
from the initial 60 sec was used for calculation of initial reaction velocities. Reduction of 
DTNB in the absence of AfTrxA was negligible (240-fold slower than Vmax) and did not 
increase in the presence of EbSe, indicating that neither DTNB nor EbSe are substrates for 
AfTrxR (65). Previous studies have shown that the activities of human Trx and E. coli Trx2 
can be inhibited by oxidation of non-catalytic cysteine residues (30, 79). In addition, EbSe 
catalyzes the formation of intermolecular and intramolecular disulfide bonds in human Trx 
(63). It is possible that AfTrxA, which contains an additional non-catalytic cysteine (Cys29), 
may be oxidized to form Trx dimers linked via intermolecular disulfides. Indeed, we observed 
a reducible high MW species after purification of recombinant AfTrxA corresponding to a Trx 
dimer (~ 25 kDa). Therefore, assuming 1 mol of EbSe can inactivate 2 mol of AfTrxA via 
oxidation and dimer formation, the effective initial concentration of substrate (Trx) in our 
assay is given by: 
 [Trx]effective = [Trx] - 2x[EbSe] 
Our assay data were adjusted accordingly and the resulting plots fit well to the standard model 
of competitive inhibition (Supplementary Fig. 1). Non-linear regression analysis was 
performed using GraphPad Prism (v7). 
Mass spectrometry. Sample preparation. AfTrxR wt, C145S and C148S protein samples were 
diluted to 12 μM in protein buffer (20 mM Tris pH 7.5, 100 mM NaCl) before being incubated 
with 20-fold molar excess DTT at 37°C for 1 hr. Samples were washed three times using 
10000 MWCO filter spin columns with protein buffer to remove DTT before incubation with 
20-fold molar excess EbSe for at least 1 hr. Samples were then digested with a modified filter-
aided sample preparation (FASP) method (80) as follows: Samples were mixed with 8 M Urea, 
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placed onto a Vivacon 500 (Sartorius) filter spin column, and centrifuged at 14 000 x g for 15 
minutes. The filter spin columns containing the samples were washed three times with 8 M 
Urea and then three times with 50 mM ammonium bicarbonate (NH4HCO3). Samples were 
digested overnight at 37°C by placing 100 ng of sequencing grade modified trypsin (Promega) 
in 5 mM NH4HCO3 onto the filter spin columns. (4) Samples were centrifuged at 14000 x g 
for 15 minutes and the flow through was collected. The volumes of the resulting peptide 
extracts were reduced by vacuum centrifugation to approximately 1 μL then resuspended with 
0.1% TFA in 2% ACN to a total volume of ~20 μL. 
Data acquisition by liquid chromatography– electrospray ionization tandem mass 
spectrometry. Nano-LC−ESI-MS/MS was performed on an Ultimate 3000 RSLC system 
(Thermo Fisher Scientific) coupled to a LTQ Orbitrap XL ETD MS instrument (Thermo-
Fisher Scientific). Peptide samples were pre-concentrated concentrated onto a C18 trapping 
column (Acclaim PepMap100 C18 75 μm × 20 mm, Thermo-Fisher Scientific) at a flow rate 
of 5 μL/min in 2% acetonitrile (ACN), 0.1% trifluoroacetic acid (TFA) for 8 minutes. Peptide 
separation was performed using a 75 μm ID C18 column (Acclaim PepMap100 C18 75 μm × 
15 cm, Thermo-Fisher Scientific) at a flow rate of 0.3 μL/min using a linear gradient from 5 
to 45% B (A: 5% ACN, 0.1% formic acid (FA); B: 80% FA) over 72 minutes, followed by a 
20 minute wash with 90% B, and 20 minute equilibration 5% A. MS scans were acquired in 
the mass range of 300 to 2000 m/z at a resolution of 60000. The six most intense precursor 
ions selected for isolation and were subjected to CID fragmentation using a dynamic exclusion 
of 5 seconds. Dynamic exclusion criteria included a minimum relative signal intensity of 1000, 
and ≥2+ charge state. An isolation width of 3.0 was used with a normalized collision energy 
40. 
Data analysis. RAW files were analyzed using the MaxQuant software (version 1.5.2.8) with 
Andromeda search engine (20) against the non-redundant Aspergillus UniProt database with 
the addition of the mutant sequences. The standard Orbitrap settings in MaxQuant were used 
with a mass error tolerance of 10 ppm. The variable modifications of oxidation of methionine 
and EbSe binding to cysteine residues was specified, with the digestion enzyme specified as 
trypsin. The false discovery rate (FDR) was set to 1% for both proteins and peptides, with a 
minimum peptide length of 7 amino acids. 
Antifungal assays. Aspergillus fumigatus (ATCC MYA-3626) was obtained from the 
National Mycology Reference Centre (South Australian Pathology, Australia). Frozen stocks 
were thawed, cultured and subcultured on Sabouraud dextrose agar. The standard inoculum 
was prepared by collecting colonies from 48 hours old culture. This organism was used for 
both the broth microdilution assay and disk diffusion assay. 
Broth microdilution assay. A. fumigatus susceptibility tests for EbSe was carried out by broth 
microdilution in RPMI 1640 broth, as described in accordance with the National Committee 
for Clinical & Laboratory Science Institute (CLSI) standard method M27-A3. Along with 
EbSe, standard antifungal reference drugs caspofungin (Selleckchem.com, USA), 
amphotericin B (Sigma-Aldrich, USA), and nystatin (TOKU-E, USA) were used. Two fold 
serial dilutions of compounds were performed to cover the concentration range 0.97 µg/mL to 
500 µg/mL for EbSe and 0.03 µg/mL to 16 µg/mL for all reference drugs and EbSe. The final 
concentration of the fungal strains was 5 x 105 CFU/mL.  Presence or absence of physical 
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growth was determined by examining the microdilution wells gradually from optically clear 
to slightly hazy to prominent decrease in turbidity. 
Disk diffusion assay. A. fumigatus susceptibility tests for EbSe was carried out by broth disk 
diffusion assay on solid media, as described by the Clinical & Laboratory Standards Institute 
document M51-P. Blank Whatman paper (6 mm) antibiotic assay disks were impregnated with 
12 µg of the test and reference compounds and allowed to dry at room temperature. A sterile 
cotton swab was dipped into each adjusted fungal suspension and used to uniformly cover the 
surface of a Mueller-Hinton with Glucose and Methylene Blue (MHGMB) agar plate. 
Antifungal disks were placed on the inoculated MHGMB plates used. Control disks without 
antifungal drugs or sample compounds were also placed on the plate. Discs impregnated with 
caspofungin (positive control) were used. The plates were incubated for 24 h at 35°C before 
measuring the diameter of the zone of inhibition in millimeters. 
Protein crystallization. Purified recombinant AfTrxR at ~ 6 mg/mL was incubated at 25°C 
for 30 min in the presence of 5 mM NADPH and 20 mM DTT before being subject to 
crystallization at 16°C by vapor diffusion using the hanging-drop method. Each drop 
contained 1 μL of well solution and 1 μL of protein solution, over a reservoir volume of 0.5 
mL. Crystals grew in 32% Tacsimate (pH 7.0) (Hampton Research) as yellow, pseudo-
hexagonal rods to a size of ~ 300 x 200 µm in < 1 week.  
X-ray data collection and refinement. Diffraction data were collected at an X-ray energy of 
13000 eV at 1° intervals with 1° oscillation at 100 K at the Australian Synchrotron (MX1 
beamline), using 70% Tacsimate (pH 7.0) as cryoprotectant. Data were processed using 
iMosflm (81), solved by molecular replacement using Phaser MR (82); the structure of S. 
cerevisiae cytoplasmic thioredoxin reductase (Trr1) (PDB ID 3D8X) was used for the search 
model. Atomic coordinates were rebuilt manually using Coot (83) and refined using 
phenix.refine (84). During refinement, non-crystallographic symmetry (NCS) restraints were 
applied, X-ray/stereochemistry and X-ray/ADP weights were optimized, and anisotropic B-
factor refinement was restricted to torsion-liberation-screw (TLS) groups (85) defined 
automatically by phenix.refine. Atoms of each FAD or NADPH molecule were grouped for 
occupancy refinement. The final model exhibited good overall geometry, with 95.28% of 
peptide bonds in favored regions of the Ramachandran plot and no outliers. Structure factors 
and atomic coordinates can be accessed at the RCSB Protein Data Bank 
(https://www.rcsb.org), with accession code 6BPY. 
In silico modeling and docking. Atomic coordinates for the FAD domain (residues 1-127, 
256-326) and NADPH domain (residues 128-255) of the AfTrxR crystal structure were 
structurally aligned separately to the corresponding domains of the crystal structure of EcTrxR 
in FR conformation (PDB ID 1F6M) (41). Chain breaks were mended in Coot (83). ICM 
Molsoft (v3.8-6a) (86) was then used to add hydrogens and refine the model by global 
optimization of side chains and annealing of the peptide backbone (20 iterations). Covalent 
docking of EbSe to Cys148 was then performed using ICM Molsoft (“Thoroughness” was set 
to 50). 
Structure visualization. Chemical structures were drawn using ChemDraw Ultra (v12.0). All 
molecular graphics images were produced using PyMol™ (v1.8.6.0) (87). Secondary 
structural elements were assigned using DSSP (88). PISA (89) was used to calculate the dimer 
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interface area. Electrostatic potential maps were calculated using APBS (90), with atomic 
charges assigned using the PDB2PQR webserver (v2.1.1) (91). 
 
ACKNOWLEDGEMENTS 
X-ray diffraction data collection was undertaken on the MX1 beamline at the Australian 
Synchrotron, part of ANSTO. We acknowledge Prof Hans Griesser, Future Industries 




1. Lu J, Vlamis-Gardikas A, Kandasamy K, Zhao R, Gustafsson TN, Engstrand L, Hoffner S, Engman L, 
Holmgren A. 2013. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting 
bacteria lacking glutathione. Faseb j 27:1394-403. 
2. Latge JP. 1999. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12:310-50. 
3. Gallien S, Fournier S, Porcher R, Bottero J, Ribaud P, Sulahian A, Socie G, Molina JM. 2008. Therapeutic 
outcome and prognostic factors of invasive aspergillosis in an infectious disease department: a review of 
34 cases. Infection 36:533-8. 
4. Thompson GR, 3rd, Patterson TF. 2008. Pulmonary aspergillosis. Semin Respir Crit Care Med 29:103-10. 
5. Warnock DW. 2007. Trends in the epidemiology of invasive fungal infections. Nihon Ishinkin Gakkai 
Zasshi 48:1-12. 
6. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. 1996. Trends in the 
postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33:23-32. 
7. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley 
JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, 
Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, 
Wingard JR, Chiller TM, Pappas PG. 2010. Prospective surveillance for invasive fungal infections in 
hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection 
Surveillance Network (TRANSNET) Database. Clin Infect Dis 50:1091-100. 
8. Espinosa V, Rivera A. 2016. First Line of Defense: Innate Cell-Mediated Control of Pulmonary 
Aspergillosis. Front Microbiol 7:272. 
9. Sugui JA, Kwon-Chung KJ, Juvvadi PR, Latge JP, Steinbach WJ. 2015. Aspergillus fumigatus and related 
species. Cold Spring Harb Perspect Med 5:a019786. 
10. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, 
Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: 
clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-60. 
11. Chowdhry R, Marshall WL. 2008. Antifungal therapies in the intensive care unit. J Intensive Care Med 
23:151-8. 
12. Hadrich I, Makni F, Neji S, Abbes S, Cheikhrouhou F, Trabelsi H, Sellami H, Ayadi A. 2012. Invasive 
aspergillosis: resistance to antifungal drugs. Mycopathologia 174:131-41. 
13. Qiao J, Liu W, Li R. 2008. Antifungal resistance mechanisms of Aspergillus. Nihon Ishinkin Gakkai 
Zasshi 49:157-63. 
14. Verweij PE, Chowdhary A, Melchers WJ, Meis JF. 2016. Azole Resistance in Aspergillus fumigatus: Can 
We Retain the Clinical Use of Mold-Active Antifungal Azoles? Clin Infect Dis 62:362-8. 
15. Lewis RE. 2011. Current concepts in antifungal pharmacology. Mayo Clin Proc 86:805-17. 
16. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, 
Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, 
Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. 2002. Voriconazole versus 
amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-15. 
17. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R. 2001. Mortality and 
costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686-93. 
18. Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, 
Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, 
Young JH, Bennett JE. 2016. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 
2016 Update by the Infectious Diseases Society of America. Clin Infect Dis doi:10.1093/cid/ciw326. 
96 | C h a p t e r  6  
 
19. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E. 
2005. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 
106:2641-5. 
20. D. Versteeg, E. Snelders, T. Rijs, W. Melchers, P. Verweij. 2012. Continued increase of azole resistance in 
Aspergillus fumigatus (Af) in Dutch Hospitals, abstr ICAAC 52nd,  
21. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers 
WJ, Verweij PE. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single 
resistance mechanism. PLoS Med 5:e219. 
22. Lestrade PP, Meis JF, Arends JP, van der Beek MT, de Brauwer E, van Dijk K, de Greeff SC, Haas PJ, 
Hodiamont CJ, Kuijper EJ, Leenstra T, Muller AE, Oude Lashof AM, Rijnders BJ, Roelofsen E, 
Rozemeijer W, Tersmette M, Terveer EM, Verduin CM, Wolfhagen MJ, Melchers WJ, Verweij PE. 2016. 
Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses 59:101-7. 
23. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup 
MC, Perlin DS, Denning DW. 2009. Frequency and evolution of Azole resistance in Aspergillus fumigatus 
associated with treatment failure. Emerg Infect Dis 15:1068-76. 
24. Toledano MB, Delaunay-Moisan A, Outten CE, Igbaria A. 2013. Functions and cellular compartmentation 
of the thioredoxin and glutathione pathways in yeast. Antioxid Redox Signal 18:1699-711. 
25. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, Taketo MM. 1996. Early embryonic 
lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 178:179-85. 
26. Thelander L, Reichard P. 1979. Reduction of ribonucleotides. Annu Rev Biochem 48:133-58. 
27. Arner ES, Holmgren A. 2000. Physiological functions of thioredoxin and thioredoxin reductase. Eur J 
Biochem 267:6102-9. 
28. Lu J, Holmgren A. 2014. The thioredoxin antioxidant system. Free Radical Biology and Medicine 66:75-
87. 
29. Poet GJ, Oka OB, van Lith M, Cao Z, Robinson PJ, Pringle MA, Arner ES, Bulleid NJ. 2017. Cytosolic 
thioredoxin reductase 1 is required for correct disulfide formation in the ER. Embo j 36:693-702. 
30. Holmgren A, Bjornstedt M. 1995. Thioredoxin and thioredoxin reductase. Methods Enzymol 252:199-208. 
31. Wahl MC, Irmler A, Hecker B, Schirmer RH, Becker K. 2005. Comparative structural analysis of oxidized 
and reduced thioredoxin from Drosophila melanogaster. J Mol Biol 345:1119-30. 
32. Arner ES, Zhong L, Holmgren A. 1999. Preparation and assay of mammalian thioredoxin and thioredoxin 
reductase. Methods Enzymol 300:226-39. 
33. Sandalova T, Zhong L, Lindqvist Y, Holmgren A, Schneider G. 2001. Three-dimensional structure of a 
mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-
dependent enzyme. Proc Natl Acad Sci U S A 98:9533-8. 
34. Fritz-Wolf K, Urig S, Becker K. 2007. The structure of human thioredoxin reductase 1 provides insights 
into C-terminal rearrangements during catalysis. J Mol Biol 370:116-27. 
35. Zhong L, Holmgren A. 2000. Essential role of selenium in the catalytic activities of mammalian 
thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. 
J Biol Chem 275:18121-8. 
36. Oliveira MA, Discola KF, Alves SV, Medrano FJ, Guimaraes BG, Netto LE. 2010. Insights into the 
specificity of thioredoxin reductase-thioredoxin interactions. A structural and functional investigation of 
the yeast thioredoxin system. Biochemistry 49:3317-26. 
37. Pedrajas JR, Kosmidou E, Miranda-Vizuete A, Gustafsson JA, Wright AP, Spyrou G. 1999. Identification 
and functional characterization of a novel mitochondrial thioredoxin system in Saccharomyces cerevisiae. 
J Biol Chem 274:6366-73. 
38. Baker LM, Raudonikiene A, Hoffman PS, Poole LB. 2001. Essential thioredoxin-dependent peroxiredoxin 
system from Helicobacter pylori: genetic and kinetic characterization. J Bacteriol 183:1961-73. 
39. Waksman G, Krishna TS, Williams CH, Jr., Kuriyan J. 1994. Crystal structure of Escherichia coli 
thioredoxin reductase refined at 2 A resolution. Implications for a large conformational change during 
catalysis. J Mol Biol 236:800-16. 
40. Williams CH, Jr. 1995. Mechanism and structure of thioredoxin reductase from Escherichia coli. Faseb j 
9:1267-76. 
41. Lennon BW, Williams CH, Jr., Ludwig ML. 2000. Twists in catalysis: alternating conformations of 
Escherichia coli thioredoxin reductase. Science 289:1190-4. 
42. Theobald AJ, Caballero I, Coma I, Colmenarejo G, Cid C, Gamo FJ, Hibbs MJ, Bass AL, Thomas DA. 
2012. Discovery and biochemical characterization of Plasmodium thioredoxin reductase inhibitors from an 
antimalarial set. Biochemistry 51:4764-71. 
43. Fritz-Wolf K, Jortzik E, Stumpf M, Preuss J, Iozef R, Rahlfs S, Becker K. 2013. Crystal Structure of the 
Plasmodium falciparum Thioredoxin Reductase–Thioredoxin Complex. Journal of Molecular Biology 
425:3446-3460. 
44. Parsonage D, Sheng F, Hirata K, Debnath A, McKerrow JH, Reed SL, Abagyan R, Poole LB, Podust LM. 
2016. X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing 
hypothesis of the mechanism of Auranofin action. J Struct Biol 194:180-90. 
T h i o r e d o x i n  R e d u c t a s e  | 97 
 
45. Zhang D, Xu Z, Yuan J, Zhao YX, Qiao ZY, Gao YJ, Yu GA, Li J, Wang H. 2014. Synthesis and 
molecular recognition studies on small-molecule inhibitors for thioredoxin reductase. J Med Chem 
57:8132-9. 
46. Liu Y, Duan D, Yao J, Zhang B, Peng S, Ma H, Song Y, Fang J. 2014. Dithiaarsanes Induce Oxidative 
Stress-Mediated Apoptosis in HL-60 Cells by Selectively Targeting Thioredoxin Reductase. J Med Chem 
57:5203-11. 
47. James LR, Xu ZQ, Sluyter R, Hawksworth EL, Kelso C, Lai B, Paterson DJ, de Jonge MD, Dixon NE, 
Beck JL, Ralph SF, Dillon CT. 2015. An investigation into the interactions of gold nanoparticles and anti-
arthritic drugs with macrophages, and their reactivity towards thioredoxin reductase. J Inorg Biochem 
142:28-38. 
48. Hu W, Sillaots S, Lemieux S, Davison J, Kauffman S, Breton A, Linteau A, Xin C, Bowman J, Becker J, 
Jiang B, Roemer T. 2007. Essential gene identification and drug target prioritization in Aspergillus 
fumigatus. PLoS Pathog 3:e24. 
49. Machado AK, Morgan BA, Merrill GF. 1997. Thioredoxin reductase-dependent inhibition of MCB cell 
cycle box activity in Saccharomyces cerevisiae. J Biol Chem 272:17045-54. 
50. Pearson GD, Merrill GF. 1998. Deletion of the Saccharomyces cerevisiae TRR1 gene encoding 
thioredoxin reductase inhibits p53-dependent reporter gene expression. J Biol Chem 273:5431-4. 
51. Grant CM. 2001. Role of the glutathione/glutaredoxin and thioredoxin systems in yeast growth and 
response to stress conditions. Mol Microbiol 39:533-41. 
52. Parnham M, Sies H. 2000. Ebselen: prospective therapy for cerebral ischaemia. Expert Opin Investig 
Drugs 9:607-19. 
53. Singh N, Sharpley AL, Emir UE, Masaki C, Herzallah MM, Gluck MA, Sharp T, Harmer CJ, Vasudevan 
SR, Cowen PJ, Churchill GC. 2016. Effect of the Putative Lithium Mimetic Ebselen on Brain Myo-
Inositol, Sleep, and Emotional Processing in Humans. Neuropsychopharmacology 41:1768-78. 
54. Mahadevan J, Parazzoli S, Oseid E, Hertzel AV, Bernlohr DA, Vallerie SN, Liu CQ, Lopez M, Harmon 
JS, Robertson RP. 2013. Ebselen treatment prevents islet apoptosis, maintains intranuclear Pdx-1 and 
MafA levels, and preserves beta-cell mass and function in ZDF rats. Diabetes 62:3582-8. 
55. Baek JM, Kim JY, Yoon KH, Oh J, Lee MS. 2016. Ebselen Is a Potential Anti-Osteoporosis Agent by 
Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In 
vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo. Int J Biol Sci 12:478-88. 
56. Kil J, Lobarinas E, Spankovich C, Griffiths SK, Antonelli PJ, Lynch ED, Le Prell CG. 2017. Safety and 
efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-
controlled, phase 2 trial. Lancet doi:10.1016/s0140-6736(17)31791-9. 
57. Thangamani S, Eldesouky HE, Mohammad H, Pascuzzi PE, Avramova L, Hazbun TR, Seleem MN. 2017. 
Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) 
production in fungal cells. Biochim Biophys Acta 1861:3002-3010. 
58. Chan G, Hardej D, Santoro M, Lau-Cam C, Billack B. 2007. Evaluation of the antimicrobial activity of 
ebselen: role of the yeast plasma membrane H+-ATPase. J Biochem Mol Toxicol 21:252-64. 
59. Bender KO, Garland M, Ferreyra JA, Hryckowian AJ, Child MA, Puri AW, Solow-Cordero DE, 
Higginbottom SK, Segal E, Banaei N, Shen A, Sonnenburg JL, Bogyo M. 2015. A small-molecule 
antivirulence agent for treating Clostridium difficile infection. Sci Transl Med 7:306ra148. 
60. Thangamani S, Younis W, Seleem MN. 2015. Repurposing ebselen for treatment of multidrug-resistant 
staphylococcal infections. Sci Rep 5:11596. 
61. Zhang Z, Bao R, Zhang Y, Yu J, Zhou CZ, Chen Y. 2009. Crystal structure of Saccharomyces cerevisiae 
cytoplasmic thioredoxin reductase Trr1 reveals the structural basis for species-specific recognition of 
thioredoxin. Biochim Biophys Acta 1794:124-8. 
62. Prongay AJ, Engelke DR, Williams CH, Jr. 1989. Characterization of two active site mutations of 
thioredoxin reductase from Escherichia coli. J Biol Chem 264:2656-64. 
63. Sakurai T, Kanayama M, Shibata T, Itoh K, Kobayashi A, Yamamoto M, Uchida K. 2006. Ebselen, a 
seleno-organic antioxidant, as an electrophile. Chem Res Toxicol 19:1196-204. 
64. Favrot L, Lajiness DH, Ronning DR. 2014. Inactivation of the Mycobacterium tuberculosis antigen 85 
complex by covalent, allosteric inhibitors. J Biol Chem 289:25031-40. 
65. Zhao R, Masayasu H, Holmgren A. 2002. Ebselen: a substrate for human thioredoxin reductase strongly 
stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc Natl Acad Sci U 
S A 99:8579-84. 
66. Veine DM, Mulrooney SB, Wang PF, Williams CH, Jr. 1998. Formation and properties of mixed 
disulfides between thioredoxin reductase from Escherichia coli and thioredoxin: evidence that cysteine-
138 functions to initiate dithiol-disulfide interchange and to accept the reducing equivalent from reduced 
flavin. Protein Sci 7:1441-50. 
67. Butts A, Krysan DJ. 2012. Antifungal drug discovery: something old and something new. PLoS Pathog 
8:e1002870. 
68. Thangamani S, Mohammad H, Younis W, Seleem MN. 2015. Drug repurposing for the treatment of 
staphylococcal infections. Curr Pharm Des 21:2089-100. 
98 | C h a p t e r  6  
 
69. Sies H. 1993. Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Radic Biol Med 
14:313-23. 
70. Zhao R, Holmgren A. 2002. A novel antioxidant mechanism of ebselen involving ebselen diselenide, a 
substrate of mammalian thioredoxin and thioredoxin reductase. J Biol Chem 277:39456-62. 
71. Yang CF, Shen HM, Ong CN. 2000. Ebselen induces apoptosis in HepG(2) cells through rapid depletion 
of intracellular thiols. Arch Biochem Biophys 374:142-52. 
72. Kade IJ, Balogun BD, Rocha JB. 2013. In vitro glutathione peroxidase mimicry of ebselen is linked to its 
oxidation of critical thiols on key cerebral suphydryl proteins - A novel component of its GPx-mimic 
antioxidant mechanism emerging from its thiol-modulated toxicology and pharmacology. Chem Biol 
Interact 206:27-36. 
73. Azad GK, Tomar RS. 2014. Ebselen, a promising antioxidant drug: mechanisms of action and targets of 
biological pathways. Mol Biol Rep 41:4865-79. 
74. Abad A, Fernandez-Molina JV, Bikandi J, Ramirez A, Margareto J, Sendino J, Hernando FL, Ponton J, 
Garaizar J, Rementeria A. 2010. What makes Aspergillus fumigatus a successful pathogen? Genes and 
molecules involved in invasive aspergillosis. Rev Iberoam Micol 27:155-82. 
75. Philippe B, Ibrahim-Granet O, Prevost MC, Gougerot-Pocidalo MA, Sanchez Perez M, Van der Meeren A, 
Latge JP. 2003. Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant 
intermediates. Infect Immun 71:3034-42. 
76. Singh N, Halliday AC, Thomas JM, Kuznetsova OV, Baldwin R, Woon EC, Aley PK, Antoniadou I, 
Sharp T, Vasudevan SR, Churchill GC. 2013. A safe lithium mimetic for bipolar disorder. Nat Commun 
4:1332. 
77. Nierman WC, Pain A, Anderson MJ, Wortman JR, Kim HS, Arroyo J, Berriman M, Abe K, Archer DB, 
Bermejo C, Bennett J, Bowyer P, Chen D, Collins M, Coulsen R, Davies R, Dyer PS, Farman M, 
Fedorova N, Fedorova N, Feldblyum TV, Fischer R, Fosker N, Fraser A, Garcia JL, Garcia MJ, Goble A, 
Goldman GH, Gomi K, Griffith-Jones S, Gwilliam R, Haas B, Haas H, Harris D, Horiuchi H, Huang J, 
Humphray S, Jimenez J, Keller N, Khouri H, Kitamoto K, Kobayashi T, Konzack S, Kulkarni R, Kumagai 
T, Lafon A, Latge JP, Li W, Lord A, Lu C, et al. 2005. Genomic sequence of the pathogenic and allergenic 
filamentous fungus Aspergillus fumigatus. Nature 438:1151-6. 
78. Aliverti A, Curti B, Vanoni MA. 1999. Identifying and quantitating FAD and FMN in simple and in iron-
sulfur-containing flavoproteins. Methods Mol Biol 131:9-23. 
79. Miranda-Vizuete A, Damdimopoulos AE, Gustafsson J, Spyrou G. 1997. Cloning, expression, and 
characterization of a novel Escherichia coli thioredoxin. J Biol Chem 272:30841-7. 
80. Wisniewski JR, Zougman A, Nagaraj N, Mann M. 2009. Universal sample preparation method for 
proteome analysis. Nat Methods 6:359-62. 
81. Leslie AGW, Powell HR. 2007. Processing Diffraction Data with Mosflm, p 41–51. In Read RJ, Sussman 
JL (ed), Evolving Methods for Macromolecular Crystallography, vol 245. Springer, Dordrecht, The 
Netherlands. 
82. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser 
crystallographic software. J Appl Crystallogr 40:658-674. 
83. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta 
Crystallographica Section D-Biological Crystallography 66:486-501. 
84. Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, Terwilliger TC, 
Urzhumtsev A, Zwart PH, Adams PD. 2012. Towards automated crystallographic structure refinement 
with phenix.refine. Acta Crystallogr D Biol Crystallogr 68:352-67. 
85. Winn MD, Isupov MN, Murshudov GN. 2001. Use of TLS parameters to model anisotropic displacements 
in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 57:122-33. 
86. Abagyan R, Totrov M, Kuznetsov D. 1994. ICM - A new method for protein modeling and design - 
applications to docking and structure prediction from the distorted native conformation. Journal of 
Computational Chemistry 15:488-506. 
87. Schrodinger, LLC. 2015. The PyMOL Molecular Graphics System, Version 1.8. 
88. Touw WG, Baakman C, Black J, te Beek TA, Krieger E, Joosten RP, Vriend G. 2015. A series of PDB-
related databanks for everyday needs. Nucleic Acids Res 43:D364-8. 
89. Krissinel E, Henrick K. 2007. Inference of macromolecular assemblies from crystalline state. J Mol Biol 
372:774-97. 
90. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. 2001. Electrostatics of nanosystems: Application 
to microtubules and the ribosome. Proceedings of the National Academy of Sciences of the United States 
of America 98:10037-10041. 
91. Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA. 2004. PDB2PQR: an automated pipeline for the 
setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Research 32:W665-W667. 
  






Aspergillus fumigatus thioredoxin reductase: structure, mechanism, and inhibition  
 
 
Andrew C. Marshall1, Mohammed A. Hossain2, Georgia Arentz4, Peter Hoffman4, 
Bryan R. Coad2,3, and John B. Bruning1,* 
 
 
1Institute for Photonics and Advanced Sensing (IPAS), School of Biological Sciences, The University of 
Adelaide, Adelaide, South Australia 5005, Australia. 
 
2Future Industries Institute, University of South Australia, Mawson Lakes, South Australia 5095, Australia. 
 
3School of Agriculture, Food & Wine, The University of Adelaide, Adelaide, South Australia 5005, Australia. 
 
4Adelaide Proteomics Centre, School of Biological Sciences, University of Adelaide, Adelaide, South Australia 
5005, Australia; Institute for Photonics and Advanced Sensing (IPAS), University of Adelaide, Adelaide, South 
Australia 5005, Australia. 
 
*To whom correspondence should be addressed. John B. Bruning, School of Biological Sciences, Adelaide, 
South Australia, Australia, Tel.: +61 (08) 8313-5218; Fax: +61 (08) 8313-4362; E-mail: 
john.bruning@adelaide.edu.au 
  
100 | C h a p t e r  6  
 
Supplementary Table 1. X-ray diffraction data collection and refinement statistics. 
 
 AfTrxR (PDB: 6BPY) 
Data collectiona  
Space group P3221 
Cell dimensions    
    a, b, c (Å) 159.22, 159.22, 121.37 
        ()  90.00, 90.00, 120.00 
Wavelength (Å) 0.9537 
Resolution (Å) 30.0 – 3.20 (3.39 – 3.20)b 
Rmerge 0.191 (2.309) 
Rpim 0.055 (0.792) 
CC(1/2) 0.994 (0.441) 
I / I 9.4 (0.8) 
Completeness (%) 95.9 (88.9) 
Redundancy 12.3 (8.2) 
  
Refinement  
Resolution (Å) 30.0 – 3.20 
No. reflections 28215 
Rwork / Rfree 0.2310 / 0.2613 
No. atoms  
    Protein 4721 
    Ligandc 237 
    Water 45 
Average B-factors (Å2)  
    Protein 104.1 
    Ligand/ion 144.5 
    Water 76.2 
RMS deviations  
    Bond lengths (Å) 0.002 
    Bond angles () 0.53 
a Data was collected from a single crystal. b Values in parentheses are for highest-resolution 
shell. c “Ligand/ion” includes atoms of two FAD and two NADP(H) (adenosine only) 
molecules, as well as seven formate, five malonate, one malate and one acetate ion. 
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Supplementary Figure 1 | In vitro inhibition of AfTrxR by EbSe. Data were collected in triplicate. 
Error bars represent standard deviation. The standard model of competitive inhibition was fit by non-
linear regression (GraphPad Prism). 
 
Supplementary Figure 2 | EbSe interacts covalently with Cys148 of AfTrxR. Full MS/MS data 
annotation of peptide isolated from AfTrxR(C145S) after incubation with excess EbSe (see Figure 2). 
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Supplementary Figure 3 (previous page)| Annotated MS/MS data for non-modified wildtype, 
C145S and C148S peptides. Active site peptides isolated from (a) wildtype, (b) C145S or (c) C148S 
AfTrxR proteins after incubation with excess EbSe, for which bound EbSe could not be detected. The 
annotated sequence for each peptide is shown below each respective spectrum. 
 
Supplementary Figure 4 | Antifungal activity of EbSe against A. fumigatus on solid media. Disc 
diffusion assay for the antifungal susceptibility testing of EbSe and caspofungin against A. fumigatus 
(ATCC MYA-3626) after 24 hours. 
 
Supplementary Figure 5 | Superposition of low MW TrxR crystal structures shown in cross-eyed 
stereo view. The tertiary structures of TrxR monomers from A. fumigatus (green; PDB ID 6BPY), S. 
cerevisiae (yellow; PDB ID 3D8X), E. coli (magenta; PDB ID 1TDF) and A. thaliana (cyan; PDB ID 
1VDC) are highly conserved, with RMSD values across all C-alphas of < 2.3 A. 
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Supplementary Figure 6 | Alignment of low MW TrxR protein sequences from fungi, bacteria 
and plant. Conserved residues are outlined by blue boxes; those that are 100% conserved are in white 
text on red background; and those that are 75% conserved, or conservative substitutions, are in red text. 
Catalytic residues are highlighted yellow. Secondary structural features (top) refer to the AfTrxR 
crystal structure: β-strands = arrows, α-helices = large coils, 310-helices = tight coils. All four sequences 
have associated crystal structures (see Supplementary Fig. 5). The sequence alignment was calculated 
using Clustal omega and presented using the ESpript 3.0 web server1. Database references: A. 
fumigatus – GenBank MG551986, S. cerevisiae – UniProt P29509, E. coli – UniProt P0A9P4, A. 
thaliana – UniProt Q39243. The N-terminal mitochondrial target peptide of A. thaliana TrxR (residues 
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Supplementary Figure 7 | EbSe–AfTrxR docking results. EbSe was reacted with Cys148 in silico. 
The top ten docked poses (shown as sticks) were grouped according to their position on the surface of 
the protein. Group A poses (wheat) bind in the groove formed by α4 and the β2-η1 loop leading to the 
FAD cavity. Group B (pink) bind exclusively to the NADPH-domain, and reach to the amphipathic 
pocket above the active site. Group C (cyan) bind exclusively to the FAD domain. The molecular 
surface of the protein is colored by electrostatic potential, -5 kT/e (red) to +5 kT/e (blue). All hydrogen 
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7.1. Structural Characterisation of Promising Targets for New Antifungals 
Resistance of pathogens to antimicrobial drugs has emerged as one of the greatest challenges 
of the 21st century (Butts and Krysan, 2012; Campoy and Adrio, 2017; Lewis, 2013; Ventola, 
2015). Despite a large international push towards the discovery and development of new 
antibiotics, the need for the development of new antifungals is an area that is often overlooked. 
It is estimated that fungal infections affect approximately 1.2 billion people worldwide, 
causing between 1.5 and 2 million deaths annually (Denning and Bromley, 2015) (also see 
www.gaffi.org). In general, targets that lack a human homologue have traditionally been the 
focus for antifungal development, as reflected by the fact that most current drugs target 
components that are unique to fungi. More recently however, consideration of proteins with 
human orthologues as drug targets has broadened the scope for possible new antifungals (Butts 
and Krysan, 2012). High-resolution structural information is invaluable, not only for 
elucidating basic molecular mechanisms that are fundamental to important biological 
processes, but also for informing drug design, particularly in cases where the existence of 
human homologues presents a challenge to achieving an acceptable toxicity profile.  
X-ray crystallography is the primary technique used for the determination of three-
dimensional structures of proteins; however, protein structure solution is commonly hindered 
by the inherent difficulty of protein crystallisation (Smyth and Martin, 2000; Zheng et al., 
2015). Here, by employing a high-throughput Structural Genomics-style approach at the 
outset, useful structural information on three proteins involved in different critical biological 
processes has been obtained within a relatively short timeframe. Following from successful 
initial screening, X-ray crystal structures have been solved and further biochemical and/or 
biophysical analyses have been performed on A. fumigatus cytosolic thiolase (afCT), 
proliferating cell nuclear antigen (AfumPCNA), and thioredoxin reductase (AfTrxR) – gaining 
a greater understanding of the basic biology of the organism and uncovering avenues for the 
development of new potential antifungals. 
 
7.2. Future Directions for Three Targets that were the Focus of the Current Study  
7.2.1. Cytosolic Thiolase 
Ergosterol biosynthesis is well validated as a viable drug target, with three different classes of 
approved antifungal agents targeting different enzymes in the pathway (Campoy and Adrio, 
2017). This is in addition to polyenes, which target ergosterol directly. Therefore, detailed 
descriptions of other enzymes involved in the ergosterol synthesis pathway could uncover 
further avenues for antifungal development. afCT is essential for the growth of A. fumigatus, 
catalysing the first step in ergosterol synthesis. In Chapter 4, the exact geometry of two 
previously-unobserved reaction intermediates in the thiolase catalytic site is reported. 
Inhibitors of acetyl-transferase enzymes that mimic tetrahedral intermediates that occur during 
acetyl-transfer between CoA and the enzyme have been investigated in the past (Martin et al., 
1994). The crystal structures presented herein are expected to be invaluable for informing 
inhibitor design, leading to potential drug leads. In addition, the differences between afCT and 
hCT regarding particular residues surrounding their active site, their activation by monovalent 
cations, and their possible substrate specificities are all factors that should be considered for 
designing specificity into thiolase-targeting drugs. 
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7.2.2. Proliferating Cell Nuclear Antigen 
PCNA is a central hub for a myriad of proteins including cell-cycle regulators and enzymes 
essential for DNA replication and repair (Moldovan et al., 2007), and therefore similarly 
presents as a promising drug target (see Chapter 5). The structural study on AfumPCNA 
presented herein strongly suggests that the mechanism by which DNA sliding-clamps interact 
with their partner proteins is largely conserved between humans and filamentous fungi. 
However, key structural differences at the PIP-box binding site – uncovered by the crystal 
structure of AfumPCNA and accompanying molecular dynamics simulation – provide a 
foundation for the future design of peptides and peptide mimetics that exhibit the necessary 
selectivity for AfumPCNA over human PCNA to serve as antifungal therapeutics. Future work 
should endeavour to establish the key determinants that confer high affinity of a peptide for 
AfumPCNA. Therefore, the next obvious step towards a peptide-based AfumPCNA inhibitor 
would be to first determine a PIP-box consensus sequence for A. fumigatus, before selecting 
for peptides that have the highest affinity for the protein. Given the availability of the entire 
A. fumigatus genomic sequence, it is expected that a bioinformatic analysis would be sufficient 
to determine an approximate PIP-box consensus. Based on the results of previous 
bioinformatics analysis of fungal PCNA interaction networks, this is likely to be similar to the 
human PIP-box consensus (Zamir et al., 2012). Various biophysical and biochemical 
techniques such as phage-display, fluorescence polarisation, surface plasmon resonance (SPR) 
and/or isothermal titration calorimetry (ITC) could be used in parallel with X-ray 
crystallography to select for and determine the interactions that contribute most to the affinity 
of a peptide for AfumPCNA. 
7.2.3. Thioredoxin Reductase 
An attractive approach to expedite the antifungal development process is to repurpose drugs 
that have already been shown to be safe for use in humans (Butts and Krysan, 2012). The 
repurposing of ebselen (EbSe) for the treatment of various drug-resistant bacterial pathogens 
has been recently investigated (Thangamani et al., 2015). The potent antifungal activity of 
EbSe against A. fumigatus demonstrated herein (see Chapter 6), along with its previously 
demonstrated activity against a number of yeast species (Chan et al., 2007; Thangamani et al., 
2017), underscores this small molecule as a promising antifungal candidate. It is expected that 
the in vivo efficacy of EbSe for the treatment of fungal infections will be established in the 
near future. In addition, the use of EbSe in combination with other currently available 
antifungals should be investigated. It is suggested herein that the primary fungal target of EbSe 
is TrxR; however, additional research is required to provide further validation. This could 
include genetic and microbiological experiments such as target over-expression, isolation of 
mutations that confer resistance, or mass spectrometry-based proteomics. 
A crystal structure of AfTrxR in complex with EbSe would allow visualisation of key drug-
protein interactions. During the timeframe of the current study, extensive screening of 
crystallisation conditions and numerous rounds of optimisation resulted in the ability to 
produce large crystals of AfTrxR(C145S) protein (truncated at the C-terminus) after incubation 
with excess EbSe, in a reproducible manner (see Appendix 4). Unfortunately, these crystals 
did not diffract X-rays to sufficient resolution to allow for structure solution. A sharp decline 
in the intensity of reflections at a resolution of approximately 5 to 10 Å was typical. It is 
possible that the large domain rotation inherent to the function of TrxR promotes a degree of 
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flexibility within the crystal lattice that is hindering high-resolution diffraction. This is 
consistent with the marked decrease in the Rfree value observed when implementing TLS 
parameters during refinement of the AfTrxR structure (without EbSe), for which the highest 
resolution diffraction data obtained was still modest (3.2 Å). Further attempts at crystal 
optimisation could include: the addition of detergents and other additives, limited proteolysis 
to remove flexible regions and determine the optimal construct, and crystal seeding to uncover 
new conditions in which nucleation is impossible but crystal growth can occur.  
In lieu of a crystal structure, in silico modelling experiments suggest that, although the major 
contribution to the EbSe-AfTrxR interaction is the covalent bond formed to Cys148, a number 
of secondary interactions may be exploited by possible EbSe analogues to enhance affinity 
and specificity. Employing other biophysical analyses, such as ITC and SPR, to determine the 
binding affinities of EbSe and EbSe analogues to stable TrxR mutants lacking the active site 
cysteines would allow determination of the relative contribution of the covalent and non-
covalent interactions to the inhibition of TrxR by EbSe. 
 
7.3. Additional Targets for Future Investigation 
In addition to the three proteins that were the focus of this study, a number of other initial 
targets showed promising preliminary results. In particular, IreA, enzymes of the β-oxidation 
pathway, and chitin synthases present as good candidates for further investigation. 
7.3.1 The Master Regulator of the UPR: IreA 
Perturbations in endoplasmic reticulum (ER) homeostasis (ER stress) may lead to the 
accumulation of unfolded proteins; therefore, maintenance of ER homeostasis is essential for 
cell survival. The unfolded protein response (UPR) is comprised of the signalling pathways 
that are activated in eukaryotic cells in response to ER stress, and collectively prevent the 
folding capacity of the ER from being overwhelmed. When activated, the UPR acts to increase 
protein folding machinery and total ER volume, stimulate degradation of misfolded proteins, 
and attenuate overall protein synthesis (Kaufman, 2002; Liu and Kaufman, 2003; Ron and 
Hubbard, 2008). Higher eukaryotes possess three distinct but overlapping pathways that 
constitute the UPR, regulated by three ER-localised transmembrane receptors: Ire1, PERK and 
ATF6. Each of these has a luminal domain that detects ER stress and a cytoplasmic effector 
domain that passes the signal on to downstream components (Ron and Hubbard, 2008). Ire1 
mediates the most conserved UPR pathway, present in all eukaryotes, whereas ATF6 and 
PERK pathways are not conserved in lower eukaryotes (Liu and Kaufman, 2003). Ire1 is a 
single pass transmembrane protein and has been extensively studied in Saccharomyces 
cerevisiae. Ire1 oligomerises in response to accumulation of unfolded proteins in the ER, 
leading to trans-autophosphorylation of its cytosolic Ser/Thr kinase domain. This activates its 
C-terminal RNase domain, which processes the HAC1 mRNA allowing it to be translated, 
producing HAC1; a potent transcription factor that activates expression of many UPR-
inducible genes (Kaufman, 2002; Shamu and Walter, 1996). The A. fumigatus Ire1 homologue, 
IreA, is the master regulator of the UPR. A recent study showed that, in addition to UPR 
activation in response to acute ER stress, IreA is essential for growth and maintenance of 
homeostasis in changing or adverse environmental conditions. IreA was shown to be an 
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important contributor to growth at mammalian body temperature, growth on complex media, 
iron acquisition, growth under hypoxic conditions and cell wall homeostasis. Together, HacA 
(the HAC1 homologue) and IreA were shown to influence expression of greater than 13% of 
all A. fumigatus ORFs (Feng et al., 2011; Krishnan and Askew, 2014). Significantly, deletion 
of IreA resulted in a mutant that was completely avirulent in a mouse model of IA. In addition, 
A. fumigatus mutants defective in UPR activation showed a significant increase in 
caspofungin, itraconazole, voriconazole and amphotericin B susceptibilities (Feng et al., 2011; 
Richie et al., 2009). The role of IreA as a master regulator of gene expression in combination 
with its multidomain structure presents it as a promising target for novel anti-fungal therapies. 
Drugs that target any of the three functional domains of IreA are conceivable. In addition, the 
three overlapping UPR pathways that are possessed by higher eukaryotes may make human 
cells more resilient to effects produced by cross-reactivity of inhibitors with human Ire1, 
reducing side-effects associated with future antifungals that target IreA. 
The crystal structure of the luminal domain of yeast Ire1 has been solved previously (Credle 
et al., 2005). Mutations in putative interaction interfaces suggested that both dimerisation and 
oligomerisation of the luminal domain are essential for UPR activation, a finding that is 
consistent with previous studies (Liu et al., 2000; Liu et al., 2002; Shamu and Walter, 1996). 
In addition, it exhibits a deep groove, formed by parallel α-helices supported by an antiparallel 
β-sheet platform; reminiscent of the peptide binding region of Major Histocompatibility 
Complex (MHC) proteins. Sequence and mutational analysis of residues involved in forming 
the base of this groove demonstrated that they are highly conserved and important for UPR 
activation by Ire1. This supports the hypothesis that the luminal domain is able to directly bind 
to linear peptides, and that this may be a mechanism by which it senses unfolded proteins in 
the ER (Credle et al., 2005). The luminal domain of IreA may therefore present as a promising 
novel target for anti-Aspergillus peptide-mimetic drugs. A crystal structure of the A. fumigatus 
IreA luminal domain would be invaluable for further investigating this hypothesis. 
So far, a large homogenous sample of the luminal domain of A. fumigatus IreA as recombinant 
soluble protein has been successfully obtained, and screening for crystallisation conditions has 
commenced (see Appendix 3). Further work is needed to produce diffraction-quality crystals. 
In addition, investigation of the peptide binding properties of this domain would be useful for 
informing inhibitor design, and shed light on its molecular mechanism and biological function. 
A protocol used previously to isolate endogenous peptides bound to a human class I MHC 
molecule (Jardetzky et al., 1991) could be used to identify peptides that are bound by IreA. 
Briefly, purified recombinant IreA luminal domain would be mixed with soluble A. fumigatus 
extract, purified a second time to remove non-interacting peptides, and washed in denaturing 
conditions by centrifugal filtration. Recovered peptides could then be identified by mass 
spectrometry. Furthermore, a co-crystal structure of IreA with a bound peptide is expected to 
shed light on key peptide binding interactions – valuable information for informing the design 
of future synthetic or peptide-based inhibitors. 
7.3.2. Chitin Synthases 
Chitin, a homopolymer of β(1,4)-linked N-acetylglucosamine, is an essential structural 
component of the fungal cell wall (Lenardon et al., 2010; Roncero, 2002). Its essentiality to 
fungal survival and its absence in mammalian cells make it an attractive target for antifungal 
drugs (Campoy and Adrio, 2017). Chitin synthases (ChS) synthesise chitin from UDP-N-
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acetylglucosamine. Despite being the second most abundant biopolymer on the planet, the 
details of the regulation and mechanism of chitin synthesis are lacking. All ChSs contain a 
signature motif (QRRRW), essential for catalytic activity, and most are zymogenic and 
plasma-membrane bound (Roncero, 2002). Based on phylogenetic analysis, ChSs can be 
divided into seven classes and two distinct families. Family 1 consists of classes I ‒ III and 
family 2 consists of classes IV – VII (Muszkieta et al., 2014; Roncero, 2002). A. fumigatus 
has eight ChS genes that encompass all seven classes. Enzymes from family 1 are: ChSA 
(Class I), ChSB (Class II), ChSC (Class III) and ChSG (Class III); family 2 are: ChSF (Class 
IV), CSMA (previously annotated as ChSE) (Class V), ChSD (Class VI) and CSMB (Class 
VII) (Jimenez-Ortigosa et al., 2012; Muszkieta et al., 2014). There exist complex and poorly 
defined relationships between the activities of these different ChSs, and between ChS activity 
and the overall content of different polysaccharides in the fungal cell wall. This, along with 
the large number of genes and a possible level of redundancy, makes assigning functions to 
specific ChSs very difficult (Muszkieta et al., 2014). It has been hypothesised that chitin may 
be structured in different ways in the cell wall by different ChSs, rather than existing as a 
simple homogenous polymer, although the functional significance of this remains unknown. 
Extensive mutagenesis studies have largely failed to establish a clear morphogenetic trend, 
and results are often difficult to interpret. Single and multiple gene deletions of ChSA, ChSB, 
ChSC, ChSD or ChSF have resulted in minor or no changes in phenotype, with no observable 
effect on growth rate or virulence, suggesting that there exists a level of redundancy (Mellado 
et al., 1996; Muszkieta et al., 2014; Rogg et al., 2011). Deletion of ChSG resulted in a 
significant growth defect on solid media, with a radial colony growth rate of approximately 
30% of the wild-type strain, and a more branched hyphal morphology. Conidial cell walls 
appeared less organised when compared to wild-type, with the melanin layer only loosely 
attached to the surface. In addition, total mycelial ChS activity was reduced by 90% compared 
to the parental strain, suggesting that ChSG is the main contributor to ChS activity (Mellado 
et al., 1996; Muszkieta et al., 2014). Notably, a ∆ChSC/∆ChSG double deletion mutant 
exhibited poor conidiation and decreased virulence in a murine model of pulmonary 
aspergillosis (Mellado et al., 1996). Deletion of CSMA results in poor conidiation and periodic 
hyphal swelling (Aufauvre-Brown et al., 1997), and reductions in colony growth rate, total 
ChS activity (30% of wild-type activity) and conidial cell wall chitin content (20% of wild-
type) (Muszkieta et al., 2014). CSMA and CSMB have both been shown to be essential for 
proper conidia cell surface modelling, with gene knockouts resulting in a loss of conidia 
surface hydrophobicity associated with malformation of the surface rodlet layer and an easily 
detachable melanin layer, an increase in exposed immunostimulatory polysaccharides leading 
to a more effective immune response in vitro, and much larger swollen conidia, suggesting 
that the cell wall is softer and more fragile under external stress (Alsteens et al., 2013; Jimenez-
Ortigosa et al., 2012; Muszkieta et al., 2014). In addition, ∆CSMA and ∆CSMB mutants 
exhibited alterations in hyphal morphology associated with irregular distribution of chitin in 
the mycelial cell wall, and much shorter chitin fibrils. Notably, these mutants displayed 
decreased sensitivity to Nikkomycin Z (a chitin synthesis inhibitor), but a significant increase 
in susceptibility to echinocandins (β-glucan synthesis inhibitors) (Jimenez-Ortigosa et al., 
2012; Muszkieta et al., 2014). This is consistent with the apparent compensatory reaction that 
occurs between cell wall β-glucan synthesis and chitin synthesis when either process is 
inhibited independently, and also the strong antifungal synergy observed between Nikkomycin 
Z and echinocandins when used in combination (Chiou et al., 2001; Stevens, 2000; Verwer et 
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al., 2012). Deletion of all four family 2 genes resulted in a significant reduction in virulence 
in an immunocompromised mouse model (Muszkieta et al., 2014). This mutant was 
completely avirulent in mice undergoing caspofungin-treatment, whereas the wild-type strain 
caused 100% mortality after 5 days. Interestingly, a family 2 triple mutant 
(∆CSMA/CSMB/CHSF) showed no growth at 50°C, but was rescued by further deletion of 
CHSD. This, along with the observation that a simple ∆CHSD mutant had higher mycelial cell 
wall chitin levels, suggests that ChSD may act as a negative regulator of chitin synthesis 
(Muszkieta et al., 2014). The most severe morphological defects were observed when ChS 
genes were deleted from both families in a single strain, suggesting the presence of a level of 
cooperation between members of the two families. A ∆CSMA/CHSG double mutant showed 
decreased ChS activity, cell wall chitin levels, colonial growth rate and conidiation, in addition 
to highly branched and swollen hyphae (Mellado et al., 2003). Further deletion of CSMB and 
CHSF (∆CSMA/CSMB/CHSF/CHSG) resulted in severe hyphal swelling and branching, 
significant alterations in cell wall polysaccharide composition, a complete inability to produce 
conidia, and a drastic reduction in growth rate at 37°C (less than 16% of wild-type growth) 
(Muszkieta et al., 2014).  
Despite its obvious potential as a target for novel antifungals, fundamental details of chitin 
biosynthesis and regulation are poorly understood. Solving the structure of even one ChS 
would be a significant step toward a detailed understanding of the molecular mechanisms that 
underlie the synthesis and regulation of this important structural polymer. 
The results presented in Chapter 3 show the successful recovery of partially purified samples 
of the putative catalytic domains of A. fumigatus CSMA and ChSF, which appear to be soluble 
when fused to MBP (see Chapter 3, Figure 5). If large-scale purification is successful, 
screening for crystallisation conditions will commence. Alternatively, other expression 
systems may be employed, such as Pichia pastoris (Ahmad et al., 2014). Here, genes codon-
optimised for P. pastoris expression would be cloned into appropriate vectors and tested for 
methanol-induced expression of recombinant protein. Using a yeast expression system 
provides the option of incorporating a tag for protein secretion, which often simplifies the 
protein purification process as it renders cell lysis unnecessary; thus, all intracellular proteins 
are simply removed when cells are separated from the growth media. 
The putative catalytic domain of a ChS from Botrytis cinerea has been successfully purified 
as recombinant protein previously (Magellan et al., 2010). Despite showing favourable affinity 
for substrate, this construct was catalytically inactive. This suggests that other domains, 
transmembrane segments and/or loops may be essential for catalysis and processivity. 
Establishing a protocol for the purification of a full length ChS would be a significant step 
forward in the investigation chitin synthesis.  
7.3.3. The β-Oxidation Pathway 
The use of fatty acids as a source of energy involves four steps, each catalysed by a different 
enzyme, to convert acyl-CoA substrates into acetyl-CoA and an acyl-CoA molecule shortened 
by two carbon atoms, which is available to undergo subsequent β-oxidation cycles (Kunau et 
al., 1995). The importance of β-oxidation for the virulence of fungal pathogens, particularly 
those for which the lung is the primary site of infection, has been indicated previously 
(Kretschmer et al., 2012; Ramirez and Lorenz, 2009). The fungal kingdom exhibits a huge 
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diversity of β-oxidation pathways (Shen and Burger, 2009) and very little is known about the 
details of this pathway in specific species. The preliminary results presented in Chapter 3 
show that the recovery of soluble MBP-fusion proteins for all four A. fumigatus β-oxidation 
enzymes is possible using the protocol contained herein (see Chapter 3, Figure 5, and 
Appendix 2). Subsequent large-scale purification and screening for crystallisation conditions 
is currently being undertaken. Crystallographic analysis of all four β-oxidation enzymes, along 
with biochemical studies to determine kinetic parameters and substrate length preference, will 
be valuable for gaining a better understanding of an important process fundamental to the basic 
biology of A. fumigatus. 
 
7.4. Concluding Remarks 
The current project has shown that applying a standardised high-throughput methodology 
within the context of a small research laboratory is an efficient approach to gain a wealth of 
new information useful for uncovering biological mechanisms and informing future 
development of drugs. Powerful structural biology methodologies – most notably X-ray 
crystallography (Zheng et al., 2015), nuclear magnetic resonance spectroscopy (Li and Kang, 
2017) and the recent advent of near atomic resolution cryo-electron microscopy (Cheng et al., 
2017) – continue to emerge and develop, improving our understanding of macromolecular 
structures and their interactions. As these technologies become more standardised, it is 
anticipated that increasing numbers of smaller research groups will be able to readily apply 
these methods, contributing to our understanding of the basic processes that underlie biological 
functions, and providing a secure foundation for the development of therapeutics to combat 
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Appendix 1 – PCR Primer Sequences for Preliminary Targets 
All sequences are typed 5’ to 3’. Gateway® recombination sites are underlined; coding 
sequence for TEV protease cleavage site is in bold; coding sequence for protein of interest is 
in capitals. 
ECH_F:  ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaATGCCCTTCAATACATCCCC 
ECH_R:  ggggaccactttgtacaagaaagctgggtaTTACAACTTGCTGTCCACCC 
ACD_F:  ggggacaagtttgtacaaaaaagcaggctacgaaaacctgtattttcagggaATGGCATCTATCGCCCGT 
ACD_R:  ggggaccactttgtacaagaaagctgggtaCTATTTAGTGTACTGCTTTTGCAGGA 
3HACD_F:  ggggacaagtttgtacaaaaaagcaggctacgaaaacctgtattttcagggaATGGCTCAATTTCATCCCAC 
3HACD_R:  ggggaccactttgtacaagaaagctgggtaCTATTGAGCCCAATCCATGC 
KAT1_F:  ggggacaagtttgtacaaaaaagcaggctacgaaaacctgtattttcagggaATGGCCGCAGATCGCCTA 
KAT1_R:  ggggaccactttgtacaagaaagctgggtaTTAAACCTGCTCGTTCACAAACAAAC 
TRR1_F:  ggggacaagtttgtacaaaaaagcaggctacgaaaacctgtattttcagggaATGGTGCACACAAAAGTTACCA 
TRR1_R:  ggggaccactttgtacaagaaagctgggtaTTAGAGAAGAGGGTTCGACTTGTATT 
GFA1_F:  ggggacaagtttgtacaaaaaagcaggctacgaaaacctgtattttcagggaATGTGCGGTATCTTCGGCTA 
GFA1_R:  ggggaccactttgtacaagaaagctgggtaTTATTCAACGGTGACCGATTT 
HEM15_F:  ggggacaagtttgtacaaaaaagcaggctacgaaaacctgtattttcagggaATGGCTCTCCGCCGGCCATTA 
HEM15_R:  ggggaccactttgtacaagaaagctgggtaCTAAACTACAAGAGAAGAAAATCGGTCGCC 
ERG10_F:  ggggacaagtttgtacaaaaaagcaggctacgaaaacctgtattttcagggaATGTCTTCGCTTCCAGCTGT 
ERG10_R:  ggggaccactttgtacaagaaagctgggtaCTAAAGTAGCTCAACCACCAGAGC 
IREA_101F:  ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaGCGCGGTCTCTGCAG 
IREA_453R:  ggggaccactttgtacaagaaagctgggtttaGCCATTCAGCGAGTGAAC 
IREA_702F:  ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaGGTGTTCTTCAAATTGGTCGTC 
IREA_1165R:  ggggaccactttgtacaagaaagctgggtttaCTCAACCGGAGTAAAATATCGTTTG 
CHSA_163F:  ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaCACGGTAACCTGGTCCTGG 
CHSA_545R:  ggggaccactttgtacaagaaagctgggtattaACTTCCGTTCAGCCATCTG 
CHSB_281F:  ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaGCTCCTGAAAAGCAAAGTCG 
CHSB_703R:  ggggaccactttgtacaagaaagctgggtattaAGAGTGGTCGGTCTTCCAAAG 
CHSC_160F:  ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaCATGAAGAATTCACGCATATGC 
CHSC_525R:  ggggaccactttgtacaagaaagctgggtattaGGAGCCATTGAGCCATCG 
CHSD_100F:  ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaACCGCTCCCAAAACAGTTG 
CHSD_396R:  ggggaccactttgtacaagaaagctgggtattaGCGCTTCCAAAGCCGC 
CHSF_635F:  ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaCACGAAGCGGTTGTCCC 
CHSF_1019R:  ggggaccactttgtacaagaaagctgggtattaTGTACCGCAAAGATCCCG 
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CHSG_141F:  ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaGCTACAAGAAAGGTCAAGTTGG 
CHSG_562R:  ggggaccactttgtacaagaaagctgggtattaTCCACTCTTGTACATCCGACC 
CSMA_1231F:  
ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaTTGGATAAGTTCATCATCTGTCAAG 
CSMA_1564R:  ggggaccactttgtacaagaaagctgggtattaGGAGTTGATCCACCGACG 
CSMB_1054F:  
ggggacaagtttgtacaaaaaagcaggctatgaaaacctgtattttcagggaCAAGATAAGTTTGTCATTTGTCTCG 
CSMB_1405R:  ggggaccactttgtacaagaaagctgggtattaGCCACACAGGTCCTTCAGAG 
 
PCR products were incorporated into appropriate Gateway® vectors using BP and LR Clonase 
enzyme mixes (ThermoFisher Scientific) according to the manufacturer’s protocol. 
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Appendix 2 – Small-Scale Protein Expression and Solubility Testing Protocol 
Expression of heterologous protein was induced in E. coli BL21(λDE3) cells in 10 mL Luria-
Bertani (LB) broth by the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
to log-phase cultures (when OD600 reached approx. 0.5), before incubation with shaking at 
16°C overnight. The next morning cultures were harvested, resuspended in 1 mL of the initial 
purification buffer (0.5 M NaCl, 20 mM Tris pH 8.0, 10% glycerol, 10 mM imidazole, 5 mM 
β-mercaptoethanol (BME)), and stored at -80°C until required. Cells were lysed by vortexing 
with 0.1 mm glass beads for 5 min at 4°C. Following clarification of cell lysate by 
centrifugation, protein was recovered by batch purification with Ni-NTA resin, eluted with 
buffer containing 500 mM imidazole, and analysed by SDS-PAGE (see Chapter 3, Figure 
5). 
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Appendix 3 – Protein Purification and Preliminary Crystallisation Screening for the 
A. fumigatus IreA Luminal Domain 
Purification of the IreA luminal domain (IreA.LD) was made difficult due to the inefficiency 
of the TEV protease digest, and subsequent inability to isolate the cleaved protein from MBP 
– which has a very similar molecular weight to IreA.LD – and the remaining MBP-IreA.LD 
fusion. This truncation was subsequently re-cloned into a vector for its expression as a 6xhis-
NusA-tagged fusion (pET-57-DEST), and expression of recombinant H6-NusA-IreA.LD was 
induced in a 4 L E. coli BL21(λDE3) culture overnight at 16°C. Cells were resuspended in 
buffer (0.5 M NaCl, 20 mM Tris pH 8.0, 10% glycerol, 10 mM imidazole, 5 mM BME) and 
lysed by mechanical disruption before insoluble cell debris was removed by centrifugation. 
Cell lysate was subject to Ni-affinity chromatography using a 5 mL Ni-NTA column (Bio-
Rad), with sequential 10 and 25 mM imidazole wash steps, followed by elution of his-tagged 
protein with buffer containing 250 mM imidazole. Fractions containing H6-NusA-IreA.LD 
were pooled and dialysed to 0.5 M NaCl, 20 mM Tris pH 
8.0, 10% glycerol, 1 mM imidazole, 5 mM BME, in the 
presence of TEV protease at an approximate 4:1 ratio of 
protein:TEV by mass. Dialysis was at room temperature 
for 30 min, then 16°C overnight. Dialysed protein was 
passed through the Ni-IMAC column again to remove the 
H6-NusA tag, with cleaved IreA.LD present in the flow-
through. This was dialysed to 20 mM NaCl, 20 mM Tris 
pH 8.0, 10% glycerol, 1 mM DTT, loaded onto a 1 mL 
ENrichQ column (Bio-Rad), and eluted using a 20–700 
mM NaCl gradient. Fractions containing IreA.LD were 
pooled (3 mL), diluted to 10 mL with 50 mM NaCl, 20 
mM Tris pH 7.5, 1 mM DTT and passed through an SEC 
Sephacryl 26/60 S-300 column (GE) (Figure A2). 
Fractions containing IreA.LD were pooled and 
concentrated to approximately 10 mg/mL. Final protein 
yield was 12 mg (from 4 L culture). This sample was 
immediately subject to crystallisation screening using the 
sitting drop vapour-diffusion method, with a 75 µL reservoir volume under 2 µL drops (1 µL 
protein sample + 1 µL reservoir solution). A range of commercial sparse matrix screens in 96-
well format (Hampton Research, Molecular Dimensions) were employed. Only very small, 
non-diffracting crystals have been obtained thus far (not shown). 
  
Figure A2. SDS-PAGE analysis of 
consecutive size-exclusion 
chromatography factions containing 
recombinant IreA.LD protein (retention 
= 0.5 to 0.6 column volumes). Protein 
standards are shown (left) with masses 
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Appendix 4 – Co-crystallisation of AfTrxR in Complex with EbSe: Preliminary 
Results 
Crystallisation of AfTrxR in complex with EbSe was attempted by both crystal soaking and 
co-crystallisation. However, it was observed that AfTrxR (apo) crystallised in FO 
conformation, whereas the in silico experiments strongly suggest that EbSe binds to AfTrxR 
in FR conformation (see Chapter 6). This makes it highly unlikely that EbSe can access the 
AfTrxR active site in the current crystallisation condition, and has prompted a focus on co-
crystallisation of the AfTrxR-EbSe complex. For this, Cys145 of AfTrxR was mutated to 
serine, and residues 328 through 373 at the C-terminus removed (disordered region in crystal 
structure; see Chapter 6), to result in AfTrxR(C145S)trunc. This was over-expressed with a 
TEV-cleavable N-terminal 6xhis and NusA tag in E. coli BL21(λDE3) from a pET-57-DEST 
vector. Protein was initially purified from lysate essentially as described for H6-NusA-
IreA.LD (see Appendix 3) – involving two stages of Ni-affinity chromatography with a TEV 
protease digest in between to remove the H6-NusA tag. AfTrxR(C145S)trunc was further 
purified by hydrophobic interaction chromatography (HIC) using a 5 mL HiPrep Phenyl 
column (GE Healthcare) equilibrated in 0.75 M (NH4)2SO4, 0.5 M NaCl, 20 mM Tris pH 8.0, 
and eluted using a gradient to a buffer containing 20 mM Tris pH 8.0 only. Fractions 
containing AfTrxR(C145S)trunc were concentrated to approx. 10 mL, incubated with 5x molar 
excess FAD for 45 min at room temperature in the dark, and passed through an SEC Sephacryl 
26/60 S-300 column (GE) equilibrated in 20 mM Tris pH 7.5, 50 mM NaCl. Protein was 
concentrated to 24 mL and incubated with 1 molar equivalent FAD, 5x molar excess NADPH 
and 40x molar excess EbSe for 5 hr at room temperature in the dark. This sample was then 
passed through the SEC Sephacryl 26/60 S-300 column (GE) equilibrated in 20 mM Tris pH 
7.5, 100 mM NaCl. Fractions containing AfTrxR(C145S)trunc were concentrated to approx. 
10 mg/mL and subject to crystallisation trials immediately using the hanging drop vapour-
diffusion method, with 500 μL reservoir volumes and 2 to 10 μL drop sizes containing 2:1, 
1:1 or 2:3 ratios of reservoir:protein sample. Large crystals grew in conditions containing 
PEG3350 and NH4NO3 or CsCl after 3 days (Figure A3). The best of these diffracted X-rays 
to approx. 5 Å at the MX1 Beamline at the Australian Synchrotron (data not shown). 
 
  
Figure A3. Crystals of AfTrxR(C145S)trunc protein co-purified with EbSe. The bound FAD cofactor gives them 
a yellow colour. These crystals have lengths (maximum dimension) of between 0.3 and 1 mm, and grew in (a) 
15% PEG3350, 75 mM KCl; (b) 16.5% PEG3350, 130 mM CsCl, 10 mM KCl; (c) 14% PEG3350, 70 mM 
NH4NO3; (d) 15% PEG3350, 60 mM NH4NO3; (e) 18% PEG3350, 120 mM NH4NO3.  
a    b           c           d           e 
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